Document:

Exhibit 10.18

Exhibit 10.18

Execution Copy

ASSET PURCHASE AGREEMENT

ASSET PURCHASE
AGREEMENT (this “Agreement”) dated December 30, 2010, by and between Grand
Canyon Education, Inc., a Delaware corporation (“Buyer”), and Mind Streams,
L.L.C., an Arizona
limited liability company (“Seller”).

RECITALS:

A. Seller is
engaged in, among other things, the business of identifying potential students
for enrollment in on-line post-secondary education programs (the “Business”).

B. Buyer and
Seller are parties to a certain Collaboration Agreement, dated July 11, 2005 (as
supplemented by Project One and Project Two) (the
“Collaboration Agreement”).

C. Buyer
desires to purchase from Seller and Seller desires to sell to Buyer certain assets of
Seller used in the Business, and Buyer and Seller desire to acknowledge the termination of the
Collaboration Agreement and settlement of amounts due thereunder.

NOW, THEREFORE,
in consideration of the foregoing and the respective representations,
warranties, covenants, agreements and conditions hereinafter set forth, and intending to be legally
bound hereby, the parties hereto agree as follows.

1. PURCHASE AND SALE OF
ASSETS.

1.1 Assets to be
Transferred. Subject to the terms and provisions of this Agreement,
Seller agrees to sell, assign, transfer and deliver to Buyer, and Buyer agrees to purchase from
Seller, at the Closing (as defined below), all legal and beneficial right, title and interest of
Seller in and to those assets of Seller that are used in the Business and that are listed on
Schedule 1.1 attached hereto (collectively, the “Purchased Assets”),
in each case free and
clear of any and all Liens.

1.2 Excluded
Assets. Anything in Section 1.1 above to the contrary notwithstanding,
Seller is not selling, assigning, transferring or delivering to Buyer, and Buyer is not purchasing,
any other assets of Seller, including, without limitation, those that are specifically listed on
Schedule 1.2 attached hereto (collectively, the “Excluded Assets”),
all of which shall be
retained by Seller and shall not constitute Purchased Assets.

 

 

 

1.3 No Assumption of
Liabilities. Buyer shall not assume or be bound by, and Seller
shall retain, pay and discharge when due, all liabilities or obligations of Seller of any kind or
nature, known or unknown, accrued, absolute, contingent or otherwise, whatsoever (all such
liabilities and obligations of Seller referred to herein as the “Excluded
Liabilities”), which
Excluded Liabilities shall include, without limitation, any liabilities or obligations of Seller:

(a) incurred
in connection with this Agreement and the transactions provided for
herein, including, without limitation, counsel, banking and accountant’s fees and expenses,
and expenses pertaining to the performance by Seller of its obligations hereunder;

(b) relating to or
arising out of the Excluded Assets;

(c) in
respect of Taxes of Seller and its Affiliates (whether relating to periods
before or after the transactions contemplated in this Agreement or incurred by Seller or its
Affiliates in connection with this Agreement and the transactions provided for herein),
including any transfer Taxes, duties and other governmental charges applicable to the
transfer of the Purchased Assets in connection with this Agreement;

(d) relating
to past or present employees or independent contractors of Seller,
including, without limitation, any amounts in respect of compensation, severance, stay
bonuses or paid time off; and

(e) in
connection with or relating to any actions, suits, claims, proceedings, demands,
assessments and judgments, costs, losses, liabilities, damages, deficiencies and expenses
(whether or not arising out of third-party claims), including, without limitation, interest,
penalties, attorneys’ and accountants’ fees and all amounts paid in investigation, defense
or settlement of any of the foregoing, which liabilities or obligations arise out of or
relate to (i) the use or ownership of the Purchased Assets or the operation of the Business
prior to the Closing Date, (ii) any actions taken by Seller or any member of Seller or any
of their respective related persons or Affiliates on or prior to the Closing Date, or (iii)
any continuing business or other activities of Seller, its members, or any of their
respective related persons or Affiliates following the Closing Date.

1.4 Access to
Information. Seller will provide Buyer with all information relating to
or otherwise constituting Purchased Assets in Seller’s databases in a format in which it currently
exists.

1.5 Termination of
Agreement; Release. Buyer and Seller acknowledge that the
Collaboration Agreement terminates by its terms effective December 30, 2010. In connection with
such termination, Buyer and Seller hereby agree as follows:

(a) Buyer
 and Seller hereby affirm the termination of the Collaboration Agreement in
accordance with its terms, effective December 30, 2010. Except as provided in this Agreement with
respect to the Payment Obligation (as defined below), those provisions of the Collaboration
Agreement that expressly survive the termination thereof shall continue to survive as set forth
therein.

(b) The
Closing Cash Payment paid by Buyer to Seller in accordance with Section 2.1(a) of this
Agreement includes and constitutes full and final payment of all amounts
due by Buyer to Seller under the Collaboration Agreement upon and as of the termination
thereof (the “Payment Obligation”).

 

2

 

(c) Seller,
for itself and on behalf of its successors and assigns, does hereby (i)
acknowledge complete and full satisfaction by Buyer of the Payment Obligation, and (ii) fully,
finally, and forever releases and discharges Buyer of and from any and all claims, causes of
action, damages, demands, liabilities, obligations, costs, expenses, and compensation of every kind
or nature whatsoever, past, present, or future, at law or in equity, whether known or unknown,
contingent or otherwise, that Seller had, has, or may have had at any time in the past and through
and including the Closing Date, against the Buyer that relate to or arise out of the Payment
Obligation (collectively, the “Causes of Action”).

(d) Seller
represents, warrants, covenants, and agrees that it (i) has not and will not assign
any Causes of Action or possible Causes of Action against Buyer, (ii) fully intends to release all
Causes of Action against Buyer, including, without limitation, unknown and contingent Causes of
Action (other than those specifically reserved above), (iii) has consulted with counsel with
respect to the matters covered hereby and has been fully apprised of the consequences hereof, and
(iv) will not institute any litigation, lawsuit, claim, or action against Buyer with respect to any
released Causes of Action

(e) Anything
in this Section 1.5 to the contrary notwithstanding, Seller is not releasing
Buyer from, and Buyer shall remain fully obligated with respect to, Buyer’s obligation to make the
Subsequent Payment described in Section 2.1(b) below.

2. CONSIDERATION.

2.1 Consideration. In consideration for the Purchased Assets, and in respect of the
Payment Obligation, Buyer shall pay to Seller (a) an aggregate amount in cash equal to $8,500,000,
such amount to be paid by Buyer to Seller at the Closing (the “Closing Cash Payment”),
 and (b)
amounts earned and payable to Seller, but not yet paid, under the Collaboration Agreement related
to Net Revenue (as such term is defined in the Collaboration Agreement) actually received by Buyer
on or prior to February 28, 2011 (the “End Date”) in respect of courses started
on or before
October 31, 2010, such amounts to be paid by Buyer to Seller no later than 15 days following the
End Date (the “Subsequent Payments”).

2.2 Payment of
Consideration. Each of the Closing Cash Payment and the Subsequent
Payments shall be paid by Buyer to Seller by wire transfer of immediately available funds, to an
account designated in writing by Seller.

2.3 Allocation of
Consideration to Purchased Assets. Within 180 days following the
Closing Date, Buyer will deliver to Seller an allocation of the consideration paid to Seller
hereunder in respect of the Purchased Assets. Seller and Buyer will follow and use such allocation
in all Tax returns, filings or other related reports made by them to any governmental agencies. To
the extent that disclosures of this allocation are required to be made by the parties to the
Internal Revenue Service (“IRS”) under the provisions of Section 1060 of the
Internal Revenue Code
of 1986, as amended (the “Code”) or any regulations thereunder, Buyer and Seller
will disclose such
reports to the other prior to filing with the IRS.

 

3

 

3. REPRESENTATIONS AND WARRANTIES OF SELLER.

Seller makes the following representations and warranties to Buyer, each of which is true and
correct and shall survive the Closing of the transactions provided for herein.

3.1 Organization and Power. Seller is a limited liability company duly organized,
validly existing and in good standing under the laws of the State of Arizona. Seller has all
requisite power and authority to own, operate and lease its properties, to carry on its business as
and where such is now being conducted, to enter into this Agreement and the other documents and
instruments to be executed and delivered by Seller pursuant hereto and to carry out the
transactions contemplated hereby and thereby.

3.2 Authority. The execution and delivery of this Agreement and the other documents
and instruments to be executed and delivered by Seller pursuant hereto and the consummation of the
transactions contemplated hereby and thereby have been duly authorized by Seller. No other limited
liability company act or proceeding on the part of Seller or its members is necessary to authorize
this Agreement or the other documents and instruments to be executed and delivered by Seller
pursuant hereto or the consummation of the transactions contemplated hereby and thereby. This
Agreement constitutes, and when executed and delivered, the other documents and instruments to be
executed and delivered by Seller pursuant hereto will constitute, valid binding agreements of
Seller, enforceable in accordance with their respective terms, except as such may be limited by
bankruptcy, insolvency, reorganization or other laws affecting creditors’ rights generally, and by
general equitable principles.

3.3 No Violation. Neither the execution and delivery of this Agreement or the other
documents and instruments to be executed and delivered by Seller pursuant hereto, nor the
consummation by Seller of the transactions contemplated hereby and thereby (a) violates any law,
regulation or governmental order applicable to Seller, (b) requires any authorization, consent,
approval, exemption or other action by or notice to any government entity, or (c) violates or
conflicts with, or constitutes a default (or an event which, with notice or lapse of time, or both,
would constitute a default) under, or will result in the termination of, or accelerate the
performance required by, or result in the creation of any Lien upon any of the assets of Seller
under, any term or provision of the articles of organization or operating agreement of Seller or of
any material contract, commitment, understanding, arrangement, agreement or restriction of any kind
or character to which Seller is a party or by which Seller or any of its assets or properties may
be bound or affected.

3.4 No Litigation or Claims. There is no action, suit, litigation, claim,
counterclaim or legal or administrative proceeding or investigation pending or, to Seller’s
knowledge, threatened against Seller in connection with the Business that would impact the
Purchased Assets. Seller is not subject to any order in connection with the Business that would
impact the Purchased Assets.

3.5 Compliance With Laws and Orders. Seller is in compliance, in all material
respects, with all applicable laws and orders in connection with the Business that impact the
Purchased Assets, including, without limitation, those applicable to student recruitment for
higher education and other applicable regulations related to Title IV of the Higher Education
Act of 1965, as amended.

 

4

 

3.6 Intellectual Property. Seller exclusively owns or possesses adequate rights to
use all of the intellectual property included within the Purchased Assets, free and clear of all
Liens. There are no pending, or, to the knowledge of Seller, threatened claims against Seller or
any of its employees alleging that any of the intellectual property included within the Purchased
Assets is invalid or unenforceable or that any of such intellectual property included within the
Purchased Assets infringes or conflicts with, or otherwise violates, the rights of others
(“Third-Party Rights”). To the knowledge of Seller, no intellectual property included within the
Purchased Assets infringes or conflicts with any Third-Party Rights, and Seller is not aware of any
violation or infringement by a third party of any of the intellectual property included within the
Purchased Assets. Seller has taken reasonable security measures to protect the secrecy,
confidentiality and value of all trade secrets included within the Purchased Assets.

3.7 Title to and Condition of Purchased Assets. Seller has good and marketable title
to all of the Purchased Assets. All of the Purchased Assets are free and clear of restrictions on
or conditions to transfer or assignment, and free and clear of Liens.

3.8 Privacy of Customer Information. Seller has used and currently uses any of the
customer information that it has received or currently receives through its website or otherwise
and that is included in the Purchased Assets in a manner that complies, in all material respects,
with applicable law, and in a manner that complies with Seller’s privacy policy and the privacy
rights of its customers. Seller has collected any customer information through its website or
otherwise that is included in the Purchased Assets in a manner that complies, in all material
respects, with applicable law, and in a manner that does not violate its privacy policy. Seller has
commercially reasonable security measures in place to protect the customer information it receives
through its website or otherwise and that is included in the Purchased Assets and which it stores
in its computer systems from illegal use by third parties or use by third parties in a manner
violative of the rights of privacy of its customers.

3.9 No Brokers or Finders. Seller has not retained, employed or used any broker or
finder in connection with the transactions provided for herein or the negotiation thereof. Seller
shall be responsible for all broker or finder’s fees on account of actions by Seller or its members
or representatives.

4. REPRESENTATIONS AND WARRANTIES OF BUYER.

Buyer makes the following representations and warranties to Seller, each of which is true and
correct on the date hereof and the Closing Date, and shall survive the Closing of the transactions
provided for herein.

4.1 Organization and Power. Buyer is a corporation duly organized, validly existing
and in good standing under the laws of the State of Delaware. Buyer has all requisite corporate
power to enter into this Agreement and the other documents and instruments to be executed and
delivered by Buyer and to carry out the transactions contemplated hereby and thereby.

 

5

 

4.2 Authority. The execution and delivery of this Agreement and the other documents
and instruments to be executed and delivered by Buyer pursuant hereto and the consummation of the
transactions contemplated hereby and thereby have been duly authorized by the Board of Directors of
Buyer. No other corporate act or proceeding on the part of Buyer or its members is necessary to
authorize this Agreement or the other documents and instruments to be executed and delivered by
Buyer pursuant hereto or the consummation of the transactions contemplated hereby and thereby. This
Agreement constitutes, and when executed and delivered, the other documents and instruments to be
executed and delivered by Buyer pursuant hereto will constitute, valid and binding agreements of
Buyer, enforceable in accordance with their respective terms, except as such may be limited by
bankruptcy, insolvency, reorganization or other laws affecting creditors’ rights generally, and by
general equitable principles.

4.3 No Brokers or Finders. Buyer has not retained, employed or used any broker or
finder in connection with the transactions provided for herein or the negotiation thereof. Buyer
shall be responsible for all broker or finder’s fees on account of actions by Buyer or its
representatives.

5. EMPLOYEES — EMPLOYEE BENEFITS.

5.1 Election. Buyer and Seller have designated each of the employees engaged in the
Business as Category 1 or Category 2 employees. If an employee is in Category 1, such employee
shall remain an employee of Seller and will not have any association with Buyer. If an employee is
in Category 2, then at the Closing, Buyer agrees to offer employment to such employee on
substantially similar terms and with substantially similar benefits as similarly situated persons
employed by Buyer. If a Category 2 employee accepts such offer of employment, then Seller shall
terminate the employment of such employee and such employee shall become an employee of Buyer.
Seller shall be responsible for any and all termination benefits in connection with its termination
of any Category 1 or Category 2 employees, as well as any related obligations or liabilities
relating to such employees or arising in connection with any such termination. Notwithstanding the
foregoing, Buyer has no obligation to hire any employees of Seller.

5.2 Payroll Tax. Seller agrees to make a clean cut-off of payroll and payroll tax
reporting with respect to the Category 2 employees hired by Buyer, paying over to the federal,
state and city governments those amounts respectively withheld or required to be withheld for
periods ending on or prior to the Closing Date. Seller also agrees to issue, by the date prescribed
by IRS Regulations, Forms W-2 for wages paid through the Closing Date for Category 2 employees
hired by Buyer.

6. OTHER MATTERS.

6.1 Confidential Information. Seller shall not at any time subsequent to the Closing,
except as explicitly requested by Buyer, use for any purpose, disclose to any person, or keep or
make copies of documents, tapes, discs, programs or other information storage media (“records”)
containing, any confidential information concerning the Purchased Assets, all such information
being deemed to be transferred to Buyer hereunder as part of the Purchased Assets. The foregoing
provisions shall not apply to any information which is not a Purchased Asset. If at
any time after Closing, Seller should discover that it is in possession of any records
containing the confidential information of Buyer, then Seller shall immediately turn such records
over to Buyer, which shall upon request make available to Seller any information contained therein
which is not confidential information acquired by Buyer.

 

6

 

7. INDEMNIFICATION.

7.1 By Seller. Subject to the terms and conditions of this Article 7, Seller hereby
agree to indemnify, defend and hold harmless Buyer, and its directors, officers, employees and
controlled and controlling persons (hereinafter “Buyer’s Affiliates”), from and against all Claims
asserted against, resulting to, imposed upon or incurred by Buyer, Buyer’s Affiliates or the
Purchased Assets, directly or indirectly, by reason of, arising out of or resulting from (a) the
inaccuracy or breach of any representation or warranty of Seller contained in or made pursuant to
this Agreement; (b) the breach of any covenant or agreement of Seller contained in this Agreement;
or (c) the Excluded Liabilities.

7.2 By Buyer. Subject to the terms and conditions of this Article 7, Buyer hereby
agrees to indemnify, defend and hold harmless Seller, and its managers, members, officers,
employees and controlled and controlling persons (hereinafter “Seller’s Affiliates”), from and
against all Claims asserted against, resulting to, imposed upon or incurred by Seller or Seller’s
Affiliates, directly or indirectly, by reason of, arising out of or resulting from (a) the
inaccuracy or breach of any representation or warranty of Buyer contained in or made pursuant to
this Agreement; or (b) the breach of any covenant or other agreement of Buyer contained in this
Agreement.

7.3 Indemnification of Third-Party Claims. The following provisions shall apply to
any Claim subject to indemnification which is (i) a suit, action or arbitration proceeding filed or
instituted by any third party, or (ii) any other form of proceeding or assessment instituted by any
governmental entity:

(a) Notice and Defense. The party or parties to be indemnified (whether one or
more, the “Indemnified Party”) will give the party from whom indemnification is sought (the
“Indemnifying Party”) prompt written notice of any such Claim, and the Indemnifying Party
will undertake the defense thereof by representatives chosen by it. The assumption of
defense shall constitute an admission by the Indemnifying Party of its indemnification
obligation hereunder with respect to such Claim, and its undertaking to pay directly all
costs, expenses, damages, judgments, awards, penalties and assessments incurred in
connection therewith. Failure to give such notice shall not affect the Indemnifying Party’s
duty or obligations under this Article 7, except to the extent the Indemnifying Party is
prejudiced thereby. So long as the Indemnifying Party is defending any such Claim actively
and in good faith, the Indemnified Party shall not settle such Claim. The Indemnified Party
shall make available to the Indemnifying Party or its representatives all records and other
materials required by them and in the possession or under the control of the Indemnified
Party, for the use of the Indemnifying Party and its representatives in defending any such
Claim, and shall in other respects give reasonable cooperation in such defense.

 

7

 

(b) Failure to Defend. If the Indemnifying Party, within a reasonable time
after notice of any such Claim, fails to defend such Claim actively and in good faith, the
Indemnified Party will (upon further notice) have the right to undertake the defense,
compromise or settlement of such Claim or consent to the entry of a judgment with respect to
such Claim, on behalf of and for the account and risk of the Indemnifying Party, and the
Indemnifying Party shall thereafter have no right to challenge the Indemnified Party’s
defense, compromise, settlement or consent to judgment.

(c) Indemnified Party’s Rights. Anything in this Article 7 to the contrary
notwithstanding, (i) if there is a reasonable probability that a Claim may materially and
adversely affect the Indemnified Party other than as a result of money damages or other
money payments, the Indemnified Party shall have the right to defend, compromise or settle
such Claim, and (ii) the Indemnifying Party shall not, without the written consent of the
Indemnified Party, settle or compromise any Claim or consent to the entry of any judgment
which does not include as an unconditional term thereof the giving by the claimant or the
plaintiff to the Indemnified Party of a release from all liability in respect of such Claim.

7.4 Payment. The Indemnifying Party shall promptly pay the Indemnified Party any
amount due under this Article 7.

7.5 Survival and Cap. Except for Claims arising from fraud, or any willful or knowing
breach or misrepresentation, which Claims may be brought without limitation as to time or amount,
no claim or action shall be brought under this Article 7 for indemnification after the lapse of one
(1) year following the Closing. Further, the maximum obligation of Seller under Section 7.1 and
Buyer under Section 7.2 shall be $250,000.

8. CLOSING.

8.1 Closing. The closing of this transaction (the “Closing”) shall be held at the
offices of DLA Piper LLP (US), 2525 E. Camelback Road, Suite 1000, Phoenix, Arizona 85016
concurrent with the execution of this Agreement. Such date and time is referred to in this
Agreement as the “Closing Date.”

8.2 Documents to be Delivered by Seller. At the Closing, Seller shall deliver to
Buyer the following documents, in each case duly executed or otherwise in proper form:

(a) Bills of Sale. Bills of sale and such other instruments of assignment,
transfer, conveyance and endorsement as will be sufficient in the reasonable opinion of
Buyer and its counsel to transfer, assign, convey and deliver to Buyer the Purchased Assets
as contemplated hereby.

(b) Certified Resolutions. A certified copy of the resolutions of the manager
and/or members of Seller authorizing and approving this Agreement and the consummation of
the transactions contemplated by this Agreement.

(c) Other Documents. All other documents, instruments or writings required to
be delivered to Buyer at or prior to the Closing pursuant to this Agreement and such other
certificates of authority and documents as Buyer may reasonably request.

 

8

 

8.3 Documents to be Delivered by Buyer. At the Closing, Buyer shall deliver to Seller
the following, in each case duly executed or otherwise in proper form:

(a) Closing Cash Payment. The Closing Cash Payment, by wire transfer of
immediately available funds.

(b) Certified Resolutions. A certified copy of the resolutions of the board of
directors of Buyer authorizing and approving this Agreement and the consummation of the
transactions contemplated by this Agreement.

(c) Other Documents. All other documents, instruments or writings required to
be delivered to Seller at or prior to the Closing pursuant to this Agreement and such other
certificates of authority and documents as Seller may reasonably request.

9. CERTAIN DEFINITIONS.

9.1 Definitions. For purposes of this Agreement, the following terms shall have the
following meanings:

“Affiliate” of a person or entity means any person or entity which directly or indirectly
controls, is controlled by, or is under common control with such person or entity.

“Claim” means (i) all liabilities; (ii) all losses, deficiencies, actual damages (but not
including consequential or punitive damages), judgments, awards, penalties and settlements; (iii)
all demands, claims, suits, actions, causes of action, proceedings and assessments; and (iv) all
costs and expenses (including, without limitation, interest (including prejudgment interest in any
litigated or arbitrated matter), court costs and fees and reasonable expenses of attorneys and
expert witnesses) of investigating, defending or asserting any of the foregoing or of enforcing
this Agreement.

“Liens” means mortgages, liens, pledges, security interests, charges, encumbrances, claims,
easements, rights of way, covenants, conditions or restrictions or any other adverse claims, rights
or encumbrances of any kind or nature whatsoever.

“Tax” or “Taxes” means any and all federal, state, provincial, local, foreign or other taxes,
including, without limitation, income taxes, estimated taxes, excise taxes, sales taxes,
transaction privilege taxes, use taxes, gross receipts taxes, franchise taxes, employment and
payroll related taxes, withholding taxes, stamp taxes, transfer and property taxes, or other tax of
any kind whatsoever, whether or not measured in whole or in part by net income, including any
interest, penalty, or addition thereto, whether disputed or not.

 

9

 

10. MISCELLANEOUS.

10.1 Further Assurance. From time to time following the Closing Date, at Buyer’s
request and without further consideration, Seller will execute and deliver to Buyer such
documents, instruments and consents and take such other action as Buyer may reasonably request in
order to effect the transactions contemplated hereby, to discharge the covenants of Seller and to
vest in Buyer good, valid and marketable title to the Purchased Assets.

10.2 Disclosures and Announcements. Both the timing and the content of all disclosure
to third parties and public announcements concerning the transactions provided for in this
Agreement by either Seller or Buyer shall be subject to the approval of Buyer.

10.3 Assignment; Parties in Interest.

(a) Assignment. Except as expressly provided herein, the rights and
obligations of a party hereunder may not be assigned, transferred or encumbered without the
prior written consent of the other party.

(b) Parties in Interest. This Agreement shall be binding upon, inure to the
benefit of and be enforceable by the respective successors and permitted assigns of the
parties hereto. Nothing contained herein shall be deemed to confer upon any other person any
right or remedy under or by reason of this Agreement.

10.4 Law Governing Agreement. This Agreement shall be construed and interpreted
according to the internal laws of the State of Arizona, excluding any choice of law rules that may
direct the application of the laws of another jurisdiction. The parties hereby stipulate that any
action or other legal proceeding arising under or in connection with this Agreement may be
commenced and prosecuted in its entirety in the federal or state courts having jurisdiction in the
State of Arizona, each party hereby submitting to the personal jurisdiction thereof, and the
parties agree not to raise the objection that such courts are not a convenient forum. Process and
pleadings mailed to a party at the address provided in Section 10.6 shall be deemed properly served
and accepted for all purposes.

10.5 Amendment and Modification. Buyer and Seller may amend, modify and supplement
this Agreement in such manner as may be agreed upon by them in writing.

10.6 Notice. All notices, requests, demands and other communications hereunder shall
be given in writing and shall be: (a) personally delivered; (b) sent by telecopier, facsimile
transmission or other electronic means of transmitting written documents; or (c) sent to the
parties at their respective addresses indicated herein by registered or certified U.S. mail, return
receipt requested and postage prepaid, or by private overnight mail courier service. The respective
addresses to be used for all such notices, demands or requests are as follows:

(a) If to Buyer, to:

	 	 	 	Dan Bachus

Grand Canyon Education, Inc.

3300 West Camelback Road

Phoenix, Arizona 85017

Facsimile: (602) 589-2510

 

10

 

or to such other person or address as Buyer shall furnish to Seller in writing.

(b) If to Seller, to:

	 	 	 	Gail Richardson

Mind Streams, L.L.C.

7227 North 16th Street, Suite 190

Phoenix, Arizona 85820

Facsimile: (602) 906- 6098

or to such other person or address as Seller shall furnish to Buyer in writing.

If personally delivered, such communication shall be deemed delivered upon actual receipt; if
electronically transmitted pursuant to this Section, such communication shall be deemed delivered
the next business day after transmission (and sender shall bear the burden of proof of delivery);
if sent by overnight courier pursuant to this Section, such communication shall be deemed delivered
upon receipt; and if sent by U.S. mail pursuant to this Section, such communication shall be deemed
delivered as of the date of delivery indicated on the receipt issued by the relevant postal
service, or, if the addressee fails or refuses to accept delivery, as of the date of such failure
or refusal. Any party to this Agreement may change its address for the purposes of this Agreement
by giving notice thereof in accordance with this Section.

10.7 Expenses. Each of the parties shall bear its own expenses and the expenses of
its counsel and other agents in connection with the transactions contemplated hereby. Seller shall
pay all applicable sales, use and similar transfer taxes relating to the sale of the Purchased
Assets hereunder.

10.8 Entire Agreement. This instrument embodies the entire agreement between the
parties hereto with respect to the transactions contemplated herein, and there have been and are no
agreements, representations or warranties between the parties other than those set forth or
provided for herein.

10.9 Counterparts. This Agreement may be executed in one or more counterparts, each
of which shall be deemed an original, but all of which together shall constitute one and the same
instrument.

10.10 Headings. The headings in this Agreement are inserted for convenience only and
shall not constitute a part hereof.

10.11 Singular and Plural in Definition. Where any group or category of items or
matters is defined collectively in the plural number, any item or matter within such definition may
be referred to using such defined term in the singular number.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.]

 

11

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date and year first
above written.

	 	 	 	 	 
	 	GRAND CANYON EDUCATION, INC.

 	 
	 	By:  	/s/ Daniel E. Bachus
 	 
	 	 	Name:  	Daniel E. Bachus 	 
	 	 	Its: 	 Chief Financial Officer 	 
	 	 	 
	 	MIND STREAMS, L.L.C.

 	 
	 	By:  	/s/ Dennis L. Little
 	 
	 	 	Name:  	Dennis L. Little 	 
	 	 	Its:	Vice President/Chief Financial Officer 	 

 

 

 

Schedule 1.1

Purchased Assets

	1.	 	Sole and exclusive ownership and use of database of self-developed customer contacts.

	 
	2.	 	Know how related to database.

	 
	3.	 	Goodwill related to database.

 

 

 

Schedule 1.2

Excluded Assets

	1.	 	University Contracts including:

	 	a.	 	Jones International University

	 
	 	b.	 	Western Governor’s University

	 
	 	c.	 	National University

	 
	 	d.	 	Nova Southeastern University

	 
	 	e.	 	Ivy Bridge College

	 
	 	f.	 	Northcentral University

	2.	 	School District Contracts including:

	 	a.	 	Los Angeles Unified School District

	 
	 	b.	 	San Diego Unifies School District

	 
	 	c.	 	Harlandale Independent School District

	 
	 	d.	 	Houston Independent School District

	 
	 	e.	 	El Paso Independent School District

	 
	 	f.	 	Riverside Unified School District

	 
	 	g.	 	Fort Worth Independent School District

	3.	 	Other Excluded Assets:

	 	a.	 	All billed and unbilled accounts receivable

	 
	 	b.	 	All cash and bank accounts

	 
	 	c.	 	All tangible personal property

	 
	 	d.	 	The business name “Mind Streams” and associated URLs

	 
	 	e.	 	All other assets of the Business except the Purchased AssetsEX-4.1

Exhibit 4.1

ANNUAL INFORMATION FORM

Financial Year Ended November 30, 2010

February 22, 2011

 

 

FORWARD-LOOKING STATEMENTS

This Annual Information Form, or AIF, contains forward-looking statements and forward-looking
information within the meaning of applicable securities laws that are based on our management’s
belief and assumptions and on information currently available to our management, collectively,
“forward-looking statements”. In some cases, you can identify forward-looking statements by terms
such as “may”, “will”, “should”, “could”, “would”, “expect”, “plan”, “anticipate”, “believe”,
“estimate”, “project”, “predict”, “intend”, “potential”, “continue” and similar expressions
intended to identify forward-looking statements. Although we believe that the expectations
reflected in these forward-looking statements are reasonable, these statements relate to future
events or our future performance, and involve known and unknown risks, uncertainties and other
factors that may cause our actual results, levels of activity, performance or achievements to be
materially different from any future results, levels of activity, performance or achievements
expressed or implied by these forward-looking statements. Forward-looking statements include, but
are not limited to, statements about:

	 	•	 	our ability, and the ability of our commercial partners, to commercialize
EGRIFTATM in the United States and other territories;
	 
	 	•	 	whether we will receive regulatory approvals for tesamorelin from regulatory agencies in
territories other than the United States in which we wish to expand the commercialization
of tesamorelin, and the timing and costs of obtaining such regulatory approvals;
	 
	 	•	 	our recognition of milestones, royalties and other revenues from our commercial partners
related to future sales of EGRIFTATM;
	 
	 	•	 	our plans to conduct a new clinical program for tesamorelin in muscle wasting in chronic
obstructive pulmonary disease, or COPD, including the timing and results of these clinical
programs;
	 
	 	•	 	the continuation of our collaborations and other significant agreements with our
existing commercial partners and our ability to establish and maintain additional
development collaborations;
	 
	 	•	 	our estimates of the size of the potential markets for EGRIFTATM, tesamorelin
and our other product candidates;
	 
	 	•	 	the rate and degree of market acceptance of EGRIFTATM and our other product
candidates;
	 
	 	•	 	our success in obtaining, and the timing and amount of, reimbursement for
EGRIFTATM and our other product candidates;
	 
	 	•	 	the benefits of tesamorelin and our other product candidates as compared to others;
	 
	 	•	 	the success and pricing of other competing drugs or therapies that are or may become
available;
	 
	 	•	 	our ability to maintain and establish intellectual property rights in tesamorelin and
our other product candidates;
	 
	 	•	 	the manufacturing capacity of third-party manufacturers, including the manufacturer of
tesamorelin in commercial quantities;
	 
	 	•	 	our expectations regarding our financial performance, including revenues, expenses,
gross margins, liquidity, capital expenditures and income taxes; and
	 
	 	•	 	our need for additional financing and our estimates regarding our capital requirements
and future revenues and profitability.

 

 

Such statements reflect our current views with respect to future events and are subject to certain
risks, uncertainties and assumptions which may cause our actual results, performance or
achievements to be materially different from any future results, performance or achievements
expressed in or implied by the forward-looking statements. Certain assumptions made in preparing
the forward-looking statements include that:

	 	•	 	tesamorelin for the reduction of excess abdominal fat in HIV-infected patients with
lipodystrophy will receive approval in territories other than the United States covered in
our commercialization agreements;
	 
	 	•	 	no additional clinical studies will be required to obtain said regulatory approval of
tesamorelin;
	 
	 	•	 	EGRIFTATM will be accepted by the marketplace in the United States and will
be on the list of reimbursed drugs by third-party payors;
	 
	 	•	 	our relations with third-party suppliers of EGRIFTATM will be conflict-free
and that such third-party suppliers will have the capacity to manufacture and supply
EGRIFTATM to meet market demand and on a timely-basis;
	 
	 	•	 	we will obtain positive results from our clinical program for the development of
tesamorelin for muscle wasting in COPD patients; and
	 
	 	•	 	our business plan will not be substantially modified.

Forward-looking statements reflect our current views with respect to future events and are based on
assumptions and subject to risks and uncertainties. Given these risks and uncertainties, the
forward-looking events and circumstances discussed in this AIF may not occur, and you should not
place undue reliance on these forward-looking statements. We discuss many of these risks in greater
detail under the heading “Risk Factors”. Also, these forward-looking statements represent our
estimates and assumptions only as of the date of this AIF. We undertake no obligation and do not
intend to update or revise these forward-looking statements, unless required by law. We qualify all
of the information presented in this AIF, and particularly our forward-looking statements, with
these cautionary statements.

This AIF also contains estimates and other statistical data made by independent parties and by us
relating to market size and growth and other data about our industry and target indications. This
data involves a number of assumptions and limitations, and you are cautioned not to give undue
weight to such estimates. In addition, projections, assumptions and estimates of our future
performance and the future performance of the markets in which we operate are necessarily subject
to a high degree of uncertainty and risk.

BASIS OF PRESENTATION

We
obtained the industry, market and competitive position data in this
AIF from our own internal estimates
and research as well as from industry and general publications and research surveys and studies conducted by third
parties. Certain statistical data and other information regarding the size of our potential markets are based on industry
publications and/or derived from our own internal analysis of such industry publications. While we believe our internal
company research and internal analysis are reliable and the market definitions, methodology and hypotheses we use are
appropriate, such research, analysis, methodology or definitions have not been verified by an independent source.
We cannot and do not provide any assurance as to the accuracy or completeness of such information. Market forecasts,
in particular, are likely to be inaccurate, especially over long periods of time.

In this AIF, the use of EGRIFTATM refers to tesamorelin for the reduction of excess
abdominal fat in HIV-infected patients with lipodystrophy regardless of the trade name used for
such product in any particular territory. EGRIFTATM is the trade name used in the United
States for tesamorelin for the reduction of excess abdominal fat in HIV-infected patients with
lipodystrophy. EGRIFTATM is our trademark. Other trademarks and service marks appearing
in this AIF are the property of their respective holders.

 

 

All monetary amounts set forth in this AIF are expressed in Canadian dollars, except where
otherwise indicated. References to “$” and “C$” are to Canadian dollars and references to “US$” are
to U.S. dollars.

In this AIF, references to “Theratechnologies”, “we”, “our” and “us” refer to Theratechnologies
Inc. and its subsidiaries, unless the context otherwise states.

All information provided in this AIF is provided as of February 21, 2011, except where otherwise
stated.

 

 

TABLE OF CONTENTS

	 	 	 	 	 	 	 

	ITEM 1
	 	CORPORATE STRUCTURE	 	 	6	 
	 
	 	 	 	 	 	 
	1.1
	 	NAME, ADDRESS AND INCORPORATION	 	 	6	 
	1.2
	 	SUBSIDIARIES	 	 	6	 
	 
	 	 	 	 	 	 
	ITEM 2
	 	OUR BUSINESS	 	 	7	 
	 
	 	 	 	 	 	 
	2.1
	 	OVERVIEW	 	 	7	 
	2.2
	 	RECENT DEVELOPMENTS	 	 	8	 
	2.3
	 	THREE YEAR HISTORY	 	 	9	 
	2.4
	 	OUR STRATEGY	 	 	12	 
	2.5
	 	OUR PRODUCT AND PRODUCT CANDIDATES	 	 	12	 
	2.6
	 	INTELLECTUAL PROPERTY	 	 	20	 
	2.7
	 	MANUFACTURING	 	 	23	 
	2.8
	 	COMPETITION	 	 	24	 
	2.9
	 	GOVERNMENT REGULATION	 	 	24	 
	2.10
	 	PHARMACEUTICAL PRICING AND REIMBURSEMENT	 	 	32	 
	2.11
	 	EMPLOYEES	 	 	34	 
	2.12
	 	FACILITIES	 	 	34	 
	2.13
	 	ENVIRONMENT	 	 	35	 
	 
	 	 	 	 	 	 
	ITEM 3
	 	RISK FACTORS	 	 	36	 
	 
	 	 	 	 	 	 
	3.1
	 	RISKS RELATED TO THE COMMERCIALIZATION OF OUR PRODUCT AND PRODUCT CANDIDATES
	 	 	36	 
	3.2
	 	RISKS RELATED TO THE REGULATORY REVIEW PROCESS	 	 	42	 
	3.3
	 	RISKS RELATED TO OUR INTELLECTUAL PROPERTY	 	 	45	 
	3.4
	 	OTHER RISKS RELATED TO OUR BUSINESS	 	 	47	 
	3.5
	 	RISKS RELATED TO OUR COMMON SHARES	 	 	51	 
	 
	 	 	 	 	 	 
	ITEM 4
	 	DIRECTORS AND EXECUTIVE OFFICERS	 	 	54	 
	 
	 	 	 	 	 	 
	4.1
	 	DIRECTORS	 	 	54	 
	4.2
	 	AUDIT COMMITTEE	 	 	57	 
	4.3
	 	EXECUTIVE OFFICERS	 	 	58	 
	4.4
	 	DECLARATION OF THE DIRECTORS' AND OFFICERS' ANTECEDENTS	 	 	61	 
	4.5
	 	SECURITIES HELD BY THE DIRECTORS AND EXECUTIVE OFFICERS	 	 	61	 
	 
	 	 	 	 	 	 
	ITEM 5
	 	INTERESTS OF EXPERTS	 	 	62	 
	 
	 	 	 	 	 	 
	ITEM 6
	 	SECURITIES OF THE COMPANY	 	 	63	 
	 
	 	 	 	 	 	 
	6.1
	 	AUTHORIZED SHARE CAPITAL	 	 	63	 
	6.2
	 	DIVIDEND POLICY	 	 	63	 
	6.3
	 	TRANSFER AGENT AND REGISTRAR	 	 	63	 
	 
	 	 	 	 	 	 
	ITEM 7
	 	MARKET FOR SECURITIES	 	 	64	 
	 
	 	 	 	 	 	 
	7.1
	 	TRADING PRICE AND VOLUME	 	 	64	 
	7.2
	 	PRIOR SALES	 	 	64	 
	 
	 	 	 	 	 	 
	ITEM 8
	 	LEGAL PROCEEDINGS	 	 	65	 
	 
	 	 	 	 	 	 
	ITEM 9
	 	MATERIAL CONTRACTS	 	 	66	 
	 
	 	 	 	 	 	 
	ITEM 10
	 	ADDITIONAL INFORMATION	 	 	68	 
	 
	 	 	 	 	 	 
	APPENDIX A — AUDIT COMMITTEE CHARTER	 	 	69	 

 

 

ITEM 1 CORPORATE STRUCTURE

1.1 NAME, ADDRESS AND INCORPORATION 

We were incorporated under the name Theratechnologies Inc. on October 19, 1993 under Part IA of the
Companies Act (Québec) (now the Business Corporations Act (Québec)) by Certificate of
Incorporation. We amended our articles on October 20, 1993 by repealing the restrictions applicable
to private companies. On December 6, 1993, we again amended our articles to increase the number of
directors and to modify our share capital. Finally, on March 26, 1997, we further modified our
share capital to consist of an unlimited number of common shares and an unlimited number of
preferred shares. Our common shares are listed on the Toronto Stock Exchange, or TSX, under the
symbol “TH”. See Item 6.1 for a complete description of our authorized share capital.

Our head office is located at 2310 Alfred-Nobel Boulevard, Montréal, Québec, Canada H4S 2B4. Our
phone number is (514) 336-7800. Our website is www.theratech.com. The information contained on our
website is not part of this AIF.

1.2 SUBSIDIARIES

As of February 21, 2011, Theratechnologies had the following three wholly-owned subsidiaries:

	 	•	 	Theratechnologies Intercontinental Inc., a company incorporated under Part 1A of the
Companies Act (Québec) and governed by the Business Corporations Act (Québec).
Theratechnologies Intercontinental Inc., formerly Theratechnologies ME Inc., controls the
worldwide rights to commercialize EGRIFTATM except in the United States, Europe,
Russia, South Korea, Taiwan, Thailand and certain central Asian countries, and Canada;
	 
	 	•	 	Theratechnologies Europe Inc., a company incorporated under Part 1A of the Companies Act
(Québec) and governed by the Business Corporations Act (Québec). Theratechnologies Europe
Inc., formerly 9176-5057 Québec Inc., controls the rights to commercialize
EGRIFTATM in Europe, Russia, South Korea, Taiwan, Thailand and certain central
Asian countries; and
	 
	 	•	 	Pharma-G Inc., a company incorporated under Part 1A of the Companies Act (Québec) and
governed by the Business Corporations Act (Québec). Pharma-G Inc. is no longer an active
subsidiary.

Theratechnologies
has retained the rights to commercialize EGRIFTATM in the United
States and in Canada.

-6-

 

ITEM 2 OUR BUSINESS

2.1 OVERVIEW

We are a specialty pharmaceutical company that discovers and develops innovative therapeutic
peptide products with an emphasis on growth-hormone releasing factor, or GRF, peptides. Our
strategy is to leverage our expertise in the field of metabolism and GRF peptides to address
serious health disorders while remaining actively involved in the commercialization of our future
products. Our first product, EGRIFTATM (tesamorelin for injection), was approved by the
United States Food and Drug Administration, or FDA, in November 2010. EGRIFTATM is
currently the only approved therapy for the reduction of excess abdominal fat in HIV-infected
patients with lipodystrophy.

We estimate that excess abdominal fat in HIV-infected patients affects approximately 29% of
HIV-infected patients treated with antiretroviral therapies and approximately 12% of untreated
patients. In HIV-infected patients, lipodystrophy may be caused by the viral infection itself, the
use of antiretroviral therapy, or both. Lipodystrophy is characterized by abnormalities in the
production and storage of fat, which lead to excess abdominal fat, or lipohypertrophy, and the loss
of fat tissue, or lipoatrophy, generally occurring in the limbs and facial area.

Excess abdominal fat in HIV-infected patients is associated with significant health risks beyond
the mortality risk of the HIV infection itself. These health risks include metabolic disturbances
such as hyperlipidemia, an increase in the amount of fat in the blood (such as triglycerides and
cholesterol), and hyperglycemia, an increase in the amount of sugar in the blood, characterized by
insulin resistance, both of which lead to increased risks of cardiovascular disease and diabetes.
While there is evidence that suggests that lipoatrophy may be reduced with certain newer HIV
therapies, we are not aware of any evidence showing that any currently-marketed HIV therapy reduces
lipohypertrophy or the incidence of lipohypertrophy.

EGRIFTATM is currently marketed exclusively in the United States by EMD Serono Inc., or
EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, pursuant to a collaboration and
licensing agreement. We have also recently entered into distribution and licensing agreements for
EGRIFTATM with Sanofi Winthrop Industries S.A., or Sanofi, granting Sanofi the exclusive
commercialization rights in Latin America, Africa and the Middle East and with Ferrer Internacional
S.A., or Ferrer, granting Ferrer the exclusive commercialization rights in Europe, Russia, South
Korea, Taiwan, Thailand and certain central Asian countries. For a description of these agreements,
see Item 2.5. Using data compiled by the United States Center for Disease Control, or CDC, and the
World Health Organization and UNAIDS, or WHO/UNAIDS, we estimate that in 2012 there will be
approximately 190,000 HIV-infected patients treated with antiretroviral therapies with
lipohypertrophy in the United States, 170,000 in Europe, and 180,000 in Latin America, or 540,000
patients in total. We also estimate that in 2012, there will be an additional 47,000 HIV-infected
untreated patients with lipohypertrophy in the United States, 42,000 in Europe, and 28,000 in Latin
America, or an additional 117,000 patients in total.

In January 2011, EMD Serono launched EGRIFTATM in the United States. EMD Serono is
executing a launch program that consists of medical education, advertising, marketing and promotion
through their experienced sales force, and supporting market access through co-pay programs,
reimbursement education and support for payors. We believe EGRIFTATM will achieve a high
degree of physician and payor acceptance, driven by our product’s safety and efficacy, the lack of
approved alternative therapies for these patients and the prominent medical and social need to
treat HIV/AIDS patients.

-7-

 

EGRIFTATM is the trade name used for our first marketed product using our most advanced
compound, tesamorelin. Tesamorelin is a GRF analogue that stimulates the synthesis and pulsatile
release of endogenous growth hormone. Tesamorelin was synthesized using our internally-developed
peptide stabilization method. This method increases a protein’s resistance to enzymatic
degradation, which prolongs its duration of action and enhances its effectiveness in clinical use.
We believe this compound and future GRF analogues that we are developing can be used in a number of
additional high-value indications. Clinical data have shown tesamorelin to have both lipolytic
(fat-burning) and anabolic (muscle-building) properties. Our initial development of
EGRIFTATM focused on the lipolytic properties of the compound.

Tesamorelin’s anabolic properties have led us to pursue its development for muscle wasting in COPD
patients as our second indication. COPD is characterized by progressive airflow obstruction due to
chronic bronchitis or emphysema leading in certain cases to muscle wasting, a decrease of muscle
mass and deterioration in functionality. We have completed a Phase 2 trial which demonstrated a
statistically significant increase in lean body mass. Based upon these trial results, we intend to
randomize our first patient in a new Phase 2 clinical study in the second half of 2011. Based on
available market data, we estimate that in 2009, the number of diagnosed COPD patients with muscle
wasting was approximately 3.1 million in the United States, France, Germany, Italy, United Kingdom,
Spain and Japan.

To solidify our leadership position in the field of GRF therapeutics, we have embarked on a program
to discover new generations of GRF analogues. We believe that GRF compounds have the potential to
improve patient outcome in many high-value indications, such as wasting in chronic heart failure
and renal failure, as well as growth deficiency with abdominal obesity. We also believe that we can
improve the route of administration of GRF peptides to make them quicker and easier to use for
patients. Our early-stage pipeline also includes compounds for the treatment of Acute Kidney
Injury, or AKI, and certain cancers.

2.2 RECENT DEVELOPMENTS

Since the end of our most recently completed financial year, we have been engaged in the following
activities:

	 	•	 	COPD indication for EGRIFTATM. On February 22, 2011, we announced a new
clinical program in muscle wasting in COPD using tesamorelin. Tesamorelin’s anabolic
properties have led us to pursue the development of tesamorelin for muscle wasting in COPD
patients for its second indication. The program will be conducted in stable ambulatory COPD
patients with muscle wasting in the Global Initiative for Chronic Obstructive Lung Disease,
or GOLD, stage II and III severity experiencing decreased functionality in daily
activities.
	 
	 	•	 	Execution of distribution and licensing agreement for EGRIFTATM for European
market. On February 3, 2011, we announced the execution, through Theratechnologies Europe
Inc., of a distribution and licensing agreement with Ferrer granting it the exclusive
commercialization rights of tesamorelin in Europe, Russia, South Korea, Taiwan, Thailand
and certain central Asian countries for the reduction of excess abdominal fat in
HIV-infected patients with lipodystrophy. For a description of this agreement, see Item
2.5.
	 
	 	•	 	Execution of distribution and licensing agreement for EGRIFTATM for the Latin
American, African and Middle Eastern Markets. On December 6, 2010, we announced the
execution, through Theratechnologies Intercontinental Inc., of a distribution and licensing
agreement with sanofi-aventis S.A., granting one of its subsidiaries, Sanofi Winthrop
Industries, the exclusive distribution rights to EGRIFTATM in Latin America,
Africa and the Middle East for the reduction

-8-

 

	 	 	 	of excess abdominal fact in HIV-infected patients with lipodystrophy. For a description of
this agreement, see Item 2.5.

2.3 THREE YEAR HISTORY

2010

	 	•	 	FDA approval received for EGRIFTATM. On November 11, 2010, we announced that
the FDA approved EGRIFTATM as the first and only drug indicated for the reduction of excess
abdominal fat in HIV-infected patients with lipodystrophy (abdominal lipohypertrophy). The
FDA approval triggered a US$25 million milestone payment pursuant to our collaboration and
licensing agreement with EMD Serono.
	 
	 	•	 	Appointment of new President and Chief Executive Officer. On September 1, 2010, we
announced the appointment of Mr. John-Michel T. Huss as President and Chief Executive
Officer of the Company, following the retirement of Mr. Yves Rosconi, effective November
30, 2010. Mr. Huss assumed his position on December 1, 2010.
	 
	 	•	 	Execution of research collaboration agreement with UQAM, Gestion Valeo and Transfert
Plus. On November 16, 2010, we entered into a research collaboration agreement with the
Université du Québec à Montréal, or UQAM, Gestion Valeo, L.P., or Gestion Valeo, and
Transfert Plus, L.P, or Transfert Plus, with the goal of discovering short peptide mimics
of melanotransferrin with the hope of developing a novel cancer treatment. For a
description of this agreement, see “Melanotransferrin peptides (Anti-cancer compounds)” at
Item 2.5.
	 
	 	•	 	Adoption of shareholder rights plan. On February 10, 2010, we announced that our board
of directors had adopted a shareholder rights plan, effective as of such date. The plan was
later ratified by our shareholders at our annual meeting held on March 23, 2010. The plan
is designed to provide adequate time for the board of directors and the shareholders to
assess an unsolicited takeover bid for Theratechnologies, to provide the board of directors
with sufficient time to explore and develop alternatives for maximizing shareholder value
if a takeover bid is made, and to provide shareholders with an equal opportunity to
participate in a takeover bid and receive full and fair value for their common shares. For
a description of the plan, see Item 9.

2009

	 	•	 	Advisory Committee reviews NDA for tesamorelin. On November 5, 2009, we announced that
the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA would be reviewing our
New Drug Application, or NDA, for tesamorelin in the reduction of excess abdominal fat in
HIV-infected patients with lipodystrophy.
	 
	 	•	 	Filing of NDA for tesamorelin. On June 1, 2009, we announced the filing of an NDA with
the FDA for tesamorelin, an analogue of the growth hormone-releasing factor, proposed for
the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

2008

	 	•	 	Closing of transaction with EMD Serono. On December 16, 2008, we announced that we
closed the transaction related to the collaboration and licensing agreement with EMD
Serono. As part of this transaction, we received an upfront payment of US$30 million which
includes a license fee of US$22 million from EMD Serono. In addition, Merck KGaA purchased
US$8 million of our common shares at a price of US$3.67 per share.

-9-

 

	 	•	 	52-week confirmatory Phase 3 clinical trial results for tesamorelin. On December 15,
2008, we announced the 52-week results of our confirmatory Phase 3 clinical trial,
evaluating the long-term safety profile of tesamorelin in patients with HIV-associated
lipodystrophy. The results reported from both the 26-week confirmatory clinical study and
52-week confirmatory clinical study were consistent with the efficacy and safety profile
observed in the first Phase 3 clinical study. This announcement concluded the Phase 3
clinical studies for tesamorelin for the reduction of excess abdominal fat in HIV-infected
patients with lipodystrophy.
	 
	 	•	 	Execution of collaboration and licensing agreement with EMD Serono for tesamorelin in
the United States. On October 29, 2008, we announced the execution of a collaboration and
licensing agreement with EMD Serono for the exclusive commercialization rights to
tesamorelin in the United States for the reduction of excess abdominal fat in HIV patients
with lipodystrophy. For a description of this collaboration and licensing agreement, see
Item 2.5.
	 
	 	•	 	26-week confirmatory Phase 3 clinical trial results for tesamorelin. On June 18, 2008,
we announced our 26-week results of our confirmatory Phase 3 clinical trial, evaluating the
efficacy of tesamorelin in patients with HIV-associated lipodystrophy. The study was
powered to detect an 8% reduction in visceral adipose tissue versus placebo. The study met
its primary endpoint as well as important secondary endpoints confirming the positive
results obtained in our initial Phase 3 study.
	 
	 	•	 	Execution of strategic agreement with Dr. Grinspoon. On May 15, 2008, we announced our
entering into an agreement with both the MGH and Dr. Grinspoon to explore the use of
tesamorelin in relative growth hormone deficient abdominally obese, or GHDAO, subjects.
MGH, under the direction of Dr. Grinspoon, is the sponsor and is conducting a Phase 2
clinical trial with tesamorelin in subjects who have excess visceral adipose tissue, or
VAT, with a moderate growth hormone deficiency and who are abdominally obese. We accepted
to provide tesamorelin for this study and the MGH will retain the rights to the results
generated by this study, and we obtained an exclusive worldwide license to commercialize
any results. Dr. Grinspoon completed subject enrolment in December 2010.
	 
	 	•	 	Initiation of process to explore strategic options. On January 29, 2008, we announced
that our board of directors initiated a process to explore strategic options available to
the Company to further enhance shareholder value.
	 
	 	•	 	US patent for tesamorelin issued. On January 8, 2008, we announced that the United
States Patent and Trademark Office, or USPTO, issued Patent Number 7,316,997 entitled “GH
Secretagogues and Uses Thereof” to Theratechnologies. This patent covers methods of
treatment of HIV-associated lipodystrophy using tesamorelin. The granting of this patent
extended the patent term protection of tesamorelin in HIV-associated lipodystrophy for
eight additional years, until 2023.
	 
	 	•	 	Phase 3 first clinical trial results for tesamorelin. On December 5, 2007, we announced
that the results of our first Phase 3 clinical trial using tesamorelin were published in
the December 6, 2007 New England Journal of Medicine (www.nejm.org). The study, entitled
“Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV”, outlines, in
detail, the 26-week data of the trial. Top-line results of this Phase 3 trial were
initially disclosed in December 2006.
	 
	 	•	 	Preclinical work for AKI. We conducted some preclinical work on a molecule known as
THG213.29 with the intent of pursuing a clinical program in AKI. Through our research and
development, we discovered a new bifunctional peptide that appears to have favourable
properties in the treatment of AKI in animal models of AKI. During our 2008 fiscal year, we

-10-

 

	 	 	 	replaced THG213.29 with the new bifunctional peptide TH0673 in the event we decide to
develop a clinical program for AKI.

-11-

 

 ·

2.4  OUR STRATEGY

Our goal is to leverage our expertise in the field of metabolism and GRF peptides to become a
leading specialty pharmaceutical company with the necessary infrastructure to take innovative
therapeutic products from research and development to full commercialization in worldwide markets.
Key elements of this strategy include:

Maximize the global commercial potential of EGRIFTATM 

In order to maximize the commercial potential of EGRIFTATM we have entered into
licensing agreements with EMD Serono, Sanofi and Ferrer for different territories around the world.
We intend to continue to support our commercial partners to ensure the successful commercialization
of EGRIFTATM in their respective territories. This will include regulatory support,
manufacture and supply of EGRIFTATM, and potential co-promotion.

We have developed a new presentation of EGRIFTATM which is quicker and easier to use
than its current presentation. We are also developing a new and more concentrated formulation of
tesamorelin. Compared to our current formulation, this new formulation requires a smaller volume of
injection and is expected to be stable at room temperature. In addition, this new formulation could
potentially be used with a new delivery device such as a pen, to facilitate patient
self-administration. We expect the new presentation and the new formulation will have a positive
impact on our manufacturing capacity and will significantly reduce our unit costs.

Develop tesamorelin for muscle wasting in COPD

We will be conducting a new clinical program in muscle wasting in COPD. We have demonstrated in a
first Phase 2 clinical trial that tesamorelin has increased muscle mass in COPD patients. We
believe tesamorelin could improve patients’ functionality in daily activities and address a
significant unmet need in a large and potentially lucrative market.

Solidify our position as a leader in the field of novel GRF products

We will leverage our expertise in peptide discovery, drug development and regulatory affairs to
continue our development of new peptides, primarily GRF peptides, in order to expand our portfolio
of product candidates and solidify our position as a leader in this field.

Be actively involved in the commercialization of our products

We intend to retain commercial rights to our future products for indications and territories where
we believe we can effectively market them. We may also co-promote EGRIFTATM in certain
territories and tesamorelin in other indications.

Pursue external growth opportunities

In addition to developing products internally, we will opportunistically pursue in-licensing
arrangements or acquisitions of complementary businesses, compounds or products.
We will also identify and evaluate commercial growth opportunities that may include collaborations
with drug delivery companies.

2.5 OUR PRODUCT AND PRODUCT CANDIDATES

The following table provides an overview of our product and product candidates and their current
stages of development:

-12-

 

EGRIFTATM
— Our Lead Product

EGRIFTATM induces the release of growth hormone which causes a reduction in excess
abdominal fat (lipohypertrophy) in HIV-infected patients without reducing or interfering with
subcutaneous fat, and, as such, has no clinically significant effect on undesired loss of
subcutaneous fat (lipoatrophy).

EGRIFTATM is currently available in the United States as a once-daily two unit dose (two
vials, each containing 1 mg of tesamorelin) of sterilized lyophilized powder to be reconstituted
with sterile water for injection. To administer EGRIFTATM, 1 ml is retrieved from each
vial into one syringe to prepare a single 2 ml patient self-administered subcutaneous injection.
EGRIFTATM is injected under the skin into the abdomen once a day.

For the purposes of FDA approval, EGRIFTATM was evaluated in two clinical trials
involving 816 HIV-infected adult men and women with lipodystrophy and excess abdominal fat. In both
studies, patients treated daily with EGRIFTATM experienced greater reductions in
abdominal fat as measured by CT scan and greater improvements in belly appearance distress,
compared with patients receiving another injectable solution (placebo). Once the treatment was
terminated, the patients’ condition reversed to its status prior to the beginning of the treatment.
The most commonly reported adverse effects in the studies included reactions due to the release of
endogenous hormone, such as joint pain (arthralgia), pain in the extremities, swelling in the lower
limbs and muscle pain (myalgia), injection site reactions such as skin redness (erythema), itching
(pruritis) and pain and clinically manageable changes in blood sugar control. Our clinical trials
did not seek to measure any potential cardiovascular benefits of EGRIFTATM on
cardiovascular events.  

In connection with its approval, the FDA has required the following three post-approval
commitments:

	 	•	 	to develop a single vial presentation of the existing formulation of
EGRIFTATM. We have developed a new presentation of EGRIFTATM which
is quicker and easier to use than its current presentation. In the new presentation,
EGRIFTATM will be available as a single unit dose (one vial containing 2 mg of
tesamorelin) of sterile, lyophilized powder to be reconstituted with sterile water for
injection. The FDA requires that this new presentation be available by November 2013 and
we expect it to be commercially available before that date. The development of the new
presentation is complete and the dossier is ready for regulatory submission.

-13-

 

	 	•	 	to conduct a long-term observational safety study using EGRIFTATM. The
purpose of the long-term observational study required by the FDA is to evaluate the safety
of long-term administration of EGRIFTATM.
	 
	 	•	 	to conduct a Phase 4 clinical trial using EGRIFTATM. The primary purpose of
the Phase 4 clinical trial is to assess whether EGRIFTATM increases the
incidence or progression of diabetic retinopathy in diabetic HIV-infected patients with
lipodystrophy and excess abdominal fat.

The FDA requires that the proposed protocols for the long-term observational safety study and Phase
4 clinical trial be submitted by the second quarter of 2011. Under the terms of our collaboration
and licensing agreement, EMD Serono is responsible for finalizing and obtaining approval of such
protocols. We will continue to support EMD Serono in developing and finalizing such protocols.

Lipodystrophy

Lipodystrophy is characterized by abnormalities in the production and storage of fat. It has two
components: lipohypertrophy, abnormal and excessive fat accumulation, and lipoatrophy, the
noticeable, localized loss of fat tissue under the skin. In patients with lipohypertrophy, fat
accumulation occurs mostly around the waist and may also occur in other regions, including breast
tissue and in dorsocervical tissues in the neck, resulting in a “buffalo hump”. Excess fat also
appears as lipomas, or benign tumors composed of fat cells. In patients with lipoatrophy, the loss
of fat tissue generally occurs in the limbs and facial area.

Excess abdominal fat in HIV-infected patients is associated with significant health risks beyond
the mortality risk of the HIV infection itself. These health risks include metabolic disturbances
such as hyperlipidemia, an increase in the amount of fat in the blood (such as triglycerides and
cholesterol), and hyperglycemia, an increase in the amount of sugar in the blood, characterized by
insulin resistance, both of which lead to increased risks for cardiovascular disease and diabetes.

In HIV-infected patients, lipodystrophy may be caused by the viral infection itself, the use of
antiretroviral therapy, or both. While there is evidence that suggests that lipoatrophy may be
reduced with certain newer HIV therapies, we are not aware of any evidence showing that any
currently-marketed HIV therapy reduces lipohypertrophy or the incidence of lipohypertrophy. Recent
data suggest that different pathophysiological mechanisms are involved in the development of
lipohypertrophy and lipoatrophy. The most common statistically significant independent risk factors
identified for lipohypertrophy are duration of antiretroviral therapy, markers of disease severity
and protease inhibitor use. Other factors include age, genetics, and gender.

Market Opportunity

Based on our analysis of 20 independent medical studies published from 2000 to 2004, we estimate
that excess abdominal fat in HIV-infected patients affects approximately 29% of HIV-infected
patients treated with antiretroviral therapies. According to a separate 2003 independent medical
study, we estimate that an additional 12% of untreated HIV-infected patients are also affected by
excess abdominal fat.

Based on the above-mentioned data, we have identified the following potential markets for
EGRIFTATM.

	 	•	 	United States. The United States market represents the largest commercial opportunity
for EGRIFTATM. We estimate the prevalence of HIV/AIDS in the United States will
rise to 1.3 million people in 2012. Of this amount, approximately 650,000 people will be
treated for 

-14-

 

	 	 	 	HIV/AIDS and, of those patients treated, approximately 190,000 will suffer
from excess abdominal fat. In addition, approximately 47,000 untreated patients will
suffer from excess abdominal fat.
	 
	 	•	 	Europe. We estimate the prevalence of HIV/AIDS in Europe will rise to 1.4 million
people in 2012. Of this amount, approximately 590,000 people will be treated for HIV/AIDS
and, of those patients treated, approximately 170,000 will suffer from excess abdominal
fat. In addition, approximately 42,000 untreated patients will suffer from excess
abdominal fat.
	 
	 	•	 	Latin America. We estimate the prevalence of HIV/AIDS in Latin America will rise to 2.2
million people in 2012. Of this amount, approximately 630,000 people will be treated for
HIV/AIDS and, of those patients treated, approximately 180,000 will suffer from excess
abdominal fat. This number is proportionately lower than the other territories due to a
lower percentage of diagnosed and treated patients. With approximately 60,000 treated
patients who will suffer from excess abdominal fat, Brazil offers the largest market in
Latin America for EGRIFTATM. In addition, approximately 28,000 untreated
patients will suffer from excess abdominal fat.

We estimate that the total number of patients diagnosed with and treated for HIV/AIDS who will
suffer from excess abdominal fat in our primary target markets will be 540,000 in 2012. We estimate
that an additional 117,000 untreated patients may develop lipohypertrophy in such markets.

The foregoing information is based on historical data from the CDC for the United States, and
WHO/UNAIDS for Europe and Latin America. We used the historical growth rates derived from that data
to estimate the prevalence of HIV/AIDS in 2012.

EGRIFTATM Commercialization Activities

We are working closely with EMD Serono to support the commercialization of EGRIFTATM. We
are also working closely with Sanofi and Ferrer to obtain regulatory approval for and the
subsequent commercialization of EGRIFTATM. Each of our commercial partners were chosen
due to their commercial and regulatory capabilities in their respective territories.

          EMD Serono Agreement — United States

On October 28, 2008, we entered into a collaboration and licensing agreement granting EMD Serono
the exclusive commercialization rights to EGRIFTATM for the reduction of excess
abdominal fat in HIV-infected patients with lipodystrophy in the United States.

Under the terms of the agreement, EMD Serono has the exclusive right to conduct
EGRIFTATM commercialization activities in the United States. We are responsible for the
manufacturing and supply of EGRIFTATM and for the development of a new formulation. The
agreement also entitles us to conduct additional clinical programs to develop tesamorelin for
potential additional indications. EMD Serono has the option to commercialize products resulting
from such additional clinical programs in the United States. If EMD Serono exercises this option,
it will pay half of the development and regulatory costs incurred and to be incurred by us in
connection with such additional clinical programs. If EMD Serono decides not to exercise its
option, we have the right to commercialize tesamorelin for such indications on our own or with
third parties. We also have the option to co-promote any product resulting from such clinical
programs under terms and conditions to be agreed with EMD Serono. This agreement extends until the
expiration of the last valid claim based on a patent right (including patent applications)
controlled by us in the United States covering EGRIFTATM or any other product based on
an additional indication for tesamorelin that EMD Serono has elected to commercialize under the
agreement.

-15-

 

We may receive up to US$215 million in upfront and milestone payments in addition to royalties
and revenues from the sale of EGRIFTATM to EMD Serono. To date, we have received US$65
million which includes an upfront payment and regulatory milestone payments of US$57 million and an
equity investment of US$8 million. Future milestone payments will be made based on the achievement
of certain sales milestones. We will also be entitled to receive royalties at an increasing rate
based on achieving specified levels of annual net sales of EGRIFTATM in the United
States.

We made our first delivery of EGRIFTATM to EMD Serono on December 13, 2010. In January
2011, EMD Serono launched EGRIFTATM in the United States. EMD Serono is executing a
launch program that consists of increasing disease awareness through medical education to doctors,
patient advocacy and advertising, marketing and promotion through their experienced sales force,
and supporting market access through patient support, co-pay programs, reimbursement education and
support for payors.

EMD Serono is responsible for establishing the sale price of EGRIFTATM in the United
States. The wholesale acquisition cost has been set at US$23,900 per patient per year. We expect to
receive our first royalty payments in the second quarter of 2011.

     Sanofi Agreement — Latin America, Africa and the Middle East

On December 6, 2010, we entered into a distribution and licensing agreement granting Sanofi, a
subsidiary of Sanofi-aventis S.A., the exclusive commercialization rights to EGRIFTATM
for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Latin
America, Africa and the Middle East.

Under the terms of the agreement, we will sell EGRIFTATM to Sanofi at a transfer price
equal to the higher of a percentage of Sanofi’s net selling price and a predetermined floor price.
Sanofi will be responsible for conducting all regulatory and commercialization activities for
EGRIFTATM for the reduction of excess abdominal fat in HIV-infected patients with
lipodystrophy in the territories subject to the agreement. We will be responsible for the
manufacture and supply of EGRIFTATM to Sanofi. We have retained all development rights
to EGRIFTATM for other indications and will be responsible for conducting development
activities for any additional potential indications. We also granted Sanofi an option to
commercialize tesamorelin for other indications in the territories mentioned above. If such option
is not exercised, or is declined, by Sanofi, we may commercialize tesamorelin for such indications
on our own or with a third party. The initial term of this agreement extends until December 2020.

Ferrer Agreement — Europe, Russia, South Korea, Taiwan, Thailand and certain central Asian
countries

On February 3, 2011, we entered into a distribution and licensing agreement granting Ferrer the
exclusive commercialization rights to EGRIFTATM for the reduction of excess abdominal
fat in HIV-infected patients with lipodystrophy in Europe, Russia, South Korea, Taiwan, Thailand
and certain central Asian countries.

Under the terms of the agreement, we will sell EGRIFTATM to Ferrer at a transfer price
equal to the higher of a percentage of Ferrer’s net selling price and a predetermined floor price.
Ferrer will be responsible for conducting all regulatory and commercialization activities in
connection with EGRIFTATM for the reduction of excess abdominal fat in HIV-
infected
patients with lipodystrophy in the territories subject to the agreement. We will be responsible for
the manufacture and supply of EGRIFTATM to Ferrer. We have retained all development
rights to EGRIFTATM for other indications and will be responsible for conducting
development activities for any additional potential indications.
We have the option to co-promote EGRIFTATM for the reduction of excess abdominal fat in
HIV-

-16-

 

infected patients with lipodystrophy in the territories. Ferrer has the option to enter into a
co-development and commercialization agreement using tesamorelin for potential additional
indications. The terms and conditions of such a co-development and commercialization agreement will
be negotiated based on any additional program chosen for development. This agreement extends until
the later of the expiration of the last valid claim based on a patent right (including patent
applications) controlled by us covering a product licensed under the agreement or ten years from
the date of the first commercial sale of EGRIFTATM for each country covered by the
agreement.

     Unpartnered Territories

We have retained full commercial rights for EGRIFTATM in certain territories, including
Canada. In territories where we do not currently have commercial partners, we may commercialize
EGRIFTATM directly or in collaboration with commercial partners.

Tesamorelin — Our Lead Compound

Tesamorelin is a stabilized 44 amino acid human GRF analogue, which was synthesized in our
laboratories in 1995 using our long-acting peptide method. Although natural peptides have
significant therapeutic potential, they are subject to enzymatic degradation which severely limits
their effectiveness in clinical use. Our long-acting peptide method is a peptide stabilization
process which increases the target protein’s resistance to enzymatic degradation, while maintaining
its natural specificity. This usually results in a more stable and efficient compound, which can
thus prolong its duration of action. Tesamorelin induces growth hormone secretion in a natural and
pulsatile way. The clinical results obtained to date using tesamorelin suggest a therapeutic
potential in both anabolic and lipolytic indications. EGRIFTATM has demonstrated the
ability to significantly reduce visceral adipose tissue, increase muscle mass and reduce waist
circumference.

     Mechanism of action

In vitro, tesamorelin binds and stimulates human GRF receptors with similar potency as the
endogenous GRF. GRF is a hypothalamic peptide that acts on the pituitary somatotroph cells to
stimulate the synthesis and pulsatile release of endogenous growth hormone, which is both anabolic
and lipolytic. Growth hormone exerts its effects by interacting with specific receptors on a
variety of target cells, including chondrocytes, osteoblasts, myocytes, hepatocytes, and
adipocytes, resulting in a host of pharmacodynamic effects. Some, but not all these effects, are
primarily mediated by insulin-like growth factor one, IGF-1, produced in the liver and in
peripheral tissues.

The effects of recombinant human growth hormone, or rhGH, and tesamorelin have been the subject of
several clinical trials in the area of HIV-associated lipodystrophy. Based on these clinical
trials, the safety profiles of rhGH and tesamorelin appear to be very different. The natural
synthesis of growth hormone is regulated by a feedback mechanism preventing its overproduction.
Tesamorelin induces optimal activity of the somatotrope function and retains the natural rhythm
(pulsatility) of the physiological secretion of growth hormone without interfering with the
feedback mechanism mentioned above. With the exogenous administration of rhGH, the feedback
mechanisms are short-circuited, which gives rise to higher levels of growth hormone. The side
effects associated with rhGH include nerve, muscle or joint pain, swelling due to fluid retention
(edema), carpal tunnel syndrome, numbness and tingling of skin and increased risk of diabetes.
These side effects are particularly frequent among older people. In addition, rhGH can cause
hyperglycemia which makes it contraindicated for patients with diabetes or pre-diabetic conditions.

Muscle Wasting in COPD — New Indication for Tesamorelin

-17-

 

We have selected COPD as our second clinical program with tesamorelin. We chose to consider muscle
wasting in COPD patients with decreased functioning in daily activities for a clinical program
based on the anabolic properties of tesamorelin. The goal of the program is to show an improvement
in functionality in daily activities in COPD patients with loss of muscle mass.

We completed a three-month Phase 2 clinical study involving 109 stable ambulatory COPD patients.
Patients were randomized to receive either 1 mg or 2 mg doses of tesamorelin, or a placebo each
day. Patients treated using 1 mg or 2 mg doses of tesamorelin experienced a statistically
significant increase in lean body mass compared with patients receiving a placebo. In addition to
the increase in lean body mass, such patients experienced improvements in three functional measures
associated with tesamorelin, particularly for the 2 mg group. The three functional measures were:

	 	•	 	Respiratory symptoms, as assessed by St. George’s Respiratory Questionnaire;
	 
	 	•	 	Leg discomfort, as assessed by the Borg Scale following an exercise endurance test; and
	 
	 	•	 	Breathing discomfort, as assessed by the Borg Scale following an exercise endurance
test.
	 
	 	 	 	COPD

COPD is characterized by progressive airflow obstruction due to chronic bronchitis or emphysema,
two commonly co-existing lung diseases. COPD results in a limitation of the flow of air to and from
the lungs resulting in a shortness of breath. In contrast to asthma, the limitation of airflow is
not easily reversible and usually gets progressively worse over time.

Many COPD patients are affected by a systemic manifestation which may lead to muscle wasting.
Muscle wasting (cachexia or involuntary weight loss), a decrease or thinning of the muscle mass, is
associated with several abnormalities, including impaired exercise capacity and functioning and
decreased muscle strength. Muscle wasting is an independent predictor of a COPD patient’s
functional deterioration and mortality, and it is a common symptom in patients with moderate to
severe COPD. The importance of improving not only muscle strength, but other functional parameters
and quality of life is well recognized in order to improve the well being of patients with COPD and
decreased functionality. We are not aware of any treatment for muscle wasting in COPD approved by
any regulatory authorities.

     Market opportunity

According to independent research, 26 million adults aged 40 or over were diagnosed with COPD in
the United States, France, Germany, Italy, the United Kingdom, Spain and Japan in 2009. The
prevalence of COPD increases with age and is much higher in adult males. The diagnosed population
is expected to increase at a compound annual growth rate of 2.5%.

Treatment varies across countries and region, however 17.9 million patients were receiving
treatment for COPD management in 2009 in the United States, France, Germany, Italy, the United
Kingdom, Spain and Japan. COPD can be classified using four levels of severity, from mild to very
severe (stages I to IV) using the GOLD classification. Our program will focus primarily on COPD
patients in GOLD stage II and III. Based on available market data, we estimate that in 2009, the
number of diagnosed COPD patients in GOLD stage II and III suffering from a muscle wasting
condition, with a body mass index of under 25, was approximately 3.1 million in those markets.

     Clinical development plan

-18-

 

Tesamorelin’s anabolic properties have led us to pursue its development for muscle wasting in COPD
patients as our second indication. This clinical development program will be conducted in stable
ambulatory COPD patients, GOLD stage II and III, with muscle wasting experiencing decreased
functionality in daily activities. It will include three studies:

	 	•	 	One Phase 2 study: This study will be a randomized, placebo controlled study in
approximately 200 COPD patients with muscle wasting. Patients will be randomized to receive
either one of two different dosages of tesamorelin or placebo each day for six months. We
intend to randomize our first patient in this Phase 2 clinical study in the second half of
2011. The Phase 2 study will evaluate the safety and efficacy of using tesamorelin in COPD
patients, GOLD stage II and III, with muscle wasting. The primary endpoint will be an
increase in lean body mass. Other efficacy endpoints will be measured, such as a six minute
walking distance test, exercise endurance time, and quality of life (daily activities).
Safety assessments will include monitoring of adverse events and laboratory evaluations.
	 
	 	•	 	Two Phase 3 studies: If the Phase 2 study is successful, we anticipate there will be two
12-month Phase 3 studies (one pivotal and one confirmatory) to be conducted in parallel. We
expect a total of approximately 1,200 patients will be included in this program.

We currently believe that the clinical trials will last approximately four years and that the
program will cost between approximately $55 and $65 million. A significant portion of the costs
will be borne by our commercial partners if they elect to exercise their option to commercialize
under their respective agreements.

Other Product Candidates

     Novel Growth Hormone-Releasing Factor Analogues

We are working on several novel analogues of GRF that have improved chemical stability compared to
tesamorelin. To date, we have synthesized over 80 different compounds. We believe that GRF
compounds have the potential to improve patient outcome in many high-value indications. We also
believe we can improve the route of administration of GRF peptides to make them quicker and easier
to use for patients.

     Compounds for Acute Kidney Injury

AKI is the acute deterioration of kidney function leading to increased urea waste products and
electrolyte imbalance in blood. AKI is common among hospitalized patients and complicates the
management of patients in intensive care units. According to a 2008 medical publication, AKI
affected 3% to 7% of patients admitted to hospital and approximately 25% to 30% of patients in the
intensive care unit within days of major surgery. The incidence of AKI was approximately 600,000 to
900,000 patients in the United States per year. Despite hospitalization and renal replacement, the
mortality rate is 50% to 60% for dialyzed patients. We believe that hemodialysis is the only
approved treatment for post-surgical AKI.

We have identified AKI as a potential clinical program for internal development. We have developed
novel peptides specifically tailored for the prevention or treatment of AKI. One of these peptides,
TH0673, is a peptide that is currently in preclinical development. We have tested TH0673 in animal
models of AKI and have found that it increases creatinine clearance, improves excretion of
nitrogenous waste compounds and limits kidney damage. We expect to have additional preclinical
results in AKI in the first half of 2011.

     Other Discovery Activities — Melanotransferrin Peptides (Anti-cancer compounds)

-19-

 

In November 2010, we entered into a discovery and collaboration agreement with the UQAM, Gestion
Valeo and Transfert Plus in connection with research led by Dr. Richard Béliveau seeking to
discover short peptide mimics of melanotransferrin for the development of a new cancer treatment.

Melanotransferrin is related to the transferrin family of proteins and is expressed normally in
melanocytes, but also in several cancer cells. Dr. Béliveau’s research has demonstrated that
soluble melanotransferrin reduces cell migration, invasion and angiogenesis, which are hallmarks of
tumorigenesis and metastasis. We have identified small peptides from the melanotransferrin protein
which could replicate the functions of the full length protein. Currently, we are optimizing the
peptides for better pharmaceutical properties so that the optimized peptides can be tested in
animal models of cancer and tumor angiogenesis.

2.6 INTELLECTUAL PROPERTY

Our Current Patent Portfolio

Our current patent portfolio is comprised of patents and patent applications for the following
compounds:

          Tesamorelin

	 	•	 	In the United States, we own a patent covering the
composition of matter (tesamorelin),
which is scheduled to expire in 2015. We have applied for a patent term extension
requesting an extension of five years to this patent term. If our request for patent term
extension for the entire five year term is granted, the patent protection for tesamorelin
in the United States would be extended until 2020. In addition, we own an issued United
States patent relating to the use of tesamorelin in the treatment of HIV-associated
lipodystrophy, which is scheduled to expire in 2023. Because tesamorelin qualifies as a new
chemical entity, we benefit from data protection for a five year period for
EGRIFTATM ending November 2015. See “Regulatory Exclusivity”.
	 
	 	•	 	In Europe, tesamorelin is covered by granted patents scheduled to expire in 2016. In the
event of receipt of marketing approval from the European Medicines Agency, or EMA, we
intend to apply for supplementary protection certificates, or SPCs, in certain countries
which, if granted, could extend the patents covering tesamorelin in the countries where
SPCs are approved until 2021. We have also filed two patent
applications relating to the use of tesamorelin in the treatment of
HIV-associated lipodystrophy where, if such patents were granted,
they would be scheduled to expire in 2023 and 2025, respectively. As discussed below, the first time a new product is approved
in Europe, the regulation provides for a 10 year exclusivity period. Assuming approval in
2012, we would benefit from protection until 2022. See “Regulatory Exclusivity”.
	 
	 	•	 	We have obtained a patent covering the composition of matter (tesamorelin) in Brazil
that expires in 2019.
	 
	 	•	 	We have filed patent applications for the therapeutic indication of muscle wasting in
COPD in several countries, including the United States, where, if such patents were
granted, they would be scheduled to expire in 2024, with the exception of a
recently granted patent in the United States, which benefits
from a patent term adjustment extending its term to 2027.
	 
	 	•	 	We have filed patent applications in several countries,
including the United States, for
the new formulation of tesamorelin where, if such patents were granted, they would be
scheduled to expire in 2028.

-20-

 

	 	•	 	We have filed United States and international Patent
Cooperation Treaty applications,
relating to combination therapies of tesamorelin with certain drugs indicated for the
treatment of HIV which, if patents issued from these applications were granted, would be scheduled to expire in
2030.
	 
	 	 	 	Novel GRF Peptides
	 
	 	•	 	We have recently filed a United States provisional patent application relating to new
GRF analogues. Patents claiming priority from this application may be pursued and, if such patents
were granted, they would be scheduled to expire in 2032.
	 
	 	 	 	AKI
	 
	 	•	 	We have filed patent applications in several countries, including the United States,
relating to our peptide TH0673 and related peptides, and their use in the treatment
of AKI, where, if such patents were granted, they would be scheduled to expire in 2028.

Our Trademarks & Other Intellectual Property

EGRIFTATM is the trademark used for tesamorelin for the reduction of excess abdominal
fat in HIV-infected patients with lipodystrophy. Trademark registration in the United States
necessitates a prior commercial use in the territory in order to be granted. We are in the process
of filing the declaration of use to obtain trademark registration.

We have obtained registration for EGRIFTATM in Europe, Japan, Australia, Norway,
Switzerland, Mexico and Lebanon and have filed trademark applications for this trademark in other
countries. The use of the trademark in each jurisdiction generally requires the approval of the
regulatory authorities in such jurisdictions.

Other trademarks related to tesamorelin have been filed as part of our business strategy. We have
also reserved certain domain names in order to support future activities.

Our Policy on Intellectual Property

Our intellectual property practice is to keep all information relating to proprietary compounds,
inventions, improvements, trade secrets, know-how and continuing technological innovation
confidential and, where practicable, file patent and trademark applications. In particular, as part
of our intellectual property protection practice, we:

	 	•	 	perform surveillance of third party patents and patent applications in order to identify
any third party patent or third party patent application which, if granted, could be
infringed by our activities;
	 
	 	•	 	where practicable, file patent applications for any new and patentable invention,
development or improvement in the United States and in other countries;
	 
	 	•	 	prosecute all pending patent applications in conformity with applicable patent laws and
in a manner that efficiently covers our activities;
	 
	 	•	 	file trademark applications in countries of interest for our trademarks;
	 
	 	•	 	register domain names in countries of interest; and

-21-

 

	 	•	 	maintain our intellectual property rights by paying such government fees
as may be necessary to ensure such rights remain in force.

Regulatory Exclusivity

The regulatory regimes of the United States and Europe may provide market exclusivity for a
pharmaceutical product. Data protection and patent term extension provide a patent holder with
additional protection against third parties who may wish to commercialize a product similar to an
approved product.

     Data Protection

In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984, also
known as the Hatch-Waxman Act, awards, in certain circumstances, non-patent marketing exclusivities
to pioneer drug manufacturers. The Hatch-Waxman Act provides five years of non-patent marketing
exclusivity within the United States to an applicant who gains approval of a New Drug Application,
or NDA, for a “new chemical entity,” a drug for which the FDA has not previously approved any other
new drug with the same active moiety, which is the molecule or ion responsible for the action of
the drug. This marketing exclusivity prevents the FDA from approving, in certain circumstances, any
abbreviated new drug application for a generic drug or any 505(b)(2) NDA. See “Government
Regulation — United States — FDA Process” below.

In Europe, when a product based on a new compound is approved, the EMA grants a 10 year exclusivity
period beginning on the date of such approval. When the same compound is approved for a second
indication within the first eight years of this 10 year period, the exclusivity period is extended
by one year, providing a total exclusivity period of 11 years for the compound.

     Patent Term Extension

In the United States, the Hatch-Waxman Act permits patent term extension for one patent per
approved drug of up to five years for patent term lost during product development and the FDA
regulatory review process. However, patent term extension cannot extend the remaining patent term
beyond a total of 14 years from the product’s approval date. The patent term extension period is
generally one-half the time between the effective date of an Investigational New Drug Application,
or IND, and the submission date of an NDA plus the time between the submission date of an NDA and
the NDA. We have applied for a patent term extension with respect to tesamorelin.

In the European Union, SPCs for medicinal products are governed by Regulation 469/2009 with effect
from May 2009. An SPC has the effect of extending the term of a patent relating to protection of a
particular medicinal product by compensating the patentee for some lost patent protection caused by
the length of time taken to obtain marketing authorisation for the product in question. An SPC is a
national right, available in member states of the European Union by application to the national
patent office of each state for which a certificate is desired. The SPC must be based on a patent
but since an SPC is only granted in respect of a very specific active ingredient in a product, it
is generally of rather more limited scope than the patent on which it is based. Typically, the term
of the SPC is equal to the period which has elapsed between filing of the patent application and
grant of the first European Union marketing authorisation less five years. The term of the SPC may
not, generally, exceed five years. However, some European Union legislation regarding pediatric
medicines provides for a six-month extension of the basic SPC term in certain circumstances. The
SPC takes effect on expiry of the basic patent. In each country for which SPC protection is sought,
a separate SPC application must be filed within six months of the grant of the first marketing
authorisation in that country for the active ingredient(s) in question.

-22-

 

2.7 MANUFACTURING

We do not own or operate commercial scale manufacturing facilities for the production of our
product or any of our product candidates, nor do we have plans to develop our own manufacturing
operations in the foreseeable future. We currently depend on third-party contract manufacturers for
all of our required raw materials, drug substance and finished product for clinical trials and
commercial sale.

We are responsible for the manufacture and supply of tesamorelin to ensure the commercialization of
EGRIFTATM under our agreements with EMD Serono, Sanofi and Ferrer. As part of our
agreement with EMD Serono, we are required to maintain certain levels of inventory. In order to
fulfill these contractual obligations, we have negotiated and entered into various third-party
supply agreements.

Bachem

We have an agreement with Bachem Inc., an American subsidiary of Swiss-based Bachem AG, providing
for the manufacturing and supply of the active pharmaceutical ingredient of tesamorelin for
clinical programs and EGRIFTATM for commercial sale in the United States.

Draxis

We have an agreement with Draxis Pharma, a division of Draxis Specialty Pharmaceuticals, Inc., or
Draxis, providing for the manufacture and supply of the finished form of tesamorelin for clinical
programs and EGRIFTATM for commercial sale. Under our agreement, Draxis must fill vials
with tesamorelin, lyophilize it, label and package those vials and deliver them to locations in
accordance with our instructions.

We have identified and initiated discussions with possible secondary suppliers of these products.
We believe that there are alternate sources of supply for these products that will be able to
satisfy our needs and will be able to receive FDA qualification. We expect our new presentation as
well as our new formulation of tesamorelin will significantly increase our production capacity for
EGRIFTATM due to the smaller quantity of vials, shorter manufacturing process times and
increased batch sizes.

We have also entered into the following manufacturing agreements as a result of our undertakings
under the distribution and licensing agreement with EMD Serono wherein we agreed to supply the
injection tool kits for EGRIFTATM namely:

Becton Dickinson

On November 6, 2009, we entered into a supply agreement with Becton Dickinson Canada Inc., or
Becton Dickinson. Under this agreement, Becton Dickinson is responsible for supplying us with
syringes and hypodermic needles which are provided with EGRIFTATM in the United States.

Hospira

On March 26, 2009, we entered into a development and supply agreement with Hospira Worldwide, Inc.,
or Hospira. Under this agreement, Hospira is responsible for manufacturing and supplying us with
sterile water for injection, filled and finished in plastic vials, in connection with the sale of
EGRIFTATM in the United States.

ABAR

On January 5, 2010, we entered into a supply agreement with Gruppo Cartotecnico ABAR Litofarma
S.R.L., or ABAR, an Italian company, in order to ensure the commercial supply of pharmaceutical
mass market folding boxes for the sale of EGRIFTATM in the United States.

-23-

 

2.8 COMPETITION

The pharmaceutical industry is characterized by intense competition and rapid innovation. Our
potential competitors include large pharmaceutical and biotechnology companies, specialty
pharmaceutical and generic drug companies, academic institutions, government agencies and research
institutions, many of whom have greater financial, technical and human resources than us. We
believe the key competitive factors that will affect the development and commercial success of
EGRIFTATM and our product candidates are efficacy, safety and tolerability profile,
reliability, product acceptance by physicians and other healthcare providers, convenience of
dosing, price and reimbursement. Also, the development of new treatment methods for the indications
we are targeting could render our drugs non-competitive or obsolete. We are not aware of other GRF
products being commercialized or in development for the reduction of excess abdominal fat in
HIV-infected patients with lipodystrophy although we may face indirect competition for
EGRIFTATM from other drugs that may be prescribed by physicians. The use of these other
drugs for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy has not
been approved by the FDA nor any other regulatory authority.

We believe that competition in the area of muscle wasting in COPD patients is limited. We are aware
of one other compound which has completed a Phase 1 clinical study in COPD muscle wasting (GOLD
stage I and II). We may face indirect competition from other drugs such as anabolic steroids,
testosterone and growth hormone that may be prescribed by physicians. However, these drugs have not
been approved by the FDA for muscle wasting in COPD.

2.9 GOVERNMENT REGULATION

Overview

The research, development, manufacture and marketing of pharmaceutical products are governed by
various governmental authorities throughout the world to ensure efficacy and safety.

Governmental authorities in the United States at the federal, state and local level, and other
countries, extensively regulate, among other things, the research, development, testing,
manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion,
advertising, distribution, marketing, export and import of products, such as EGRIFTATM
and other product candidates that we are developing. The process of obtaining regulatory approvals
and the subsequent compliance with appropriate federal, state, local and foreign statutes and
regulations require the expenditure of substantial time and financial resources. Failure to comply
with the applicable United States or foreign requirements at any time during the product
development process, approval process or after approval, may subject an applicant to administrative
or judicial sanctions. Sanctions could include refusal to approve pending applications, withdrawal
of an approval, a clinical hold, warning letters, product recalls, product seizures, total or
partial suspension of production or distribution injunctions, fines, refusals of government
contracts, restitution, disgorgement or civil or criminal penalties.

On November 10, 2010, the FDA approved EGRIFTATM as the first approved treatment for
excess abdominal fat in HIV-infected patients with lipodystrophy. Our other product candidates must
receive regulatory approval from the FDA or other relevant foreign regulatory authorities before
they may legally be marketed in the United States or other countries.

In Canada, these activities are governed by the provisions of the Food and Drugs Act and its
regulations, which is enforced by the Therapeutic Products Directorate of the Health Products and
Food Branch of Health Canada. We have not yet applied to market EGRIFTATM in Canada.

United States — FDA Process

-24-

 

Before new pharmaceutical products may be sold in the United States, clinical trials of the product
candidates must be conducted and the results submitted to the FDA for approval. The drug approval
process requires, among other things, a demonstration of product safety and efficacy. Generally, a
demonstration of safety and efficacy includes preclinical testing and clinical trials of product
candidates. The testing, manufacture and marketing of pharmaceutical products in the United States
requires the approval of the FDA. The FDA enforces laws and regulations which apply to preclinical
testing, clinical trials, and manufacture of these products. The drug approval process in the
United States is described in brief below.

Pre-Clinical Testing: Before testing of any compounds with potential therapeutic value in human
subjects may begin in the United States, stringent government requirements for pre-clinical data
must be satisfied. Pre-clinical testing includes laboratory evaluations of product pharmacology and
toxicity in animal studies of the drug candidates. In parallel, the chemistry of the drug
candidates must be elucidated and their manufacturing, including formulation and stability, clearly
defined and controlled.

Investigational New Drug Application: Among other things, pre-clinical testing results obtained
from animal studies and in vitro studies, are submitted to the FDA as part of an IND application
and are reviewed by the FDA prior to the commencement of human clinical trials. An IND sponsor must
also include a protocol detailing, among other things, the objectives of the initial clinical
trial, the parameters to be used in monitoring safety and the effectiveness criteria to be
evaluated if the initial clinical trial lends itself to an efficacy evaluation. Some preclinical
testing may continue even after the IND is submitted. Unless the FDA objects to an IND (referred to
as a clinical hold), the IND becomes effective 30 days following its receipt by the FDA. Once
trials have commenced, the FDA may stop the trials at any time by placing them on “clinical hold”
because of safety concerns or noncompliance. If the FDA issues a clinical hold, the IND sponsor and
the FDA must resolve any outstanding concerns before the clinical study can begin. Accordingly, we
cannot be sure that submission of a IND will result in the FDA allowing clinical trials to begin or
that, once began, issues will not arise that suspend or terminate such trials.

Clinical Trials: Clinical trials involve the administration of the drug to healthy human volunteers
or to patients under the supervision of a qualified investigator pursuant to an FDA-approved
protocol. Each clinical trial must be conducted under the auspices of an Institutional Review
Board, or IRB, that considers, among other things, ethical factors, the safety of human subjects
and approves the patient informed consent, which must be agreed to by all participants prior to
participation in the clinical trial. Once an IND is in effect, each new clinical protocol and any
amendments to the protocol must be submitted to the FDA for review, and to the IRBs for approval.
Protocols detail, among other things, the objectives of the clinical trial, dosing procedures,
subject selection and exclusion criteria, and the parameters to be used to monitor subject safety.
Human clinical trials are typically conducted in three sequential phases, although the phases may
overlap with one another.

All phases of clinical trials must be conducted in conformance with Good Clinical Practices, or
GCP, which are ethical and scientific quality standards for conducting, recording, and reporting
clinical trials to assure that the rights, safety, and well-being of trial participants are
protected, and the FDA’s regulations for the protection of human subjects.

Phase 1 Clinical Trials: Phase 1 clinical trials represent the initial administration of the
investigational drug to a small group of healthy human subjects or, more rarely, to a group of
select patients with the targeted disease or disorder. The goal of Phase 1 clinical trials is
typically to test for safety, dose tolerance, absorption, bio-distribution, metabolism, excretion
and clinical pharmacology and, if possible, to gain early evidence regarding efficacy.

Phase 2 Clinical Trials: Phase 2 clinical trials involve a small sample of the actual intended
patient population and seek to assess the efficacy of the drug for specific targeted indications,
to determine

-25-

 

dose response and the optimal dose range and to gather additional information relating to safety
and potential adverse effects.

Phase 3 Clinical Trials: Once an investigational drug is found to have some efficacy and an
acceptable safety profile in the targeted patient population, Phase 3 clinical trials are initiated
to establish further clinical safety and efficacy of the investigational drug in a broader sample
of the patient population with the target disease or disorder at geographically dispersed study
sites in order to determine the overall risk-benefit ratio of the drug and to provide an adequate
basis for regulatory approval and product labeling.

New Drug Application: All data obtained from a comprehensive development program including research
and product development, manufacturing, pre-clinical and clinical trials and related information
are submitted in an NDA to the FDA. In addition to reports of the trials conducted under the IND,
the NDA includes information pertaining to the preparation of the new drug, chemistry manufacturing
and controls, or CMC, analytical methods, details of the manufacture of finished products and
proposed product packaging and labeling. The submission of an application is no guarantee that the
FDA will find the application complete and accept it for filing. The FDA may refuse to file the
application and request additional information rather than accept the application for filing, in
which case, the application must be resubmitted with the supplemental information. The re-submitted
application is also subject to review before the FDA accepts it for filing. Once an application is
accepted for filing, an FDA review team — medical doctors, chemists, statisticians,
microbiologists, pharmacologists, and other experts — evaluates whether the studies the sponsor
submitted show that the drug is safe and effective for its proposed use and whether the applicant’s
manufacturing complies with Good Manufacturing Practices, or GMP, to assure and preserve the
product’s identity, strength, quality and purity. As part of the approval process, the FDA will
inspect the facility or facilities where the product is manufactured. The FDA review process may be
extended by FDA requests for additional information or clarification. In some cases, the FDA may
decide to expedite the review of new drugs that are intended to treat serious or life threatening
conditions and demonstrate the potential to address unmet medical needs.

As part of its review, the FDA may refer the application to an advisory committee for evaluation
and a recommendation as to whether the application should be approved. The FDA is not bound by the
recommendation of an advisory committee, but it generally follows such recommendations.

Under legislation enacted in 2007, the FDA may determine that a risk evaluation and mitigation
strategy, or REMS, is necessary to ensure that the benefits of a new product outweigh its risks. If
required, a REMS may include various elements, such as publication of a medication guide, patient
package insert, a communication plan to educate healthcare providers of the drug’s risks,
limitations on who may prescribe or dispense the drug, or other measures that the FDA deems
necessary to assure the safe use of the drug.

In reviewing an NDA, the FDA may grant marketing approval, request additional information or deny
the application if it determines the application does not provide an adequate basis for approval.
The FDA may require larger or additional clinical trials, leading to unanticipated delay or
expense. Even if such additional information and data are submitted, the FDA may ultimately decide
that the NDA does not satisfy the criteria for approval. Data from clinical trials may be subject
to different interpretation, and the FDA may interpret data differently than the applicant. The
receipt of regulatory approval often takes a number of years, involving the expenditure of
substantial resources and depends on a number of factors, including the severity of the disease in
question, the availability of alternative treatments and the risks and benefits demonstrated in
clinical trials. The FDA may require, as a condition of approval, restricted distribution and use,
enhanced labeling, special packaging or labeling, expedited reporting of certain adverse events,
pre-approval of promotional materials, or restrictions on direct-to-consumer advertising or
commitments to conduct additional research post-approval. The FDA will

-26-

 

issue a complete response letter if the agency decides not to approve the NDA in its present form.
The complete response letter usually describes all of the specific deficiencies in the NDA
identified by the FDA. The deficiencies may be minor, for example, requiring labeling changes, or
major, for example, requiring additional clinical studies. If a complete response letter is issued,
the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the
letter, or withdraw the application. In addition, changes in FDA approval policies or requirements
may occur, or new regulations may be promulgated, which may result in delay or failure to receive
FDA approval.

Changes to an approved product, such as adding a new indication, making certain manufacturing
changes, or changing manufacturers or suppliers of certain ingredients or components requires
review and approval of the FDA.

Under the Hatch-Waxman Act, the U.S. Congress created an abbreviated FDA review process for generic
versions of pioneer (brand name) drug products. The Hatch-Waxman Act requires NDA applicants and
NDA holders to provide certain information about patents related to the drug for listing in the
FDA’s publication, “Approved Drug Products with Therapeutic Equivalence Evaluations”, commonly
known as the Orange Book. The Hatch-Waxman Act allows for, under certain circumstances, an
abbreviated NDA, or ANDA, where an applicant seeks to determine that its proposed product is
biologically equivalent to the reference drug. ANDA applicants do not have to conduct extensive
clinical trials to prove the safety or efficacy of the drug product; rather, they are required to
conduct less rigorous bioequivalence testing. Drugs approved in this way are commonly referred to
as “generic equivalents” to the listed drug, are listed as such by the FDA, and can often be
substituted by pharmacists under prescriptions written for the original listed drug. In addition,
in certain cases, an application for marketing approval may include information regarding safety
and efficacy of a proposed drug that comes from studies not conducted by or for the applicant and
for which the applicant has not obtained a specific right to reference those studies.
Such applications, known as a 505(b)(2) NDA, are permitted for new drug products that incorporate
previously approved active ingredients, even if the proposed new drug incorporates an approved
active ingredient in a novel formulation or for a new indication. Section 505(b)(2) also permits
the FDA to rely for such approvals on literature or on a finding by the FDA of safety and/or
efficacy for a previously approved drug product. In addition, a 505(b)(2) NDA for changes to a
previously approved drug product may rely on the FDA’s finding of safety and efficacy of the
previously approved product coupled with new clinical information needed by FDA to support the
change. FDA approval of the NDA or ANDA is required before marketing of the product may begin in
the United States.

The Pediatric Research Equity Act, or PREA, requires NDAs (or NDA supplements) for a new active
ingredient, new indication, new dosage form, new dosing regimen, or new route of administration to
contain data assessing the safety and efficacy for the claimed indication in all relevant pediatric
subpopulations. Data to support dosing and administration also must be provided for each pediatric
subpopulation for which the drug is safe and effective. FDA may grant deferrals for the submission
of data, or full or partial waivers from the PREA requirements. Unless otherwise required by
regulation, PREA does not apply to any drug for an indication for which orphan designation, as
described below, has been granted.

If a product receives regulatory approval, the approval may be significantly limited to specific
diseases and dosages or the indications for use may otherwise be limited, which could restrict the
commercial value of the product. Further, the FDA may require that certain contraindications,
warnings or precautions be included in the product labeling. In addition, the FDA may
require Phase 4 testing which involves clinical trials designed to further assess a drug safety and
effectiveness and may require testing and surveillance programs to monitor the safety of approved
products that have been commercialized.

-27-

 

Post-Approval Studies and Registries: Post-approval studies, also referred to as Phase 4 clinical
trials are studies that are conducted after a product has been approved. These trials can be
conducted for a number of purposes, including to collect long-term safety information or to collect
additional data about a specific population. As part of a product approval, the FDA may require
that certain Phase 4 studies be conducted post-approval, and in these cases these Phase 4 studies
are called post-marketing commitments.

Adverse Event Reporting: Regulatory authorities track information on side effects and adverse
events reported during clinical studies and after marketing approval. Non-compliance with FDA
safety reporting requirements may result in FDA regulatory action that may include civil action or
criminal penalties. Side effects or adverse events that are reported during clinical trials can
delay, impede or prevent marketing approval. Similarly, adverse events that are reported after
marketing approval can result in additional limitations being placed on the product’s use and,
potentially, withdrawal or suspension of the product from the market. Furthermore, in September
2007 the Food and Drug Administration Amendments Act of 2007 was enacted, which provides the FDA
with expanded authority over drug products after approval. This legislation enhances the FDA’s
authority with respect to post-marketing safety surveillance including, among other things, the
authority to require additional post-approval studies or clinical trials and mandate label changes
as a result of safety findings, including the development and implementation of a REMS.

Orphan Drug Designation

Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a “rare
disease or condition,” which is a disease or condition that affects fewer than 200,000 individuals
in the United States, or more than 200,000 individuals in the United States and for which there is
no reasonable expectation that the cost of developing and making a drug available in the United
States for this type of disease or condition will be recovered from sales in the United States of
the drug. Orphan product designation must be requested before submitting an NDA. After the FDA
grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use
are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in, or
shorten the duration of the regulatory review and approval process.

If a drug that has orphan designation subsequently receives the first FDA approval for the disease
or condition for which it has such designation, the product is entitled to orphan drug exclusivity,
which means that the FDA may not approve any other applications to market the same drug for the
same indication for seven years, except in limited circumstances, such as a showing of clinical
superiority to the product with orphan exclusivity. Competitors, however, may receive approval of
different drugs for the indication for which the orphan product has exclusivity or may obtain
approval for the same drug but for a different indication for which the orphan product has
exclusivity. Orphan product exclusivity also could block the approval of one of our product
candidates for seven years if a competitor obtains approval of the same drug or if our product
candidate is determined to be contained within the competitor’s product for the same indication or
disease. If a drug designated as an orphan drug receives marketing approval for an indication
broader than what is designated, it may not be entitled to orphan product exclusivity. Orphan drug
status in the European Union has similar but not identical benefits in the European Union.

Expedited Development and Review Programs

The FDA has a fast track program that is intended to expedite or facilitate the process for
reviewing new drugs that meet certain criteria. Specifically, new drugs are eligible for fast track
designation if they are intended to treat a serious or life-threatening condition and demonstrate
the potential to address unmet medical needs for the condition. Fast track designation applies to
the combination of the product and the specific indication for which it is being studied. Unique to
a fast track product, the

-28-

 

FDA may consider for review sections of the NDA on a rolling basis before the complete application
is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the
FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the
sponsor pays any required user fees upon submission of the first section of the NDA.

Any product submitted to the FDA for market, including a fast track program, may also be eligible
for other types of FDA programs intended to expedite development and review, such as priority
review and accelerated approval. Any product is eligible for priority review if it has the
potential to provide safe and effective therapy where no satisfactory alternative therapy exists or
a significant improvement in the treatment, diagnosis or prevention of a disease compared to
marketed products. The FDA will attempt to direct additional resources to the evaluation of an
application for a new drug designated for priority review in an effort to facilitate the review.
Additionally, a product may be eligible for accelerated approval. Drug products studied for their
safety and effectiveness in treating serious or life-threatening illnesses and that provide
meaningful therapeutic benefit over existing treatments may receive accelerated approval, which
means that they may be approved on the basis of adequate and well-controlled clinical studies
establishing that the product has an effect on a surrogate endpoint that is reasonably likely to
predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival
or irreversible morbidity. As a condition of approval, the FDA may require that a sponsor of a drug
receiving accelerated approval perform adequate and well-controlled post-marketing clinical
studies. In addition, the FDA currently requires as a condition for accelerated approval
pre-approval of promotional materials, which could adversely impact the timing of the commercial
launch of the product. Fast track designation, priority review and accelerated approval do not
change the standards for approval but may expedite the development or approval process.

Non-U.S. Regulation

In addition to regulations in the United States, we will be subject to a variety of regulations
governing clinical studies and commercial sales and distribution of our products in other
jurisdictions around the world. Whether or not we obtain FDA approval for a product, we must obtain
approvals from the comparable regulatory authorities of foreign countries before we can commence
clinical studies or marketing of the product in those countries. The approval process varies from
country to country and the time may be longer or shorter than that required for FDA approval. The
requirements governing the conduct of clinical studies, product licensing, pricing and
reimbursement vary greatly from country to country. In some international markets, additional
clinical trials may be required prior to the filing or approval of marketing applications within
the country.

In the European Union, medicinal products must be authorized either through the decentralized
procedure by the competent authorities of the European Union Member States, or through the
centralized procedure by the European Commission following an opinion by the EMA. The centralized
procedure provides for the grant of a single marketing authorization that is valid for all European
Union member states. The centralized procedure is compulsory for medicines produced by certain
biotechnological processes, products with a new active substance indicated for the treatment of
certain diseases such as neurodegenerative disorder or diabetes and products designated as orphan
medicinal products, and optional for those products which are highly innovative or for which a
centralized process is in the interest of patients. The decentralized approval procedure provides
for approval by one or more “concerned” member states based on an assessment of an application
performed by one member state, known as the reference member state. Under the decentralized
approval procedure, an applicant submits an application, or dossier, and related materials (draft
summary of product characteristics, draft labeling and package leaflet) to the reference member
state and concerned member states. The reference member state prepares a draft assessment and
drafts of the related materials within 120 days after receipt of a valid application. Within 90
days of receiving the reference member state’s assessment report, each concerned member state must
decide whether to approve the assessment report and related materials. If a member state objects to
approval of the

-29-

 

assessment report and related materials on the grounds of potential serious risk to public health,
the disputed points may eventually be referred to the European Commission, whose decision is
binding on all member states. In many European Union countries, pricing and reimbursement
negotiations must also take place before the product is sold in their national market between the
company marketing the product and the competent national authorities.

In order to obtain approval for commercializing new drugs in Canada, we must satisfy many
regulatory conditions. We must complete preclinical studies in order to file a Clinical Trial
Application, or CTA, in Canada. We then receive different clearance authorizations to proceed with
Phase 1 clinical trials, which can then lead to Phase 2 and Phase 3 clinical trials. Once all three
phases of trials are completed, we file a registration file named a New Drug Submission, or NDS, in
Canada. If the NDS demonstrates that the product was developed in accordance with the regulatory
authorities’ rules, regulations and guidelines and demonstrates favourable safety, efficacy and
receives a risk/benefit analysis, then the regulatory authorities issue a notice of compliance,
which allows us to market the product.

Good Manufacturing Practices

The FDA, the EMA, the competent authorities of the European Union Member States and other foreign
regulatory agencies regulate and inspect equipment, facilities, and processes used in the
manufacturing of pharmaceutical and biologic products prior to approving a product. Among the
conditions for NDA or equivalent foreign approval is the requirement that the prospective
manufacturer’s quality control and manufacturing procedures adhere to the FDA’s or other competent
authorities’ current GMP. Before approval of an NDA or equivalent foreign approval, the FDA or
other competent authority may perform a pre-approval inspection of a manufacturing facility to
determine its compliance with GMP and other rules and regulations. In complying with GMP,
manufacturers must continue to expend time, money and effort in the area of production and quality
control to ensure full technical compliance. Similarly, NDA or equivalent foreign approval may be
delayed or denied due to GMP non-compliance or other issues at contract sites or suppliers included
in the NDA or equivalent foreign approval, and the correction of these shortcomings may be beyond
our control. Facilities are also subjected to the requirements of other government bodies, such as
the U.S. Occupational Safety & Health Administration and the U.S. Environmental Protection Agency.

If, after receiving clearance from regulatory agencies or competent authorities, a company makes
certain changes in manufacturing equipment, location, or process, additional regulatory review and
approval may be required. Our third-party suppliers must adhere to GMP and product-specific
regulations enforced by the FDA or other competent authorities following product approval. The FDA,
the European Union and other national competent authorities and regulatory agencies also conduct
regular, periodic visits to re-inspect equipment, facilities and processes following the initial
approval of a product. If, as a result of these inspections, it is determined that our suppliers’
equipment, facilities or processes do not comply with applicable regulations and conditions of
product approval, regulatory agencies may seek civil, criminal or administrative sanctions and/or
remedies against them, including the suspension of manufacturing operations.

Good Clinical Practices

The FDA, the EMA and other competent authorities promulgate regulations and standards, commonly
referred to as GCP, for designing, conducting, monitoring, auditing and reporting the results of
clinical trials to ensure that the data and results are accurate and that the trial participants
are adequately protected. The FDA, the European Union and other foreign national competent
authorities and regulatory agencies enforce GCP through periodic inspections of trial sponsors,
principal investigators and trial sites. We rely on third-party service providers to conduct our
clinical trials. If our study sites fail to comply with applicable GCP, the clinical data generated
in our clinical trials may be deemed

-30-

 

unreliable and relevant regulatory agencies may require us to perform additional clinical trials
before approving our marketing applications.

Good Laboratory Practices

The FDA and other regulatory authorities promulgate regulations and standards, commonly referred to
as Good Laboratory Practices, or GLP, for the conduct of non-clinical, commonly referred to as
“preclinical,” non-human studies to provide a framework within which laboratory studies are
planned, performed, monitored, recorded, reported and archived. Compliance with GLP is intended to
assure regulatory authorities of the quality and integrity of the results obtained during the
preclinical studies. Before we may test our product candidates on humans in clinical trials, we
must first conduct preclinical testing, including animal studies, in accordance with GLP. The FDA
or other regulatory authorities may inspect the testing facilities where our pre-clinical studies
are conducted. The results of preclinical studies in the United States, Europe or other countries,
not conducted in accordance with GLP, might be inadmissible in support of an NDA in the United
States, or comparable applications in other countries.

United States Sales and Marketing

Our commercial partner, EMD Serono, will be subject to various United States regulations relating
to the sales and marketing of EGRIFTATM in the United States. The FDA regulates all
advertising and promotion activities for products under its jurisdiction both prior to and after
approval. A company can make only those claims relating to safety and efficacy that are approved by
the FDA. Drugs may be promoted only for the approved indications and in accordance with the
provisions of the approved label. The FDA actively enforces the laws and regulations prohibiting
the promotion of off-label uses, and a company that is found to have improperly promoted off-label
uses may be subject to significant sanctions. The FDA does not regulate the practice of medicine by
physicians in their choice of treatment, but FDA regulations do impose stringent restrictions on
manufacturers’ communications regarding off-label uses. Failure to comply with applicable FDA
requirements may subject a company to adverse publicity, enforcement action by the FDA, corrective
advertising, and the full range of civil and criminal penalties available to the FDA.

Marketing of EGRIFTATM within the United States is also subject to various federal and
state laws pertaining to health care “fraud and abuse,” including anti-kickback laws and false
claims laws. Anti-kickback laws make it illegal for a prescription drug manufacturer to solicit,
offer, receive, or pay any remuneration in exchange for, or to induce, the referral of business,
including the purchase or prescription of a particular drug. Due to the breadth of the statutory
provisions and the absence of guidance in the form of regulations and very few court decisions
addressing industry practices, it is possible that our commercial partners’ practices might be
challenged under anti-kickback or similar laws. False claims laws prohibit anyone from knowingly
and willingly presenting, or causing to be presented for payment to third-party payors (including
Medicare and Medicaid) claims for reimbursed drugs or services that are false or fraudulent.

In addition, several states require that companies implement compliance programs or comply with
industry ethics codes, adopt spending limits, and report to state governments any gifts,
compensation, and other remuneration provided to physicians. The recently enacted health care
reform legislation will require record-keeping and disclosure to the federal government of payments
to physicians commencing in 2012. Any activities relating to the sale and marketing of our products
may be subject to scrutiny under these laws. Violations of fraud and abuse laws may be punishable
by criminal and/or civil sanctions, including fines and civil monetary penalties, as well as the
possibility of exclusion from federal health care programs (including Medicare and Medicaid). If
the government were to allege or convict our commercial partner of violating these laws, our
business could be harmed. In addition, there is ability for private individuals to bring similar
actions.

-31-

 

Further, there are an increasing number of state laws that require manufacturers to make reports to
states on pricing and marketing information. Our activities could be subject to challenge for the
reasons discussed above and due to the broad scope of these laws and the increasing attention being
given to them by law enforcement authorities.

2.10 PHARMACEUTICAL PRICING AND REIMBURSEMENT

In the United States and in other countries, sales of EGRIFTATM and our other product
candidates will depend in part on the availability of reimbursement from third-party payors.
Third-party payors include government health administrative authorities (such as the Centers for
Medicare & Medicaid Services in the United States), managed care providers, private health insurers
and other organizations. We believe EGRIFTATM will achieve a high degree of physician
and payor acceptance, driven by our product’s safety and efficacy, the lack of approved alternative
therapies for these patients and the prominent medical and social need to treat HIV/AIDS patients.

However, these third-party payors are increasingly challenging the price and examining the
cost-effectiveness of medical products and services. In addition, significant uncertainty exists as
to the reimbursement status of newly approved healthcare product candidates. We, or our commercial
partners, may need to conduct expensive pharmacoeconomic studies in order to demonstrate the
cost-effectiveness of EGRIFTATM or our other product candidates. EGRIFTATM or
our other product candidates may not be considered cost-effective. It is time consuming and
expensive for us, and our commercial partners, to seek reimbursement from third-party payors.
Reimbursement may not be available or sufficient to allow us to sell EGRIFTATM or our
other product candidates on a competitive and profitable basis.

United States

Pursuant to our agreement with EMD Serono, they are responsible for identifying and obtaining
possible reimbursements under such government programs in the United States. The U.S. Congress and
state legislatures from time to time propose and adopt initiatives aimed at cost containment, which
could impact our ability to sell our products profitably. For example, in March 2010, President
Obama signed into law the Patient Protection and Affordable Care Act, and the associated
reconciliation bill, which we refer to collectively as the Health Care Reform Law, a sweeping law
intended to broaden access to health insurance, reduce or constrain the growth of healthcare
spending, enhance remedies against fraud and abuse, add new transparency requirements for
healthcare and health insurance industries, impose new taxes and fees on the health industry and
impose additional health policy reforms. Effective October 1, 2010, the Health Care Reform Law
revises the definition of “average manufacturer price” for reporting purposes, which could increase
the amount of Medicaid drug rebates to states once the provision is effective. Further, beginning
in 2011, the new law imposes a significant annual fee on companies that manufacture or import
certain branded prescription drug products and biologic agents. Substantial new provisions
affecting compliance also have been enacted, which may require us, or EMD Serono, to modify our
business practices with healthcare practitioners. We will not know the full effects of the Health
Care Reform Law until applicable federal and state agencies issue regulations or guidance under the
new law. Although it is too early to determine the effect of the Health Care Reform Law, the new
law appears likely to continue the pressure on pharmaceutical pricing, especially under the
Medicare program, and also may increase our regulatory burdens and operating costs.

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or MMA, imposed new
requirements for the distribution and pricing of prescription drugs for Medicare beneficiaries, and
included a major expansion of the prescription drug benefit under a new Medicare Part D. Medicare
Part D went into effect on January 1, 2006. Under Part D, Medicare beneficiaries may enroll in
prescription drug plans offered by private entities which will provide coverage of outpatient

-32-

 

prescription drugs. Part D plans include both stand-alone prescription drug benefit plans and
prescription drug coverage as a supplement to Medicare Advantage plans. Unlike Medicare Part A and
B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required to
pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that
identifies which drugs it will cover and at what tier or level. However, Part D prescription drug
formularies must include drugs within each therapeutic category and class of covered Part D drugs,
though not necessarily all the drugs in each category or class. Any formulary used by a Part D
prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee.

It is not clear what effect the MMA will have on the prices paid for EGRIFTATM and our
other product candidates. Some studies indicate that Part D lowered the average price and increased
the utilization of prescription drugs by Medicare beneficiaries. Government payment for some of the
costs of prescription drugs may increase demand for products for which we receive marketing
approval. However, any negotiated prices for our products covered by a Part D prescription drug
plan will likely be lower than the prices we might otherwise obtain. Moreover, while the MMA
applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare
coverage policy and payment limitations in setting their own payment rates. Any reduction in
payment that results from the MMA may result in a similar reduction in payments from
non-governmental payors.

There are also laws that govern a company’s eligibility to participate in Medicare and Medicaid
reimbursements. For example, a company may be debarred from participation if it is found to have
violated federal anti-kickback laws, which could have a significant effect on a company’s ability
to operate its business.

The cost of pharmaceuticals continues to generate substantial governmental and third-party payor
interest. We expect that the pharmaceutical industry will experience pricing pressures due to the
trend toward managed healthcare, the increasing influence of managed care organizations, and
additional legislative proposals. Indeed, we expect that there will continue to be a number of U.S.
federal and state proposals to implement governmental pricing controls and limit the growth of
healthcare costs, including the cost of prescription drugs. At the present time, Medicare is
prohibited from negotiating directly with pharmaceutical companies for drugs. However, the U.S.
Congress is considering passing legislation that would lift the ban on federal negotiations. While
we cannot predict whether such legislative or regulatory proposals will be adopted, the adoption of
such proposals could harm our business, financial condition and results of operations.

Some third-party payors also require pre-approval of coverage for new or innovative drug therapies
before they will reimburse healthcare providers that use such therapies. While we cannot predict
whether any proposed cost-containment measures will be adopted or otherwise implemented in the
future, the announcement or adoption of these proposals could have a material adverse effect on our
ability to obtain adequate prices for our product candidates and operate profitably.

Europe and other countries covered by our agreements

Outside of the United States, sales of EGRIFTATM and our other product candidates will
depend in part on the availability and level of reimbursement from third-party payers. Third-party
payers can be public or private or a combination of both. In order to obtain public reimbursement,
prescription drugs are often evaluated by specialized bodies in a country. This process is in many
cases independent of marketing approval and the time to carry out the evaluation differs in each
country, often extending beyond the initial regulatory approval date of the drug.

The requirements and aspects considered during the assessment of a new prescription drug are not
necessarily the same in each country and are given different weight depending on the countries’
attitudes towards providing public healthcare and the government’s willingness to pay for these new

-33-

 

drugs. We or our commercial partners could be required to conduct specific health economic and
other studies or analyses in order to satisfy such requirements. The decision to comply with such
requirements will depend on the prospects of obtaining a positive opinion and the costs involved in
the process and the profitability of the market.

In many jurisdictions, pricing plays an important role in the evaluation of prescription drugs for
reimbursement and in most cases, there are price controls that can include, but are not limited to,
reference pricing to drugs sold within the country and in other countries, the evaluation of what a
fair price would be based on the condition that is being treated and innovative quality of the new
drug.

Many countries, particularly in Europe, have initiated cost-cutting measures which have been
reflected in reduced budgets for drugs, higher discounts imposed on manufacturers and price
negotiations between authorities and manufacturers among other actions. We expect the current
reimbursement evaluation process and pricing policies to keep evolving in ways that we may not
foresee.

In Latin America, Brazil has a formal price procedure through Agência Nacional de Vigilância
Sanitoria (ANVISA) which determines the price of a pharmaceutical based on five reference
countries, including the United States. However, there is uncertainty in pricing of pharmaceutical
drugs in Latin America in general.

Pursuant to our agreements with Sanofi and Ferrer, each is responsible for identifying and
obtaining possible reimbursements under such government programs in their respective territories.

2.11 EMPLOYEES

As at November 30, 2010, we had 99 employees, all of whom were employed in Canada. All of our
employees are engaged in administration, finance, research and development, regulatory and business
development functions. None of our employees are unionized. We believe the relations with our
employees are good.

2.12 FACILITIES

We carry out our activities at 2310 Alfred-Nobel Boulevard in the Technoparc Montréal in Ville
Saint-Laurent, Québec, Canada. We lease a 36,400 square-foot building, which houses both offices
and laboratories which enable us to conduct small-scale peptide manufacturing, discovery and manage
preclinical and clinical research.

The facilities contain laboratories which enable us to conduct small-scale peptide manufacturing,
discovery and preclinical research. Peptide compounds are synthesized by our pharmaceutical
development department using manual and semiautomatic methods with reactors of different sizes
(from 50 to 8000 ml) and also a 12-channel automated peptide synthesizer. The peptides are purified
using preparative high performance liquid chromatography, or HPLC, comprising either the Dynamic
Axial Compression column, or a number of pre-packed columns. The final peptides are dried to a
solid form using lyophilization equipment. The analyses on the quality of the peptides are done
using a variety of equipment including HPLC instruments Agilent 1100 and 1200, UV
spectrophotometers and a water content analyzer.

We also have discovery and preclinical research laboratories which include two cell culture rooms
and several chemical hoods. A Mesoscale chemiluminometer (Sector PR100) is used for sensitive
immunological and cell-based assays. Several HPLC instruments for preformulation and purity
determinations, scintillation spectrophotometers for radioactivity measurements, and
fluorospectrophotometers and colorimetric plate readers for cell-based screens and immunoassays

-34-

 

enable in-house discovery and preclinical research. A designated laboratory section is equipped to
conduct studies according to GLP.

2.13 ENVIRONMENT

To our
knowledge, at our current development stage, environmental protection requirements do not
have a significant financial or operational impact on our capital expenditures, income or
competitive position within the normal course of our operating activities.

-35-

 

ITEM 3 RISK FACTORS

Before you invest in our common shares, you should understand the high degree of risk involved. You
should consider carefully the following risks and uncertainties described below before you decide
to purchase our common shares. The following risks may adversely impact our business, financial
condition, operating results and prospects. Additional risks and uncertainties, including those
that we do not know about or that we currently believe are immaterial, may also adversely affect
our business, financial condition, operating results or prospects. As a result, the trading price
of our common shares could decline and you could lose all or part of your investment.

3.1 RISKS RELATED TO THE COMMERCIALIZATION OF OUR PRODUCT AND PRODUCT CANDIDATES

          Our commercial success depends largely on the commercialization of EGRIFTATM; the
failure of EGRIFTATM to obtain commercial acceptance would have a material adverse
effect on us.

Our ability to generate revenues in the future is primarily based on the commercialization of
EGRIFTATM for the reduction of excess abdominal fat in HIV-infected patients with
lipodystrophy. In the short-term, these revenues should be primarily derived from the U.S. market
alone. Although we have entered into a collaboration and licensing agreement with EMD Serono for
the commercialization of EGRIFTATM in the United States, there can be no assurance that
EGRIFTATM will be successfully commercialized in the United States, or in any other
country. Although we are developing other peptides, all of them are at earlier stages of
development and none of them may reach the clinical trial phase, obtain regulatory approval or,
even if approved, be successfully commercialized.

The overall commercialization success of EGRIFTATM for the reduction of excess abdominal
fat in HIV-infected patients with lipodystrophy will depend on several factors, including:

	 	•	 	receipt of regulatory approvals for EGRIFTATM from regulatory agencies in the
territories other than the United States in which we wish to expand the commercialization
of tesamorelin;
	 
	 	•	 	market acceptance of EGRIFTATM by the medical community, patients and
third-party payors (such as governmental health administration authorities and private
health coverage insurers);
	 
	 	•	 	the amount of resources devoted by our commercial partners to commercialize
EGRIFTATM in their respective territories;
	 
	 	•	 	maintaining manufacturing and supply agreements to ensure the availability of commercial
quantities of EGRIFTATM through validated processes;
	 
	 	•	 	the number of competitors in our market; and
	 
	 	•	 	protecting and enforcing our intellectual property and avoiding patent infringement
claims.

The inability to successfully commercialize EGRIFTATM in the United States for the
reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in the short term
would delay our capacity to generate revenues and would have a material adverse effect on our
financial condition and operating results.

-36-

 

          We are or will be dependent on a limited number of collaboration and licensing agreements for
the commercialization of EGRIFTATM in the United States, Europe, Latin America, Africa
and the Middle East. These agreements place the commercialization of EGRIFTATM in these
markets outside of our control.

Although our collaboration and licensing agreements with EMD Serono, Sanofi and Ferrer contain
provisions governing their respective responsibilities as partners for the commercialization of
EGRIFTATM in their respective territories, our dependence on these partners to
commercialize EGRIFTATM is subject to a number of risks, including:

	 	•	 	our limited control of the amount and timing of resources that our commercial partners
will be devoting to the commercialization, marketing and distribution of tesamorelin,
including obtaining patient reimbursement for EGRIFTATM, which could adversely
affect our ability to obtain or maximize our royalty payments;
	 
	 	•	 	disputes or litigation that may arise between us and our commercial partners, which
could adversely affect the commercialization of tesamorelin, all of which would divert our
management’s attention and our resources;
	 
	 	•	 	our commercial partners not properly defending our intellectual property rights or using
them in such a way as to expose us to potential litigation, which could, in both cases,
adversely affect the value of our intellectual property rights; and
	 
	 	•	 	corporate reorganizations or changes in business strategies of our commercial partners,
which could adversely affect a commercial partner’s willingness or ability to fulfill its
obligations under its respective agreement.

Our collaboration and licensing agreements may be terminated by our partners in the event of a
breach by us of our obligations under such agreements, including our obligation to supply
EGRIFTATM, for which we rely on third parties. Our collaboration and licensing agreement
with EMD Serono can also be terminated by EMD Serono for their convenience on 180 days notice to
us. Such a termination could have an adverse effect on our revenues related to the
commercialization of EGRIFTATM in the United States. In addition, EMD Serono has listed
a patent held by one of its affiliates in the Orange Book under the Hatch-Waxman Act with respect
to EGRIFTATM in HIV-associated lipodystrophy. In the event of a termination of our
agreement with EMD Serono, EMD Serono could assert that such patent would be infringed by our
continued sale of EGRIFTATM in the United States. Any such assertion would divert our
management’s attention and, if successful, could expose us to damages or require us to obtain a
license from EMD Serono in order to continue selling EGRIFTATM in the United States, all
of which could have a material adverse effect on our results of operations, cash flows and
financial conditions.

If any one of our commercial partners terminates their agreement with us or fails to effectively
commercialize EGRIFTATM, for any of the foregoing or other reasons, we may not be able
to replace the commercial partner and any of these events would have a material adverse effect on
our business, results of operations and our ability to achieve future profitability, and could
cause our share price to decline.

          We rely on third parties for the manufacture and supply of EGRIFTATM and
tesamorelin and such reliance may adversely affect us if the third parties are unable or unwilling
to fulfill their obligations.

The manufacture of pharmaceutical products requires significant expertise and capital investment,
including the development of advanced manufacturing techniques and process controls. We do not

-37-

 

own or operate manufacturing facilities for the production of tesamorelin or any of our other
product candidates, nor do we have plans to develop our own manufacturing operations in the
foreseeable future. We currently rely on third parties to manufacture and supply all of our
required raw materials, drug substance and drug product for our preclinical research, clinical
trials and commercial sales. For tesamorelin for clinical studies and EGRIFTATM for
commercial sales, we are currently using, and relying on, single suppliers and single manufacturers
for starting materials and the final drug substance. Although potential alternative suppliers and
manufacturers have been identified, we have not qualified these vendors to date and no assurance
can be given that such suppliers will be qualified in the future or receive necessary regulatory
approval.

Our reliance on third-party manufacturers exposes us to a number of risks. We may be subject to
delays in or suspension of the manufacturing of EGRIFTATM and tesamorelin if a
third-party manufacturer:

	 	•	 	becomes unavailable to us for any reason, including as a result of the failure to comply
with GMP regulations;
	 
	 	•	 	experiences manufacturing problems or other operational failures, such as equipment
failures or unplanned facility shutdowns required to comply with GMP or damage from any
event, including fire, flood, earthquake, business restructuring or insolvency; or
	 
	 	•	 	fails to perform its contractual obligations under our agreement, such as failing to
deliver the quantities requested on a timely basis.

Any delay in or suspension of the supply of EGRIFTATM could delay or prevent the sale of
EGRIFTATM and, accordingly, adversely affect our revenues and results of operations. In
addition, any manufacturing delay or delay in delivering EGRIFTATM may result in our
being in default under our collaboration agreements. If the damage to a supplier’s manufacturer
facility is extensive, or, for any reason, it does not operate in compliance with GMP or the
third-party manufacturer is unable or refuses to perform its obligations under our agreement, we
would need to find an alternative third-party manufacturer. The selection of a replacement
third-party manufacturer would be time-consuming and costly since we would need to validate the
manufacturing facility of such new third-party manufacturer. The validation process would include
an assessment of the capacity of such third-party manufacturer to produce the quantities that we
may request from time to time, the manufacturing process and its compliance with GMP. In addition,
the third-party manufacturer would have to familiarize itself with our technology. Any delay in
finding an alternative third-party manufacturer of tesamorelin and EGRIFTATM could
result in a shortage of such analogue or product, which could materially adversely affect our
business and results of operations.

Any delay in or suspension of the supply of tesamorelin could delay or interrupt the conduct of
clinical trials of our new clinical programs relating to muscle wasting in COPD.

          Even though we have received regulatory approval for EGRIFTATM in the United
States, we still may not be able to successfully commercialize it if we do not gain market
acceptance and the revenue that we generate from its sales, if any, may be limited.

The commercial success of EGRIFTATM or any future products for which we obtain marketing
approval from the FDA or other regulatory authorities, will depend upon the acceptance of such
product by the medical community, including physicians, patients and health care payors. The degree
of market acceptance of any of our products will depend on a number of factors, including:

	 	•	 	acceptance of the product by physicians and patients as safe and effective treatments
and addressing a significant unmet medical need;

-38-

 

	 	•	 	product price;
	 
	 	•	 	the effectiveness of our sales and marketing efforts (or those of our commercial
partners);
	 
	 	•	 	storage requirements and ease of administration;
	 
	 	•	 	dosing regimen;
	 
	 	•	 	safety and efficacy;
	 
	 	•	 	prevalence and severity of side effects;
	 
	 	•	 	competitive products;
	 
	 	•	 	the ability to obtain and maintain sufficient third-party coverage or reimbursement from
government health care programs, including Medicare and Medicaid, private health insurers
and other third-party payors; and
	 
	 	•	 	the willingness and ability of patients to pay out-of-pocket in the absence of
third-party coverage.

If EGRIFTATM does not achieve an adequate level of acceptance by physicians, health care
payors and patients, we may not generate sufficient revenue from this product, and we may not be
able to achieve profitability. Our efforts, and the efforts of our commercial partners, to educate
the medical community and third-party payors on the benefits of tesamorelin may require significant
resources and may never be successful.

          We have no internal sales, marketing or distribution capabilities so we must rely on strategic
alliance agreements with third parties for the sale and marketing of EGRIFTATM or any
future products.

We currently have no internal sales, marketing or distribution capabilities and we rely on our
commercial partners to market and sell EGRIFTATM in their respective territories. Our
agreements with our commercial partners contain termination provisions which, if exercised, could
delay or suspend the commercialization of EGRIFTATM or any future products.

In the event of any such termination, in order to continue commercialization, we would be required
to build our own sales force or enter into agreements with third parties to provide such
capabilities. We currently have limited marketing capabilities and we have limited experience in
developing, training or managing a sales force. The development of a sales force would be costly
and would be time-consuming given the limited experience we have in this area. To the extent we
develop a sales force, we could be competing against companies that have more experience in
managing a sales force than we have and that have access to more funds than we with which to manage
a sales force. Consequently, there can be no assurance that a sales force which we develop would be
efficient and would maximize the revenues derived from the sale of EGRIFTATM or any
future products.

          We are substantially dependent on revenues from EGRIFTATM.

Our current and future revenues depend substantially upon sales of EGRIFTATM by our
commercial partners, EMD Serono, Sanofi and Ferrer. Any negative developments relating to this
product, such as safety or efficacy issues, the introduction or greater acceptance of competing
products, including those marketed and sold by our commercial partners, or adverse regulatory or
legislative developments, would have a material adverse effect on our business, prospects and
results of

-39-

 

operations. Although we continue to develop additional product candidates for commercialization, we
expect to be substantially dependent on sales from EGRIFTATM for the foreseeable future.
A decline in sales from this product would have a material adverse affect on our business and
financial condition.

          Our levels of revenues are highly dependent on obtaining patient reimbursement for
EGRIFTATM.

Market acceptance and sales of EGRIFTATM will substantially depend on the availability
of reimbursement from third party payors such as governmental authorities, including U.S. Medicare
and Medicaid, managed care providers, and private insurance plans and may be affected by healthcare
reform measures in the United States and elsewhere. Government authorities and third-party payors,
such as private health insurers and health maintenance organizations, decide which medications they
will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry
and elsewhere is cost containment. Government authorities and these third-party payors have
attempted to control costs by limiting coverage and the amount of reimbursement for particular
medications. Increasingly, third-party payors have been challenging the prices charged for
products.

Under our agreements with our commercial partners, they are responsible for seeking reimbursement
of EGRIFTATM in their respective territories and as a result we have no control over
whether or what level of reimbursement is achieved.

We cannot be sure that reimbursement by insurers, government or other third parties will be
available for EGRIFTATM and, if reimbursement is available, the level of reimbursement
provided to patients. Reimbursement may impact the demand for, or the price of,
EGRIFTATM and our future products for which we obtain marketing approval. If
reimbursement is not available or is available only in limited amount, our commercial partners may
not be able to successfully commercialize EGRIFTATM or our future products and it will
have a material adverse effect on our revenues and royalties, business and prospects.

          A variety of risks associated with our international business relationships could materially
adversely affect our business.

International business relationships in the United States, Europe, Latin America, Africa, the
Middle East and elsewhere subject us to additional risks, including:

	 	•	 	differing regulatory requirements for drug approvals in foreign countries;
	 
	 	•	 	potentially reduced protection for intellectual property rights;
	 
	 	•	 	potential third-party patent rights in foreign countries;
	 
	 	•	 	the potential for so-called parallel importing, which is what happens when a local
seller, faced with high or higher local prices, opts to import goods from a foreign market,
with low or lower prices, rather than buying them locally;
	 
	 	•	 	unexpected changes in tariffs, trade barriers and regulatory requirements;
	 
	 	•	 	economic weakness, including inflation, or political instability, particularly in
foreign economies and markets;
	 
	 	•	 	compliance with tax, employment, immigration and labour laws for employees traveling
abroad;

-40-

 

	 	•	 	foreign taxes;
	 
	 	•	 	foreign exchange contracts and foreign currency fluctuations, which could result in
increased operating expenses and reduced revenue, and other obligations incident to doing
business in another country;
	 
	 	•	 	workforce uncertainty in countries where labour unrest is more common than in the United
States and Canada;
	 
	 	•	 	production shortages resulting from any events affecting raw material supply or
manufacturing capabilities abroad; and
	 
	 	•	 	business interruptions resulting from geo-political actions, including war and
terrorism, or natural disasters, including earthquakes, volcanoes, typhoons, floods,
hurricanes and fires.

These and other risks of international business relationships may materially adversely affect our
business, prospects, results of operations and financial condition.

          Governments outside the United States tend to impose strict price controls, which may
adversely affect our revenues, if any.

In several countries, including countries which are in Europe, Latin America, Africa, and the
Middle East, the pricing of prescription drugs may be subject to governmental control. In these
countries, pricing negotiations with governmental authorities can take considerable time and delay
the marketing of a product. To obtain reimbursement or pricing approval in some countries, a
clinical trial that compares the cost-effectiveness of a product candidate to other available
therapies may be required. If reimbursement of our product is unavailable or limited in scope or
amount, or if pricing is set at unsatisfactory levels, our commercial partners may not be willing
to devote resources to market and commercialize EGRIFTATM or may decide to cease
marketing such product. In such case, our business, prospects and results of operations could be
materially adversely affected.

          We face competition and the development of new products by other companies could materially
adversely affect our business and products.

The biopharmaceutical and pharmaceutical industries are highly competitive and we must compete with
pharmaceutical companies, biotechnology companies, academic and research institutions as well as
governmental agencies for the development and commercialization of products, most of which have
substantially greater financial, technical and personnel resources than us. Although we believe
that we have no direct competitors for the reduction of excess abdominal fat in HIV-infected
patients with lipodystrophy, we could face indirect competition from other companies developing
and/or commercializing metabolic products and/or other products that reduce or eliminate the
occurrence of lipodystrophy.

In the other clinical programs that we are currently evaluating for development, there may exist
companies that are at a more advanced stage of developing a product to treat the diseases for which
we are evaluating clinical programs. Some of these competitors could have access to capital
resources, research and development personnel and facilities that are superior to ours. In
addition, some of these competitors could be more experienced than we are in the development and
commercialization of medical products and already have a sales force in place to launch new
products. Consequently, they may be able to develop alternative forms of medical treatment which
could compete with our products and which could be commercialized more rapidly and effectively than
our products.

-41-

 

          If we fail to comply with government regulations regarding the import and export of products
and raw materials, we could be subject to fines, sanctions and penalties that could adversely
affect our ability to operate our business.

We import and export products and raw materials from and to several jurisdictions around the world.
This process requires us and our commercial partners to operate in a number of jurisdictions with
different customs and import/export regulations. The regulations of these countries are subject to
change from time to time and we cannot predict the nature, scope or impact of these changes upon
our operations. We and our commercial partners are subject to periodic reviews and audits by U.S.
and foreign authorities responsible for administering these regulations. To the extent that we or
our commercial partners are unable to successfully defend against an audit or review, we may be
required to pay assessments, penalties and increased duties, which may, individually or in the
aggregate, negatively impact our business, operating results and financial condition.

3.2 RISKS RELATED TO THE REGULATORY REVIEW PROCESS

          Even after regulatory approval has been obtained regulatory agencies may impose limitations on
the indicated uses for which our products may be marketed, subsequently withdraw approval or take
other actions against us that would be adverse to our business.

Even though we have obtained marketing approval of EGRIFTATM in the United States, the
FDA and regulatory agencies in other countries have the ability to limit the indicated use of a
product. Also, the manufacture, marketing and sale of our products will be subject to ongoing and
extensive governmental regulation in the country in which we intend to market our products. For
example, although we obtained marketing approval of EGRIFTATM for the reduction of
excess abdominal fat in HIV-infected patients with lipodystrophy in the United States, the
marketing of EGRIFTATM will be subject to extensive regulatory requirements administered
by the FDA, such as adverse event reporting and compliance with marketing and promotional
requirements. The FDA has also requested that we comply with certain post-approval requirements in
connection with the approval of EGRIFTATM for the reduction of excess abdominal fat in
HIV-infected patients with lipodystrophy, namely, the development of a single vial formulation of
EGRIFTATM (the development of a new presentation of the same formulation), a long-term
observational safety study using EGRIFTATM; and a Phase 4 clinical trial. Although we
have received marketing approval from the FDA of tesamorelin for the reduction of excess abdominal
fat in HIV-infected patients with lipodystrophy, there can be no guarantee that regulatory agencies
in other countries will approve tesamorelin for this treatment in their respective countries.

Our third party manufacturing facilities for EGRIFTATM will also be subject to
continuous reviews and periodic inspections and approval of manufacturing modifications by
regulatory agencies, including the FDA. The facilities must comply with GMP regulations. The
failure to comply with FDA requirements can result in a series of administrative or judicial
sanctions or other setbacks, including:

	 	•	 	restrictions on the use of the product, manufacturers or manufacturing processes;
	 
	 	•	 	warning letters;
	 
	 	•	 	civil or criminal penalties;
	 
	 	•	 	fines;
	 
	 	•	 	injunctions;
	 
	 	•	 	product seizures or detentions;

-42-

 

	 	•	 	import or export bans or restrictions;
	 
	 	•	 	product recalls and related publicity requirements;
	 
	 	•	 	suspension or withdrawal of regulatory approvals;
	 
	 	•	 	total or partial suspension of production; and
	 
	 	•	 	refusal to approve pending applications for marketing approval of new product candidates
or supplements to approved applications.

Addressing any of the foregoing or any additional requirements of the FDA or other regulatory
authorities may require significant resources and could impair our ability to successfully
commercialize our product candidates.

          To date, we do not have the required regulatory approvals to commercialize
EGRIFTATM outside of the United States and cannot guarantee that we will obtain such
regulatory approvals or that any of our product candidates will be approved for commercialization
in any country, including the United States.

The commercialization of EGRIFTATM outside of the United States and our future products
first requires the approval of the regulatory agencies in each of the jurisdictions where we intend
to sell such products. In order to obtain the required approvals, we must demonstrate, following
preclinical and clinical studies, the safety, efficacy and quality of a product.

The rules and regulations relating to the approval of a new drug are complex and stringent.
Although we have received marketing approval in the United States from the FDA for
EGRIFTATM, there can be no guarantee that regulatory agencies in other territories will
approve EGRIFTATM in their respective countries.

All of our product candidates are subject to preclinical and clinical studies. If the results of
such studies are not positive, we may not be in a position to make any filing to obtain the
regulatory approval for the product candidate or, even where a product candidate has been filed for
approval, we may have to conduct additional clinical trials or testing on such product candidate in
an effort to obtain results that further support the safety and efficacy of such product candidate.
Such studies are often costly and may also delay a filing or, where additional studies or testing
are required after a filing has been made, the approval of a product candidate.

While an application for a new drug is under review by a regulatory agency, it is standard for such
regulatory agency to ask questions regarding the application that was submitted. If these questions
are not answered quickly and in a satisfactory manner, the marketing approval of the product
candidate subject to the review and its commercialization could be delayed or, if the questions are
not answered in a satisfactory manner, denied. If EGRIFTATM is not approved by the
appropriate regulatory agencies for commercialization outside of the United States, our capacity to
generate revenues in the long-term will be impaired and this will have an adverse effect on our
financial condition and our operating results.

Obtaining regulatory approval is subject to the discretion of regulatory agencies in each relevant
jurisdiction. Therefore, even if we obtain regulatory approval from one agency, or succeed in
filing the equivalent of an NDA, in other countries, or have obtained positive results relating to
the safety and efficacy of a product candidate, a regulatory agency may not accept the filing or
the results contained therein as being conclusive evidence of the safety and efficacy of a product
candidate in order to allow us to sell the product candidate in its country. A regulatory agency
may require that additional

-43-

 

tests on the safety and efficacy of a product candidate be conducted prior to granting approval of
such product candidate. These additional tests may delay the approval of such product candidate,
can have a material adverse effect on our financial condition and results of operations based on
the type of additional tests to be conducted and may not necessarily lead to the approval of the
product candidate.

          We have only obtained FDA approval for EGRIFTATM and we must complete several
preclinical studies and clinical trials for our other product candidates which may not yield
positive results and, consequently, could prevent us from obtaining regulatory approval.

Obtaining FDA approval for the commercialization of drug products requires a demonstration through
preclinical studies and clinical trials that the drug is safe and effective. All of our product
candidates are at the discovery stage, except our peptide for the treatment of AKI, which is in
preclinical development. In addition, in order to market tesamorelin for other indications, we will
need to demonstrate its effectiveness and safety through additional studies and clinical trials.
Favourable results in our trials of tesamorelin for the reduction of excess abdominal fat in
HIV-infected patients with lipodystrophy may not be predictive of the efficacy and safety results
in our Phase 2 clinical trials of tesamorelin for the treatment of muscle wasting in COPD.

If any of our preclinical studies or clinical trials fail to show positive efficacy data or result
in adverse patient reactions, we may be required to perform additional preclinical studies or
clinical trials, to extend the term of our studies and trials, to increase the number of patients
enrolled in a given trial or to undertake ancillary testing. Any of these events could cause an
increase in the cost of product development, delay filing of an application for marketing approval
or result in the termination of a study or trial and, accordingly, could cause us to cease the
development of a product candidate. In addition, the future growth of our business could be
negatively impacted since there can be no guarantee that we will be able to develop new compounds,
license or purchase compounds or product candidates that will result in marketed products.

          Recently enacted and future legislation may increase the difficulty and cost for us to obtain
marketing approval of and commercialize our product candidates and affect the prices we may obtain.

In the United States and some foreign jurisdictions, there have been a number of legislative and
regulatory changes and proposed changes regarding the healthcare system that could prevent or delay
marketing approval for our product candidates, restrict or regulate post-approval activities and
affect our ability to profitably sell EGRIFTATM or any of our other product candidates
for which we intend to seek marketing approval.

Legislative and regulatory proposals have been made to expand post-approval requirements and
restrict sales and promotional activities for pharmaceutical products. We are not sure whether
additional legislative changes will be enacted, or whether the FDA regulations, guidance or
interpretations will be changed, or what the impact of such changes on the marketing approvals of
our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the
FDA’s approval process may significantly delay or prevent marketing approval, as well as subject us
to more stringent product labeling and post-marketing testing and other requirements.

In the United States, the MMA changed the way Medicare covers and pays for pharmaceutical products.
The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new
reimbursement methodology based on average sales prices for drugs. In addition, this legislation
authorized Medicare Part D prescription drug plans to use formularies where they can limit the
number of drugs that will be covered in any therapeutic class. As a result of this legislation and
the expansion of federal coverage of drug products, we expect that there will be additional

-44-

 

pressure to contain and reduce costs. These cost reduction initiatives and other provisions of this
legislation could decrease the coverage and sales price that we receive for EGRIFTATM or
any other approved products and could seriously harm our business. While the MMA applies only to
drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and
payment limitations in setting their own reimbursement rates, and any reduction in reimbursement
that results from the MMA may result in a similar reduction in payments from private payors.

More recently, in March 2010, U.S. President Obama signed into law the Health Care Reform Law, a
sweeping law intended to broaden access to health insurance, reduce or constrain the growth of
healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements
for healthcare and health insurance industries, impose new taxes and fees on the health industry
and impose additional health policy reforms. Effective October 1, 2010, the Health Care Reform Law
revised the definition of “average manufacturer price” for reporting purposes, which could increase
the amount of Medicaid drug rebates to states. Further, beginning in 2011, the new law imposes a
significant annual fee on companies that manufacture or import branded prescription drug products.
We will not know the full effects of the Health Care Reform Law until applicable U.S. federal and
state agencies issue regulations or guidance under the new law. Although it is too early to
determine the effect of the Health Care Reform Law, the new law appears likely to continue to apply
the pressure on pharmaceutical pricing. Pressure on pharmaceutical pricing may adversely affect the
amount of our royalties in the United States.

3.3 RISKS RELATED TO OUR INTELLECTUAL PROPERTY

          Our failure to protect our intellectual property may have a material adverse effect on our
ability to develop and commercialize our products.

We will be able to protect our intellectual property rights from unauthorized use by third parties
only to the extent that our intellectual property rights are covered and protected by valid and
enforceable patents or are effectively maintained as trade secrets. We try to protect our
intellectual property position by, among other things, filing patent applications related to our
proprietary technologies, inventions and improvements that are important to the development of our
business.

Because the patent position of pharmaceutical companies involves complex legal and factual
questions, the issuance, scope, validity, and enforceability of patents cannot be predicted with
certainty. Patents, if issued, may be challenged, invalidated or circumvented. If our patents are
invalidated or found to be unenforceable, we would lose the ability to exclude others from making,
using or selling the inventions claimed. Moreover, an issued patent does not guarantee us the right
to use the patented technology or commercialize a product using that technology. Third parties may
have blocking patents that could be used to prevent us from developing our product candidates,
selling our products or commercializing our patented technology. Thus, patents that we own may not
allow us to exploit the rights conferred by our intellectual property protection.

Our pending patent applications may not be issued or granted as patents. Even if issued, they may
not be issued with claims of sufficient breadth to protect our product candidates and technologies
or may not provide us with a competitive advantage against competitors with similar products or
technologies. Furthermore, others may independently develop products or technologies similar to
those that we have developed or may reverse engineer or discover our trade secrets through proper
means. In addition, the laws of many countries do not protect intellectual property rights to the
same extent as the laws of Canada, the United States and the European Patent Convention, and those
countries may also lack adequate rules and procedures for defending intellectual property rights
effectively.

-45-

 

Although we have received patents from the USPTO for the treatment of HIV-related lipodystrophy
with tesamorelin, there can be no guarantee that, in the other countries where we filed patent
applications for the treatment of HIV-related lipodystrophy, we will receive a patent or obtain
granted claims of similar breadth to those granted by the USPTO.

We also rely on trade secrets, know-how and technology, which are not protected by patents, to
maintain our competitive position. We try to protect this information by entering into
confidentiality agreements with parties who have access to such confidential information, such as
our current and prospective suppliers, distributors, manufacturers, commercial partners, employees
and consultants. Any of these parties may breach the agreements and disclose confidential
information to our competitors. It is possible that a competitor will make use of such
information, and that our competitive position could be disadvantaged.

Enforcing a claim that a third party infringes on, has illegally obtained or is using an
intellectual property right, including a trade secret or know-how, is expensive and time-consuming
and the outcome is unpredictable. In addition, enforcing such a claim could divert management’s
attention from our business. If any intellectual property right were to be infringed, disclosed to
or independently developed by a competitor, our competitive position could be harmed. Any adverse
outcome of such litigation or settlement of such a dispute could subject us to significant
liabilities, could put one or more of our pending patent applications at risk of being invalidated
or interpreted narrowly, could put one or more of our patents at risk of not issuing, or could
facilitate the entry of generic products. Any such litigation could also divert our research,
technical and management personnel from their normal responsibilities.

Our ability to defend ourselves against infringement by third parties of our intellectual property
in the United States with respect to tesamorelin for the treatment of HIV-related lipodystrophy
depends, in part, on our commercial partner’s decision to bring an action against such third party.
Under the terms and conditions of our collaboration and licensing agreement with EMD Serono, EMD
Serono has the first right to bring an action against a third party for infringing our patent
rights with respect to tesamorelin for the treatment of HIV-related lipodystrophy. Any delay in
pursuing such action or in advising us that it does not intend to pursue the matter could decrease
sales, if any, of tesamorelin for the treatment of HIV-related lipodystrophy and adversely affect
our revenues.

Furthermore, because of the substantial amount of discovery required in connection with
intellectual property litigation, there is a risk that some of our confidential information could
be compromised by disclosure during this type of litigation. For example, confidential information
may be disclosed, inadvertently or as ordered by the court, in the form of documents or testimony
in connection with discovery requests, depositions or trial testimony. This disclosure would
provide our competitors with access to our proprietary information and may harm our competitive
position.

          Our commercial success depends, in part, on our ability not to infringe on third party patents
and other intellectual property rights.

Our capacity to commercialize our product candidates, and more particularly tesamorelin, will
depend, in part, upon our ability to avoid infringing third party patents and other third-party
intellectual property rights. The biopharmaceutical and pharmaceutical industries have produced a
multitude of patents and it is not always easy for participants, including us, to determine which
patents cover various types of products, processes of manufacture or methods of use. The scope and
breadth of patents is subject to interpretation by the courts and such interpretation may vary
depending on the jurisdiction where the claim is filed and the court where such claim is litigated.
The fact that we own patents for tesamorelin and for the treatment of HIV-related lipodystrophy
does not guarantee that we are not infringing one or more third-party patents and there can be no
guarantee that we will not infringe or

-46-

 

violate third-party patents and other third-party intellectual property rights in the United States
or other jurisdictions.

Patent analysis for non-infringement is based in part on a review of publicly available databases.
Although we review from time to time certain databases to conduct patent searches, we do not have
access to all databases. It is also possible that we will not have reviewed some of the information
contained in the databases or we found it to be irrelevant at the time we conducted the searches.
In addition, because patents take years to issue, there may be currently pending applications that
have not yet been published or that we are unaware of, which may issue later as patents. As a
result, there can be no guarantee that we will not violate third-party patents.

Because of the difficulty in analyzing and interpreting patents, there can be no guarantee that a
third party will not assert that we infringe such third-party’s patents or any of its other
intellectual property rights. Under such circumstances, there is no guarantee that we would not
become involved in litigation. Litigation with any third party, even if the allegations are without
merit, is expensive, time-consuming and would divert management’s attention from the daily
execution of our business plan. Litigation implies that a portion of our financial assets would be
used to sustain the costs of litigation instead of being allocated to further the development of
our business.

If we are involved in patent infringement litigation, we would need to prevail in demonstrating
that our products do not infringe the asserted patent claims of the relevant patent, that the
patent claims are invalid or that the patent is unenforceable. If we are found to infringe a
third-party patent or other intellectual property right, we could be required to enter into royalty
or licensing agreements on terms and conditions that may not be favourable to us, and/or pay
damages, including up to treble damages in the United Sates (for example, if found liable of wilful
infringement) and/or cease the development and commercialization of our product candidates. Even if
we were able to obtain a license, the rights may be nonexclusive, which could result in our
competitors gaining access to the same intellectual property and to compete with us.

We have not been served with any notice alleging that we infringe a third-party patent, but there
may be issued patents that we are unaware of that our products may infringe, or patents that we
believe we do not infringe but ultimately could be found to infringe. We are aware of third-party
patents for the reduction of accumulation of fat tissue in HIV patients and, if a patent
infringement suit was brought against us, we believe that we should not be found to infringe any
valid claims of these patents. If we were to challenge the validity of a competitor’s issued United
States patent in a United States court, we would need to overcome a statutory presumption of
validity that attaches to every United States patent. This means that, in order to prevail, we
would have to present clear and convincing evidence as to the invalidity of the patent’s claims. We
cannot guarantee that a court would find in our favour on questions of infringement and validity.
Any finding that we infringe or violate a third-party patent or other intellectual property right
could materially adversely affect our business, financial condition and operating results.

3.4 OTHER RISKS RELATED TO OUR BUSINESS

          We have a history of net losses and we may never achieve high profitability.

We have been reporting losses since our inception (except for the financial years ended November
30, 2010, 2001 and 2000) and, as at November 30, 2010, we had an accumulated deficit of
$235,116,000. We do not expect to generate significant recurrent revenues sufficient to cover our
overall activities in the immediate future. As a result of the foregoing, we will need to generate
significant revenues to achieve profitability.

-47-

 

Our profitability will depend on, among other things, our commercial partners’ ability and
willingness to successfully commercialize EGRIFTATM and to obtain regulatory approval
for the use of tesamorelin in the reduction of excess abdominal fat in HIV-infected patients with
lipodystrophy in Europe, Latin America, Africa and the Middle East. However, there is no guarantee
that our commercial partners will succeed in commercializing EGRIFTATM or that our
product candidates will ever receive approval for commercialization in any jurisdiction and,
accordingly, we may never sustain profitability.

          We rely on third-party service providers to conduct our preclinical studies and clinical
trials and the failure by any of these third parties to comply with their obligations may delay the
studies which could have an adverse effect on our development programs.

We have limited human resources to conduct preclinical studies and clinical trials and must rely on
third-party service providers to conduct our studies and trials and carry out certain data
gathering and analyses. If our third-party service providers become unavailable for any reason,
including as a result of the failure to comply with the rules and regulations governing the conduct
of preclinical studies and clinical trials, operational failures such as equipment failures or
unplanned facility shutdowns, or damage from any event such as fire, flood, earthquake, business
restructuring or insolvency or, if they fail to perform their contractual obligations pursuant to
the terms of our agreements with them, such as failing to perform the testing, compute the data or
complete the reports further to the testing, we may incur delays which may be significant in
connection with the planned timing of our trials and studies which could adversely affect the
timing of the development program of a product candidate or the filing of an application for
marketing approval in a jurisdiction where we rely on third-party service providers to make such
filing. In addition, where we rely on such third-party service provider to help in answering any
question raised by a regulatory agency during its review of one of our files, the unavailability of
such third-party service provider may adversely affect the timing of the review of an application
and, could ultimately delay the approval. If the damages to any of our third-party service
providers are material, or, for any reason, such providers do not operate in compliance with GLP or
are unable or refuse to perform their contractual obligations, we would need to find alternative
third-party service providers.

If we needed to change or select new third-party service providers, the planned working schedule
related to preclinical studies and/or clinical trials could be delayed since the number of
competent and reliable third-party service providers of preclinical and clinical work in compliance
with GLP is limited. In addition, if we needed to change or select new third-party service
providers to carry out work in response to a regulatory agency review of one of our applications,
there may be delays in responding to such regulatory agency which, in turn, may lead to delays in
commercializing a product candidate.

Any selection of new third-party service providers to carry out work related to preclinical studies
and clinical trials would be time-consuming and would result in additional delays in receiving
data, analysis and reports from such third-party service providers which, in turn, would delay the
filing of any new drug application with regulatory agencies for the purposes of obtaining
regulatory approval to commercialize our product candidates. Furthermore, such delays could
increase our expenditures to develop a product candidate and materially adversely affect our
financial condition and operating results.

          The conduct of clinical trials requires the enrolment of patients and difficulties in
enrolling patients could delay the conduct of our clinical trials or result in their
non-completion.

The conduct of clinical trials requires the enrolment of patients. We may have difficulties
enrolling patients for the conduct of our future clinical trials as a result of design protocol,
the size of the patient population, the eligibility criteria to participate in the clinical trials,
the availability of competing therapies, the patient referral practices of physicians and the
availability of clinical trial sites. Difficulty

-48-

 

in enrolling patients for our clinical trials could result in the cancellation of clinical trials
or delays in completing them. Once patients are enrolled in a clinical trial, the occurrence of any
adverse drug effects or side effects observed during the trial could result in the clinical trial
being cancelled. Any of these events would have material adverse consequences on the timely
development of our product candidates, the filing of an NDA, or its equivalent, with regulatory
agencies and the commercialization of such product candidates.

          We may require additional funding and may not be able to raise the capital necessary to fund
all or part of our capital requirements, including to continue and complete the research and
development of our product candidates and their commercialization.

We do not generate significant recurrent revenues and may need financing in order to fund all or
part of our capital requirements to sustain our growth, to continue research and development of new
product candidates, to conduct clinical programs, to develop our marketing and commercial
capabilities and to meet our compliance obligations with various rules and regulations to which we
are subject. In the past, we have been financed through public equity offerings in Canada and
private placements of our equity securities and we may need to seek additional equity offerings to
raise capital, the size of which cannot be predicted. However, the market conditions or our
business performance may prevent us from having access to the public market in the future at the
times or in the amounts necessary. Therefore, there can be no guarantee that we will be able to
continue to raise additional equity capital by way of public or private equity offerings in the
future. In such a case, we would have to use other means of financing, such as issuing debt
instruments or entering into private financing or credit agreements, the terms and conditions of
which may not be favourable to us. If adequate funding is not available to us, we may be required
to delay, reduce, or eliminate our research and development of new product candidates, our clinical
trials or our marketing and commercialization efforts to launch and distribute new products,
curtail significant portions of our product development programs that are designed to identify new
product candidates and sell or assign rights to our technologies, products or product candidates.
In addition, the issuance and sale of substantial amounts of equity, or other securities, or the
perception that such issuances and sales may occur could adversely affect the market price of our
common shares.

          If product liability lawsuits are brought against us, they could result in costly and
time-consuming litigation and significant liabilities.

Despite all reasonable efforts to ensure the safety of EGRIFTATM and our other product
candidates, it is possible that we or our commercial partners will sell products which are
defective, to which patients react in an unexpected manner, or which are alleged to have side
effects. The manufacture and sale of such products may expose us to potential liability, and the
industries in which our products are likely to be sold have been subject to significant product
liability litigation. Any claims, with or without merit, could result in costly litigation, reduced
sales, significant liabilities and diversion of our management’s time and attention and could have
a material adverse effect on our financial condition, business and results of operations.

If a product liability claim is brought against us, we may be required to pay legal and other
expenses to defend the claim and, if the claim is successful, damage awards may be substantial
and/or may not be covered, in whole or in part, by our insurance. We may not have sufficient
capital resources to pay a judgment, in which case our creditors could levy against our assets. We
may also be obligated to indemnify our commercial partners and make payments to other parties with
respect to product liability damages and claims. Defending any product liability claims, or
indemnifying others against those claims, could require us to expend significant financial and
managerial resources.

          The development and commercialization of our drugs could expose us to liability claims which
could exceed our insurance coverage.

-49-

 

A risk of product liability claims is inherent in the development and commercialization of human
therapeutic products. Product liability insurance is very expensive and offers limited protection.
A product liability claim against us could potentially be greater than the available coverage and,
therefore, have a material adverse effect upon us and our financial condition. Furthermore, a
product liability claim could tarnish our reputation, whether or not such claims are covered by
insurance or are with or without merit.

          We depend on our key personnel to research, develop and bring new products to the market and
the loss of key personnel or the inability to attract highly qualified individuals could have a
material adverse effect on our business and growth potential.

The operation of our business requires qualified scientific and management personnel. The loss of
scientific personnel or members of management could have a material adverse effect on our business.
In addition, our growth is and will continue to be dependent, in part, on our ability to hire and
retain the employment of qualified personnel. There can be no guarantee that we will be able to
continue to retain our current employees or will be able to attract qualified personnel to achieve
our business plan.

          We may be unable to identify and complete in-licensing or acquisitions. In-licensing or
acquisitions could divert management’s attention and financial resources, may negatively affect our
operating results and could cause significant dilution to our shareholders.

In the future, we may engage in selective in-licensing or acquisitions of products or businesses
that we believe are complementary to our products or business. There is a risk that we will not be
able to identify suitable in-licensing or acquisition candidates available for sale at reasonable
prices, complete any in-licensing or acquisition, or successfully integrate any in-licensed or
acquired product or business into our operations. We are likely to face competition for
in-licensing or acquisition candidates from other parties including those that have substantially
greater available resources. In-licensing or acquisitions may involve a number of other risks,
including:

	 	•	 	diversion of management’s attention;
	 
	 	•	 	disruption to our ongoing business;
	 
	 	•	 	failure to retain key acquired personnel;
	 
	 	•	 	difficulties in integrating acquired operations, technologies, products or personnel;
	 
	 	•	 	unanticipated expenses, events or circumstances;
	 
	 	•	 	assumption of disclosed and undisclosed liabilities;
	 
	 	•	 	inappropriate valuation of the acquired in-process research and development, or the
entire acquired business; and
	 
	 	•	 	difficulties in maintaining customer relations.

If we do not successfully address these risks or any other problems encountered in connection with
an acquisition, the acquisition could have a material adverse effect on our business, results of
operations and financial condition. Inherited liabilities of or other issues with an acquired
business could have a material adverse effect on our performance or our business as a whole. In
addition, if we proceed with an acquisition, our available cash may be used to complete the
transaction, diminishing

-50-

 

our liquidity and capital resources, or shares may be issued which could cause significant dilution
to our existing shareholders.

          We may not achieve our publicly announced milestones on time.

From time to time, we publicly announce the timing of certain events to occur. These statements are
forward-looking and are based on the best estimate of management at the time relating to the
occurrence of such events. However, the actual timing of such events may differ from what has been
publicly disclosed. Events such as completion of a clinical program, discovery of a new product
candidate, filing of an application to obtain regulatory approval, beginning of commercialization
of our products or announcement of additional clinical programs for a product candidate may vary
from what is publicly disclosed. These variations may occur as a result of a series of events,
including the nature of the results obtained during a clinical trial or during a research phase,
problems with a supplier or a commercial partner or any other event having the effect of delaying
the publicly announced timeline. We undertake no obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise, except as otherwise
required by law. Any variation in the timing of certain events having the effect of postponing such
events could have an adverse material effect on our business plan, financial condition or operating
results.

          The outcome of scientific research is uncertain and our failure to discover new compounds
could slow down the growth of our portfolio of products.

We conduct research activities in order to increase our portfolio of product candidates. The
outcome of scientific research is uncertain and may prove unsuccessful and, therefore, may not lead
to the discovery of new molecules and progression of existing compounds to an advanced development
stage. Our inability to develop new compounds or to further develop the existing ones could slow
down the growth of our portfolio of products.

3.5 RISKS RELATED TO OUR COMMON SHARES

          Our share price has been volatile, and an investment in our common shares could suffer a
decline in value.

Since our initial public offering in Canada, our valuation and share price have had no meaningful
relationship to current or historical financial results, asset values, book value or many other
criteria based on conventional measures of the value of common shares. The market price of our
common shares will fluctuate due to various factors including the risk factors described herein and
other circumstances beyond our control.

In the past, when the market price of a stock has been volatile, shareholders have often instituted
securities class action litigation against that company. If any of our shareholders brought a
lawsuit against us, we could incur substantial costs defending the lawsuit. The lawsuit could also
divert the time and attention of our management.

          Our quarterly operating results may fluctuate significantly.

We expect our operating results to be subject to quarterly fluctuations. Our net loss and other
operating results will be affected by numerous factors, including:

	 	•	 	variations in the level of revenues and royalties received related to
EGRIFTATM;
	 
	 	•	 	variations in the level of expenses related to our development programs;

-51-

 

	 	•	 	addition or termination of clinical trials;
	 
	 	•	 	any intellectual property infringement lawsuit in which we may become involved;
	 
	 	•	 	regulatory developments affecting our product candidates;
	 
	 	•	 	our execution of any collaborative, licensing or similar arrangements, and the timing of
payments we may make or receive under these arrangements; and
	 
	 	•	 	the achievement and timing of milestone payments under our existing strategic
partnership agreements.

If our quarterly operating results fall below the expectations of investors or securities analysts,
the price of our common shares could decline substantially. Furthermore, any quarterly fluctuations
in our operating results may, in turn, cause the price of our stock to fluctuate substantially.

          We do not intend to pay dividends on our common shares and, consequently, your ability to
achieve a return on your investment will depend on appreciation in the price of our common shares.

We have never declared or paid any cash dividend on our common shares and do not currently intend
to do so for the foreseeable future. We currently anticipate that we will retain future earnings
for the development, operation and expansion of our business and do not anticipate declaring or
paying any cash dividends for the foreseeable future. Therefore, the success of an investment in
our common shares will depend upon any future appreciation in their value. There is no guarantee
that our common shares will appreciate in value or even maintain the price at which our
shareholders have purchased their shares. See “Dividend Policy”.

          Our revenues and expenses may fluctuate significantly and any failure to meet financial
expectations may disappoint securities analysts or investors and result in a decline in the price
of our common shares.

Our revenues and expenses have fluctuated in the past and are likely to do so in the future. These
fluctuations could cause our share price to decline. Some of the factors that could cause revenues
and expenses to fluctuate include the following:

	 	•	 	the inability to complete product development in a timely manner that results in a
failure or delay in receiving the required regulatory approvals or allowances to
commercialize product candidates;
	 
	 	•	 	the timing of regulatory submissions and approvals;
	 
	 	•	 	the timing and willingness of any current or future collaborators to invest the
resources necessary to commercialize the product candidates;
	 
	 	•	 	the outcome of any litigation; changes in foreign currency fluctuations;
	 
	 	•	 	the timing of achievement and the receipt of milestone payments from current or future
third parties;
	 
	 	•	 	failure to enter into new or the expiration or termination of current agreements with
third parties; and

-52-

 

	 	•	 	failure to introduce the product candidates to the market in a manner that generates
anticipated revenues.

          We may be adversely affected by currency fluctuations.

A substantial portion of our revenue is earned in U.S. dollars, but a substantial portion of our
operating expenses are incurred in Canadian dollars. Fluctuations in the exchange rate between the
U.S. dollar and other currencies, such as the Canadian dollar, may have a material adverse effect
on our business, financial condition and operating results. We do not currently engage in
transactional hedging schemes but we do attempt to hedge or mitigate the risk of currency
fluctuations by actively monitoring and managing our foreign currency holdings relative to our
foreign currency expenses.

          Our shareholder rights plan and certain Canadian laws could delay or deter a change of
control.

Our shareholder rights plan entitles a rights holder, other than a person or group holding 20% or
more of our common shares, to subscribe for our common shares at a discount of 50% to the market
price at that time, subject to certain exceptions. See “Material Contracts-Shareholder Rights Plan
Agreement”.

The Investment Canada Act (Canada) subjects an acquisition of control of a company by a
non-Canadian to government review if the value of the assets as calculated pursuant to the
legislation exceeds a threshold amount. A reviewable acquisition may not proceed unless the
relevant minister is satisfied that the investment is likely to be a net benefit to Canada.

Any of the foregoing could prevent or delay a change of control and may deprive or limit strategic
opportunities for our shareholders to sell their shares.

-53-

 

ITEM 4 DIRECTORS AND EXECUTIVE OFFICERS

4.1 DIRECTORS

The following table lists the names of our directors, their province or state and country of
residence, their principal occupation, their position or office held (if any), the year in which
each of them first became a director and the number of common shares and deferred share units each
of them beneficially owned, directly or indirectly, or over which they exercised control or
direction as of February 21, 2011. Each elected director remains in office until the next annual
meeting of shareholders, unless he resigns or his position becomes vacant following his death,
destitution or for any other reason before the next annual meeting of shareholders.

-54-

 

DIRECTORS

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	Number of	 	Number of
	Name and Place of	 	 	 	Director	 	Common	 	Deferred
	Residence	 	Principal Occupation	 	Since	 	Shares	 	Share Units
	Paul Pommier(1) (2) (3) (4) (5)

Québec, Canada
	 	Chairman of the Board	 	 	1997	 	 	 	190,100	 	 	 	20,998	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	John-Michel T. Huss(4)

Québec, Canada
	 	President and Chief Executive Officer of the Company	 	 	2010	 	 	 	—	 	 	 	44,248	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Gilles Cloutier(3) (5)

North Carolina, United States
	 	Corporate Director	 	 	2003	 	 	 	71,000	 	 	 	3,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	A. Jean de Grandpré(2) (3) (4) (5)

Québec, Canada
	 	Corporate Director	 	 	1993	 	 	 	200,000	 	 	 	5,250	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Robert G. Goyer(3) 

Québec, Canada
	 	Emeritus Professor Faculty of Pharmacy Université de Montreal	 	 	2005	 	 	 	10,000	 	 	 	5,250	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Gérald A. Lacoste(1) (3) (5) 

Québec, Canada
	 	Corporate Director	 	 	2006	 	 	 	11,000	 	 	 	5,250	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Bernard Reculeau(2) 

Paris, France
	 	Corporate Director	 	 	2005	 	 	 	18,100	 	 	 	3,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Jean-Denis Talon(1) (2) (4)

Québec, Canada
	 	Chairman of the Board

AXA Canada (Insurance Company)	 	 	2001	 	 	 	60,000	 	 	 	3,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Luc Tanguay(4) 

Québec, Canada
	 	Senior Executive Vice President and Chief Financial Officer of the Company	 	 	1993	 	 	 	83,000	 	 	 	27,572	 

 

			
	(1)	 	Member of the Audit Committee
	 
	(2)	 	Member of the Compensation Committee
	 
	(3)	 	Member of the Nominating and Corporate Governance Committee
	 
	(4)	 	Member of the Finance Committee
	 
	(5)	 	Member of the Strategic Review Committee

-55-

 

Biographical Notes of the Directors

Paul Pommier, MBA. Chairman of the Board. Mr. Paul Pommier worked for more than 25 years at
National Bank Financial Inc., his last position being Senior Executive Vice President, Corporate
and Government Finance. Throughout his career, he oversaw public and private financings, mergers
and acquisitions, as well as the marketing of investment offerings. Under his leadership, National
Bank Financial Inc. developed notable expertise in tax-shelter financings.

John-Michel T. Huss, MBA. President & Chief Executive Officer. John-Michel T. Huss brings more than
20 years of global experience in the pharmaceutical industry to Theratechnologies. He began his
career at Merck & Co., occupying various sales and marketing positions in the United States and in
Europe. In 1996, he accepted an International Product Manager position at the headquarters of F.
Hoffman-La Roche, in Basel, Switzerland. Mr. Huss joined Sanofi-Synthelabo GmbH in 1999, where he
held positions in Germany and in Canada. He was appointed General Manager of the Swiss subsidiary
at Sanofi in 2007 (Sanofi-Synthelabo merged with Aventis in 2004), and in 2009 was promoted to the
position of Chief of Staff, Office of the CEO, in Paris.

Gilles Cloutier, Ph.D. Corporate Director. Dr. Gilles Cloutier has over 30 years of experience in
the pharmaceutical industry including five years with contract research organizations, providing
strategic support to biotechnology and pharmaceutical companies. Dr. Cloutier has also held key
positions with large North-American pharmaceutical companies, where he developed expertise in the
field of clinical research. His experience includes the development and approval of several drugs
in Canada, the United States and Europe. Dr. Cloutier sits on our board of directors and is also
Chairman of the Fondation André Delambre for amyotrophic lateral sclerosis (ALS).

A. Jean de Grandpré, C.C., Q.C. Corporate Director. A. Jean de Grandpré contributed to Bell
Canada’s significant growth as Chairman of the Board and Chief Executive Officer, and went on to
become the founding Chairman of the Board and Chief Executive Officer of BCE. In recognition of
these achievements, he was inducted into the Canadian Business Hall of Fame. Mr. de Grandpré also
served on the boards of directors of other important Canadian and US corporations, namely Northern
Telecom Limited, Chrysler Corporation, Sun Life Financial Inc. and Toronto Dominion Bank, and as a
member of the international advisory boards of Chemical Bank and Goldman Sachs. He has been a
member of our board of directors since our founding in October 1993 and was appointed Chairman in
1996. He resigned his position as Chairman in March 2007.

Robert G. Goyer, Ph.D. Emeritus professor, Faculty of Pharmacy of the Université de Montréal. Dr.
Goyer has more than 40 years of experience in the pharmaceutical field. Dr. Goyer is the former
President of Jouveinal Canada and is also a former dean of the Faculty of Pharmacy of Université de
Montréal. Recognized for his broad expertise in drug development, he has served on the boards of
several companies and governmental organizations. He was notably Chairman of the Advisory Committee
on drug approval procedures of Health Canada’s Therapeutic Products Directorate and a member of the
board of directors of the Régie de l’assurance maladie du Québec. He was Chairman of the Conseil du
médicament du Québec from 2003 to 2005.

Gérald A. Lacoste, Q.C. Corporate Director. Gérald A. Lacoste is a lawyer with extensive experience
in the fields of securities regulation, financing and corporate governance. He was previously
Chairman of the Québec Securities Commission (now known as the Autorité des marchés financiers) and
was also President and CEO of the Montreal Stock Exchange. During his career, Mr. Lacoste acted as
legal counsel to the Canadian Standing Senate Committee on Banking, Trade and Commerce, he chaired
the Québec Advisory Committee on Financial Institutions, and was a member of the task force on the
capitalization of life insurance companies in Québec. Mr. Lacoste is currently a corporate
director, actively involved in the biotechnology industry, and is a member of the North American
Free Trade Agreement (NAFTA) arbitration panel.

-56-

 

Bernard Reculeau. Corporate Director. Mr. Bernard Reculeau brings over 25 years of pharmaceutical
industry experience to Theratechnologies. From September 2006 to December 2009, he was the
President of CIS Bio International, a French company specializing in nuclear medicine and
biomedical technologies. Prior to joining CIS Bio International, Mr. Reculeau was Senior Vice
President Pharmaceutical Operations of Sanofi for the InterContinental Region. In his previous
functions, he was responsible for product development and commercialization in numerous countries
around the world. Mr. Reculeau has close to 25 years in pharmaceutical operations, notably in
France where he ran the pharmaceutical operations for Rhône-Poulenc and Rhône-Poulenc Rorer as well
as in other countries in the European Union. Mr. Reculeau retired in early 2010.

Jean-Denis Talon. Chairman of the Board, AXA Canada. Mr. Jean-Denis Talon had a successful career
with AXA Insurance over a period of more than 20 years, ultimately becoming President and Chief
Executive Officer. He is currently Chairman of the Board of AXA Canada. Mr. Talon is also former
President of the Financial Affairs Committee at the Insurance Bureau of Canada.

Luc Tanguay, M.Sc., CFA. Senior Executive Vice President and Chief Financial Officer of the
Company. Mr. Luc Tanguay has been active in the biotechnology industry for over 15 years. As a
member of our senior management since 1996, he has contributed to our growth by facilitating access
to public and private capital funding. A member of the board of directors since 1993, he has held
various management positions since joining the Company. Prior to joining us, Mr. Tanguay had a
career in investment banking at National Bank Financial Inc.

4.2 AUDIT COMMITTEE

Our board of directors has established an Audit Committee to review our annual financial statements
prior to their approval by the board of directors and also to perform other duties, as is described
in the Audit Committee’s charter adopted by the board of directors and attached hereto as Appendix
A.

As of November 30, 2010, the Audit Committee was composed of three members: Paul Pommier, its
Chair, Jean-Denis Talon and Gérald A. Lacoste. All three are independent and financially literate.
The details mentioned hereunder describe the education and experience of the Audit Committee
members that is relevant to the performance of their responsibilities, in particular any experience
in preparing, auditing, analyzing and evaluating financial statements.

Paul Pommier. Mr. Pommier holds an MBA degree and has more than 25 years of experience in the
financial field, notably in public and private company financings, as well as in merger and
acquisition activities. While acting as a director of Royal Aviation Inc., he was also a member of
its audit committee.

Jean-Denis Talon. Mr. Talon has more than 20 years of experience in the insurance field as a senior
officer. Mr. Talon acted as a member of the audit committee of AXA Canada from March 1995 to April
2008. He has been a member of the audit committee of InnovAssur since March 1999 and since November
1999, he has been acting as Chairman of its audit committee.

Gérald A. Lacoste. Mr. Lacoste has more than 30 years of experience in the fields of securities
regulation, corporate finance and corporate governance. Mr. Lacoste was president of the audit
committee of Amisco Ltd. from 2002 to 2009 and was also a member of the audit committee of Andromed
Inc. from 2004 to 2007. Mr. Lacoste has been a member of the audit committee of Génome Québec from
2006 to 2009.

Each member of the Audit Committee has acquired in-depth financial expertise giving each the
ability to read and understand a set of financial statements which presents the breadth and level
of

-57-

 

complexity of accounting issues that are generally comparable to those that can reasonably be
expected to be raised in the issuer’s financial statements.

External Auditors Service Fees

	 	 	 	 	 	 	 	 	 
	 	 	Financial Year Ended	 	Financial Year Ended
	 	 	November 30, 2010	 	November 30, 2009
	Audit Fees
	 	$	122,000	 	 	$	80,000	 
	Audit-Related Fees (1)
	 	$	158,025	 	 	$	17,500	 
	Tax Fees (2)
	 	$	56,600	 	 	$	39,626	 
	All Other Fees
	 	 	—	 	 	 	—	 

 

			
	(1)	 	Audit-related fees relate principally to services rendered in connection with
our annual financial statements and, for the financial year ended November 30, 2010, audit
fees paid to KPMG also included fees related to services rendered in connection with the audit
of IFRS adjustments and the translation of the financial statements to IFRS standards.
	 
	(2)	 	Tax fees relate to services rendered in connection with the preparation of corporate
tax returns and general tax advice.

4.3 EXECUTIVE OFFICERS

The following table lists the names of all executive officers, their province or state and country
of residence, their office and the number of common shares and deferred share units beneficially
owned, directly or indirectly, by each of them or over which they exercised control or direction as
at February 21, 2011.

-58-

 

EXECUTIVE OFFICERS

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	Number of	 	 
	 	 	 	 	 	 	Common Shares	 	 
	 	 	 	 	 	 	of the Company	 	 
	 	 	 	 	 	 	over which	 	 
	 	 	 	 	 	 	Control or	 	Number of
	Name and Place of	 	 	 	 	 	Direction is	 	Deferred
	Residence	 	Office	 	Exercised	 	Share Units
	Paul Pommier
 Québec, Canada
	 	Chairman of the Board	 	 	190,100	 	 	 	20,998	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	John-Michel T. Huss
 Québec, Canada
	 	President and Chief Executive Officer	 	 	—	 	 	 	44,248	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Luc Tanguay
 Québec, Canada
	 	Senior Executive Vice President and Chief Financial Officer	 	 	83,000	 	 	 	27,572	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Marie-Noël Colussi
 Québec, Canada
	 	Vice President, Finance	 	 	10,075	 	 	 	3,182	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Chantal Desrochers
 Québec, Canada
	 	Vice President, Business Development and Commercialization	 	 	16,300	 	 	 	—	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Andrea Gilpin
 Québec, Canada
	 	Vice President, Investor Relations and Communications	 	 	6,000	 	 	 	2,005	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Jocelyn Lafond
 Québec, Canada
	 	Vice President, Legal Affairs, and Corporate Secretary	 	 	—	 	 	 	5,000	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Christian Marsolais 
Québec, Canada
	 	Vice President, Clinical Research and Medical Affairs	 	 	8,597	 	 	 	6,312	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Martine Ortega
 Québec, Canada
	 	Vice President, Compliance and Regulatory Affairs	 	 	3,000	 	 	 	7,532	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Pierre Perazzelli
 Québec, Canada
	 	Vice President, Pharmaceutical Development	 	 	1,800	 	 	 	4,061	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	Krishna Peri
 Québec, Canada
	 	Vice President, Research	 	 	35,000	 	 	 	—	 

Biographical Notes of the Executive Officers

For the biographical notes of Paul Pommier, John-Michel T. Huss and Luc Tanguay, please refer to
Item 4 of this AIF.

Marie-Noël Colussi, CA. Vice President, Finance. Ms. Marie-Noël Colussi is a graduate of Université
du Québec à Montréal in business administration. Prior to joining us, Ms. Colussi worked for eight
years with KPMG, a major accounting firm. Ms. Colussi has experience in accounting, auditing,
control and taxation, particularly in research and development. She joined us in March 1997, and
prior to her appointment as Vice President, Finance in February 2002, she held the positions of
Director, Accounting and Internal Control and Controller.

Chantal Desrochers, B.Ph., MBA. Vice President, Business Development and Commercialization. Ms.
Chantal Desrochers obtained her degrees in pharmacy and business from the Université de Montréal.
She began her career at Schering-Plough in sales and ultimately became a Product Director. After
obtaining her M.B.A., Ms. Desrochers joined Bristol-Myers Squibb Company in Canada as Marketing
Director, Pharmaceuticals and became Vice President, Institutional Business in 1995. In 1997, Ms.
Desrochers was promoted to European Franchise Marketing Director, Cardiovascular, in

-59-

 

France where she contributed to the commercial development of cardiovascular products. This led to her
appointment as International Marketing Director, Cardiovascular, at Bristol-Myers Squibb in
Princeton, New Jersey. Prior to joining us in 2005, Ms. Desrochers offered consulting services in
business development and product development strategies.

Andrea Gilpin, Ph.D., MBA. Vice President, Investor Relations and Communications. Prior to joining
us in 2007, Dr. Gilpin was Director, Investor Relations at MethylGene Inc. and held various
positions at biotechnology companies. Dr Gilpin has a Ph.D. (Genetics/Biochemistry) from the
University of Toronto and an MBA from the Asper School of Business.

Jocelyn Lafond, LL.B., LL.M. Vice President, Legal Affairs, and Corporate Secretary. Mr. Lafond has
over 15 years of experience in the fields of corporate and securities law. Mr. Lafond holds a law
degree from Université Laval and a Masters Degree in Law from the University of Toronto. He has
been a member of the Barreau du Québec since 1992. Prior to joining us in 2007, Mr. Lafond was a
partner with the international law firm of Fasken Martineau DuMoulin LLP.

Christian Marsolais, Ph.D. Vice President, Clinical Research and Medical Affairs. Dr. Christian
Marsolais has over 15 years of experience in clinical research for large pharmaceutical companies,
such as Sandoz Canada Inc. and BioChem Therapeutics Inc. Before joining us in 2007, Dr. Marsolais
held various positions at Pfizer Global Pharmaceuticals, where he was appointed Director of Medical
Affairs, Therapeutic Areas, in 2004. In this position, Dr. Marsolais was responsible for the
clinical program and scientific initiatives development, as well as the integration of the
Scientific Affairs and Clinical Research for the oncology and HIV Franchise. Dr. Marsolais holds a
Ph.D. in Biochemistry from the Université de Montréal.

Martine Ortega, Pharm. D. Vice President, Compliance and Regulatory Affairs. Ms. Martine Ortega
joined us in 2006. A graduate in pharmacy from the Université d’Aix-Marseille II, she holds a
postdoctoral degree in dermatology. Ms. Ortega has close to 20 years of experience in the
pharmaceutical industry, where she has gained knowledge of the drug development process. During her
career, she has acquired broad expertise in GLP, GCP and GMP practices and procedures as well as in
computerized systems validation. She is also experienced in relations with US, European and
Canadian regulatory agencies. Prior to joining us, she held senior management positions at Ventana
Clinical Research Corporation, MDS Pharma Services and Sandoz Canada Inc.

Pierre Perazzelli, B. Sc. Vice President, Pharmaceutical Development. A graduate of Université
Laval, Mr. Perazzelli has been working in the pharmaceutical manufacturing industry for over 20
years. Throughout his career, he has held various positions in large pharmaceutical companies,
including Bristol Myers Squibb and Abbott Laboratories, Ltd. He was Director of the LAB Laboratory,
a research centre specializing in pharmaceutical formulation. He is also experienced in the
production of generic drugs. Mr. Perazzelli joined us in May 2000.

Krishna Peri, Ph.D. Vice President, Research. Co-inventor of the ExoPepTM technology and a founder
of Pharma-G, Dr. Krishna Peri holds a Ph.D. in biochemistry from the University of Saskatchewan,
Canada. He pursued post-doctoral research in cancer as an NCI fellow at McGill University and at
Ste. Justine Hospital Research Center. After our acquisition of Pharma-G in 2000, he served as
director of discovery research, and was subsequently appointed Vice-President, Research, in June
2004.

-60-

 

4.4 DECLARATION OF THE DIRECTORS’ AND OFFICERS’ ANTECEDENTS

Except as described below, to our knowledge, no director or executive officer (a) is, as at the
date of this Annual Information Form, or has been within the ten years before the date of this
Annual Information Form, a director or executive officer of any company (including us) that, while
that person was acting in that capacity, (i) was the subject of a cease trade or similar order or
an order that denied the relevant company access to any exemption under securities legislation, for
a period of more than thirty consecutive days; (ii) was subject to an event that resulted, after
the director or executive officer ceased to be a director or executive officer, in the company
being the subject of a cease trade or similar order or an order that denied the relevant company
access to any exemption under securities legislation, for a period of more than thirty consecutive
days; or (iii) within a year of that person ceasing to act in that capacity, became bankrupt, made
a proposal under any legislation relating to bankruptcy or insolvency or was subject to or
instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver
manager or trustee appointed to hold its assets; or (b) has, within the ten years before the date
of this Annual Information Form, become bankrupt, made a proposal under any legislation relating to
bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or
compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold his
assets.

Paul Pommier was a member of the board of directors of Royal Aviation Inc. from September 1996
until it was acquired by Canada 3000 Inc. in March 2001. Subsequently, at the end of 2001, Canada
3000 Inc. and its subsidiaries, including Royal Aviation Inc., made assignments in bankruptcy under
Item 49 of the Bankruptcy and Insolvency Act (R.S. 1985, c. B-3), or Bankruptcy Act.

Jean-Denis Talon was a member of the board of directors of Toptent Inc., or Toptent, from August 1,
2007 to November 26, 2009. On December 3, 2009, Toptent filed a notice of intention to make a
proposal under the Bankruptcy Act. Subsequently, on May 7, 2010, Toptent filed a proposal under the
Bankruptcy Act. The proposal was accepted by Toptent’s creditors on May 20, 2010.

Luc Tanguay was a member of the board of directors of Ambrilia Biopharma Inc., or Ambrilia, from
August 22, 2006 to March 30, 2010. On July 31, 2009, Ambrilia obtained court protection from its
creditors under the Companies’ Creditors Arrangement Act (Canada). The purpose of the order issued
by the court granting Ambrilia protection from its creditors was to provide Ambrilia and its
subsidiaries the opportunity to restructure its affairs. On July 31, 2009, the TSX halted the
trading of Ambrilia’s shares pending its review of Ambrilia’s meeting the requirements for
continuous listing. On January 31, 2011, TSX determined to delist the common shares of Ambrilia at
the close of market on March 4, 2011 for failure to meet the continued listing requirements of TSX.
The common shares will remain suspended from trading.

4.5 SECURITIES HELD BY THE DIRECTORS AND EXECUTIVE OFFICERS

As at February 21, 2011, the total number of common shares (the only securities carrying a voting
right) held by our directors and executive officers amounted to 723,972, which represented 1.20% of
our outstanding common shares.

-61-

 

ITEM 5 INTERESTS OF EXPERTS

KPMG LLP, our auditors, is the only person or company who is named as having prepared or certified
a statement, report or evaluation, included or mentioned in a filing under securities regulations
during our most recently completed financial year.

KPMG LLP and its partners are independent in accordance with the auditor’s rules of professional
conduct in the jurisdiction of Québec.

-62-

 

ITEM 6 SECURITIES OF THE COMPANY

6.1 AUTHORIZED SHARE CAPITAL

We are authorized to issue an unlimited number of common shares and an unlimited number of
preferred shares issuable in series.

Subject to the priority rights of holders of preferred shares, holders of common shares are
entitled to any dividend declared by the board of directors, to one vote per share at meetings of
our shareholders and, in the event of our liquidation or dissolution, to participate in the
distribution of the assets.

Preferred shares carry no voting rights. Preferred shares may be issued at any time in one or more
series. Our articles of incorporation give our board of directors the power to fix the number of
preferred shares and the consideration per share, as well as to determine the provisions attached
to the preferred shares of each series (including dividends, redemption and conversion rights, if
any). The shares of every series of preferred shares will have priority over all our other shares,
including common shares, with respect to the payment of dividends and return of capital in the
event of our liquidation or dissolution.

The common shares issued represent the total voting rights pertaining to our securities.

6.2 DIVIDEND POLICY

We have never declared or paid cash dividends on our common shares and do not anticipate paying any
cash dividends on our common shares in the foreseeable future. We presently intend to retain future
earnings, if any, to finance the expansion and growth of our business. Any future determination to
pay dividends will be at the discretion of our board of directors and will depend on our financial
condition, results of operations, capital requirements and other factors the board of directors
deems relevant. In addition, the terms of any future debt or credit facility may preclude us from
paying dividends.

6.3 TRANSFER AGENT AND REGISTRAR

Our transfer agent and registrar is Computershare Trust Company of Canada which holds, at its
Montreal office, the registers related to our common shares, shareholders and transfers.

-63-

 

ITEM 7 MARKET FOR SECURITIES

7.1 TRADING PRICE AND VOLUME

The following table sets forth the high and low closing sale prices for our common shares for the
periods indicated, as reported on the TSX. However, you should not view this presentation as an
indication that the market price of our common shares will continue at such levels.

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Price	 	 
	Period	 	$ High	 	$ Low	 	Volume
	February 1
to February 18, 2011
	 	$	5.88	 	 	$	5.01	 	 	 	4,371,300	 
	January 2011
	 	$	5.90	 	 	$	5.43	 	 	 	3,319,500	 
	December 2010
	 	$	5.69	 	 	$	5.27	 	 	 	4,038,000	 
	November 2010
	 	$	5.80	 	 	$	4.91	 	 	 	8,127,400	 
	October 2010
	 	$	5.15	 	 	$	4.44	 	 	 	2,944,000	 
	September 2010
	 	$	4.98	 	 	$	4.78	 	 	 	1,230,300	 
	August 2010
	 	$	5.08	 	 	$	4.75	 	 	 	1,934,900	 
	July 2010
	 	$	5.48	 	 	$	4.82	 	 	 	3,795,500	 
	June 2010
	 	$	5.59	 	 	$	4.61	 	 	 	6,188,600	 
	May 2010
	 	$	5.02	 	 	$	2.09	 	 	 	11,593,700	 
	April 2010
	 	$	5.20	 	 	$	4.82	 	 	 	1,960,000	 
	March 2010
	 	$	5.50	 	 	$	4.80	 	 	 	2,612,100	 
	February 2010
	 	$	5.03	 	 	$	4.67	 	 	 	2,205,500	 
	January 2010
	 	$	5.42	 	 	$	4.28	 	 	 	4,505,000	 
	December 2009
	 	$	4.45	 	 	$	3.55	 	 	 	5,517,800	 

7.2 PRIOR SALES

The following table summarizes the distribution of securities other than our common shares that we
issued during the most recently completed financial year, identifying the type of security, the
price per security, the number of securities issued, and the date on which the securities were
issued.

	 	 	 	 	 	 	 	 	 	 	 	 	 
	Date	 	Type of Security	 	Price per Security	 	Number of Securities
	December 8, 2009
	 	Options	 	$	3.84	 	 	 	265,000	 
	June 8, 2010
	 	Options	 	$	4.75	 	 	 	70,000	 

-64-

 

ITEM 8 LEGAL PROCEEDINGS

On July 26, 2010, we received a motion for authorization to institute a class action lawsuit
against us, our chairman and our former chief executive officer. This motion was filed in the
Superior Court of Québec, district of Montreal. The applicant is seeking to initiate a class action
suit and to certify and represent a class of persons who were shareholders at May 21, 2010 and who
sold their common shares on May 25 or 26, 2010. This applicant alleges that we did not comply with
our continuous disclosure obligations as a reporting issuer by failing to disclose certain alleged
adverse effects relating to the administration of EGRIFTATM. We are of the view that the
allegations contained in the motion are entirely without merit and intend to take all appropriate
actions to vigorously defend our position. The Motion has not yet been heard by the Superior Court
of Québec and no date has been set for the hearing. We have subscribed for insurance covering our
potential liability and the potential liability of our directors and officers in the performance of
all their duties for us subject to a $200,000 deductible and standard terms, conditions and
exclusions.

We are not otherwise currently subject to any material legal proceedings.

-65-

 

ITEM 9 MATERIAL CONTRACTS

Licensing Agreements. We have executed commercialization agreements with third parties for the
exclusive distribution rights to EGRIFTATM for the reduction of excess abdominal fact in
HIV-infected patients with lipodystrophy for (i) the United States; (ii) Latin America, Africa and
the Middle East; and (iii) Europe, Russia, South Korea, Taiwan, Thailand and certain central Asian
countries. For a description of these agreements, see Item 2.5.

Supply Agreements. We have executed five supply agreements with Bachem, Draxis, Becton Dickinson,
Hospira and ABAR. For a description of these agreements, see Item 2.7.

Shareholder Rights Plan Agreement. On February 10, 2010, we entered into a shareholder rights plan
agreement, or Rights Plan. The Rights Plan entitles a holder of rights (other than the Acquiring
Person, as defined below, or any affiliate or associate of an Acquiring Person or any person acting
jointly or in concert with an Acquiring Person or any affiliate or associate of an Acquiring
Person) to purchase to our common shares at a discount of 50% to the market price upon a person
becoming an “Acquiring Person”, subject to certain exceptions and the terms and conditions set out
in the Rights Plan. An “Acquiring Person” is defined in the Rights Plan as a beneficial owner of
20% or more of our common shares. The Rights Plan will expire at the close of our annual meeting of
shareholders in 2013.

In order to implement the Rights Plan, we issued one right in respect of each common share
outstanding as of 6:00 p.m. (Montreal time) on February 9, 2010, the “Effective Date”. One right
will also be issued and attached to each subsequently issued common share. The rights will separate
and trade separately from the common shares to which they are attached and will become exercisable
after the “Separation Time”, as defined below:

The “Separation time” is the close of business on the tenth business day following the earliest of:

	 	(a)	 	the date of the first public announcement made by us or an Acquiring Person that a
person has become an Acquiring Person;
	 
	 	(b)	 	the date of the commencement of, or first public announcement of the intent of any
Person to commence, a take-over bid (other than a Permitted Bid (as defined in the Rights
Plan) or a Competing Permitted Bid (as defined in the Rights Plan)) by any person for our
common shares;
	 
	 	(c)	 	the date upon which a Permitted Bid or Competing Permitted Bid ceases to be such; or
	 
	 	(d)	 	such later date as may be determined by the board of directors.

After the time at which a person becomes an Acquiring Person, and subject to the terms and
conditions set out in the shareholder rights plan agreement, each right would, upon exercise,
entitle a rights holder, other than the Acquiring Person and related persons, to purchase common
shares at a 50% discount to the market price at the time.

Under the Rights Plan, a “Permitted Bid” is a bid made to all holders of the common shares and
which is open for acceptance for not less than 60 days. If at the end of 60 days at least 50% of
the outstanding common shares, other than those owned by the offeror and certain related parties,
have been tendered, the offeror may take up and pay for the common shares but must extend the bid
for a further 10 days to allow other shareholders to tender.

-66-

 

Lease Agreement. In October 2009, we entered into a new lease agreement with Société de
portefeuille immobilier GE Q-Tech inc. for the renewal of our lease for our offices and
laboratories located in Montréal, Québec. The new lease became effective on May 1, 2010 and will
expire on April 30, 2021. Under the terms of this new lease agreement, we have two five year
renewal options. If exercised, the first renewal option will start on May 1, 2021 and expire on
April 30, 2026 and the second renewal option, if exercised, will start on May 1, 2026 and expire on
April 30, 2031.

-67-

 

ITEM 10 ADDITIONAL INFORMATION

Additional information with respect to our company, including directors’ and officers’
compensation, principal holders of our securities and securities authorized for issuance under
equity compensation plans, where applicable, is contained in our Management Proxy Circular for our
most recent annual and special meeting of shareholders. Our financial information is provided in
our comparative financial statements and Management Discussion & Analysis for our financial year
ended November 30, 2010.

Additional information regarding our company is available on SEDAR at www.sedar.com or upon request
addressed to Jocelyn Lafond, Corporate Secretary, at 2310 Alfred Nobel Boulevard, Montreal, Québec,
Canada H4S 2B4. Except when our securities are in the process of distribution pursuant to a
prospectus, we may charge reasonable fees if the request is from a person who does not hold any of
our securities.

-68-

 

APPENDIX A — AUDIT COMMITTEE CHARTER

	I.	 	Mandate

The Audit Committee (the “Committee”) is responsible for assisting the Company’s Board of
Directors (the “Board”) in overseeing the following:

	 	A.	 	the integrity of the Company’s financial statements and related information;
	 
	 	B.	 	the internal control systems of the Company;
	 
	 	C.	 	the appointment and performance of the external auditor; and
	 
	 	D.	 	the supervision of the Company’s Risk Management.

	II.	 	Obligations and Duties

The Committee carries out the duties usually entrusted to an audit committee and any other
duty assigned from time to time by the Board. Management has the responsibility to ensure
the integrity of the financial information and the effectiveness of the Company’s internal
controls. The external auditor has the responsibility to verify and certify the accurate
presentation of the Company’s financial statements; at the same time evaluating the internal
control process to determine the nature, extent and chronology of the auditing procedures
used. The Committee has the responsibility to supervise the participants involved in the
preparation process of the financial information and to report on this to the Board.

Specifically, the Committee is charged with the following obligations and duties:

	 	A.	 	Integrity of the Company’s Financial Statements and Related Information

	 	1.	 	Review annual and quarterly consolidated financial statements and
all financial information legally required to be disclosed by the Company, i.e.
financial information contained in the “Management Discussion and Analysis”
report, the annual information form and the press releases, as the case may be,
discuss such with management and the external auditor, and suggest
recommendations to the Board, as the case may be.
	 
	 	2.	 	Approve the interim Financial Statements, the interim “Management
Discussion and Analysis” reports and all supplements to these “Management
Discussion and Analysis” reports which have to be filed with regulatory
authorities.
	 
	 	3.	 	On a periodic basis, review and discuss with management and the
external auditor the following:

	 	a.	 	major issues regarding accounting principles and
financial statement presentations, including any significant changes in
the Company’s selection or application of accounting principles, and
major issues as to the adequacy of the Company’s internal controls and
any special audit steps adopted in light of material control
deficiencies;
	 
	 	b.	 	the effect of regulatory and accounting
initiatives, as well as off-balance sheet structures, on the financial
statements of the Company; and
	 
	 	c.	 	the type and presentation of information to be
included in press releases dealing with financial results (paying
particular attention to any use of pro-forma information or information
adjusted by means of non-generally accepted accounting principles).

-69-

 

	 	4.	 	Review and discuss reports from the external auditor on:

	 	a.	 	all critical accounting policies and practices used
by the Company; and
	 
	 	b.	 	all material alternative treatments of financial
information within generally accepted accounting principles that have
been discussed with management, including the ramifications of the use of
such alternate treatments and disclosures and the treatment preferred by
the external auditor.

	 	B.	 	Supervision of the Company’s Internal Control Systems

	 	1.	 	Review and discuss with management and with the external auditor
present reports and, when appropriate, provide recommendations to the Board on
the following:

	 	a.	 	actual financial data compared with budgeted data;
	 
	 	b.	 	the Company’s internal control system;
	 
	 	c.	 	the relationship of the Committee with the
management and audit committees of the Company’s consolidated
subsidiaries. With respect to the subsidiaries, the Committee must:

	 	•	 	obtain precisions as to the mandate of the audit committees;
	 
	 	•	 	enquire about internal controls and study related risks;
	 
	 	•	 	obtain the external auditors’ report to the audit committees on
the planning of external auditing;
	 
	 	•	 	obtain the external auditors’ report to the audit committees on
the auditing results;
	 
	 	•	 	obtain copy of the minutes of the audit committees’ meetings;
and
	 
	 	•	 	ensure that the critical accounting policies and practices are
identical to the Company’s.

	 	2.	 	Study the feasibility of implementing an internal auditing system
and when implemented, establish its responsibilities and supervise its work.
	 
	 	3.	 	Establish procedures for the receipt, retention and treatment of
complaints received by the Company regarding accounting, internal accounting
controls or auditing matters, and procedures for the confidential, anonymous
submission by employees of concerns regarding questionable accounting or
auditing matters.

	 	C.	 	Appointment and Performance Supervision of the External Auditor

	 	1.	 	Provide recommendations to the Board on the selection of the
external auditor to be appointed by the shareholders.
	 
	 	2.	 	Approve in advance and recommend to the Board the external
auditor’s remuneration and more specifically fees and terms of all audit, review
or certification services to be provided by the external auditor to the Company
and any consolidated subsidiary.
	 
	 	3.	 	Supervise the performance of the external auditor in charge of
preparing or issuing an audit report or performing other audit services or
certification services for the Company or any consolidated subsidiary of the
Company,

-70-

 

	 	 	 	where required, and review all related questions as to the terms of its
mission and the revision of its mission.

	 	4.	 	Pre-approve all engagements for permitted non-audit services
provided by the external auditor to the Company and any consolidated subsidiary,
and to this effect and at its convenience, establish policies and procedures for
the engagement of the external auditor to provide to the Company and any
consolidated subsidiary permitted non-audit services, which shall include
approval in advance by the Committee of all audit/review services and permitted
non-audit services to be provided to the Company and any consolidated subsidiary
by the external auditor.
	 
	 	5.	 	At least annually, consider, assess and report to the Board on:

	 	a.	 	the independence of the external auditor, including
whether the external auditor’s performance of permitted non-audit
services is compatible with the external auditor’s independence;
	 
	 	b.	 	the obtaining from the external auditor of a
written statement i) describing all relationships between the external
auditor and the Company; ii) assuring that lead audit partner rotation is
carried out, as required by law; and iii) describing any other
relationship that may adversely affect the independence of the external
auditor; and
	 
	 	c.	 	the evaluation of the lead audit partner, taking
into account the opinions of management and the internal auditor.

	 	6.	 	At least annually, obtain and review a report by the external
auditor describing:

	 	a.	 	the external auditor’s internal quality-control
procedures; and
	 
	 	b.	 	any material issues raised by the most recent
internal quality-control review (or peer review) of the external
auditor’s firm, or by any inquiry or investigation by governmental or
professional authorities, within the preceding five years, with respect
to one or more independent audits carried out by the external auditor’s
firm, and any steps taken to deal with any such issues.

	 	7.	 	Resolve any disagreement between management and the external
auditor regarding financial reporting.
	 
	 	8.	 	Review the audit process with the external auditor.
	 
	 	9.	 	Review and discuss with the Chief Executive Officer and Chief
Financial Officer of the Company the process for the certifications to be
provided in the Company’s public disclosure documents.
	 
	 	10.	 	Meet periodically with the external auditor in the absence of
management.
	 
	 	11.	 	Establish procedures with respect to hiring the external
auditor’s employees and former employees.

	 	D.	 	Supervision of the Company’s Risk Management

Review, report and, where appropriate, provide recommendations to the Board on the
following:

	 	1.	 	the Company’s processes for identifying, assessing and managing
risk;
	 
	 	2.	 	the Company’s major financial risk exposures and the steps the
Company has taken to monitor and control such exposures;

-71-

 

	 	3.	 	the Company’s insurance portfolio and the adequacy of the
coverage; and
	 
	 	4.	 	the Company’s investment policy.

	III.	 	External Advisors

In discharging its duties and responsibilities, the Committee is empowered to retain
external legal counsel or other external advisors, as appropriate. The Company shall provide
the necessary funds to secure the services of such advisors.

	IV.	 	Composition of the Committee

The Committee is composed of any number of Directors, but no less than
three, as may be determined by the Board from time to time by
resolution. Each member of the Committee shall be independent from the
Company and is financially literate, as determined by the Board and in
conformity with applicable laws, rules and regulations.

	V.	 	Term of the Mandate

Committee members are appointed by Board resolution to carry out their mandate extending
from the date of the appointment to the next annual general meeting of the shareholders or
until their successors are so appointed.

	VI.	 	Vacancy

The Board may fill vacancies at any time by resolution. Subject to
the constitution of the quorum, the Committee’s members can continue
to act even if there is one or many vacancies on the Committee.

	VII.	 	Chairman

The Board appoints the Committee Chairman who will call and chair the meetings. The Chairman
reports to the Board the deliberations of the Committee and its recommendations.

	VIII.	 	Secretary

Unless otherwise determined by resolution of the Board, the Secretary of the Company shall
act as Committee Secretary. The Secretary must attend Committee meetings and prepare the
minutes. He/she must provide notification of meetings as directed by the Committee Chairman.
The Secretary is the guardian of the Committee’s records, books and archives.

	IX.	 	Meeting Proceedings

The Committee establishes its own procedures as to how meetings are called and conducted.
Unless it is otherwise decided, the Committee shall meet privately and independently from
Management at each regularly scheduled meeting. In the absence of the regularly appointed
Chairman, the meeting shall be chaired by another Committee member selected among attending
participants and appointed accordingly. In the absence of the regularly appointed Secretary,
Committee members shall designate someone to carry out this duty.

The Committee shall meet at least four times a year with management and the external
auditor, and at least once a year, separately in executive session in the absence of
management and the external auditor. At least once a year, the Committee invites the Chief

-72-

 

Financial Officer of each subsidiary to present the financial information and internal
control systems related to such subsidiary.

	X.	 	Quorum and Voting

Unless the Board otherwise specifies by resolution, two Committee
members shall constitute an appropriate quorum for deliberation of
items on the agenda. During meetings, decisions are reached by a
majority of votes from Committee members, unless the quorum is of two
members, in which case decisions are made by consensus of opinion.

	XI.	 	Records

The Committee keeps records that are deemed necessary of its
deliberations and reports regularly to the Board on its activities
and recommendations.

	XII.	 	Effective Date

This charter was adopted by the Directors at its May 3, 2004 Board
meeting. It was amended by the Directors during the April 13, 2005
and February 8, 2006 Board meetings.

-73-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}]]